Heterocyclic compounds as ubiquitin-specific protease 7 inhibitors
By designing a new USP7 inhibitor that contains a specific connection method of the dangled morpholinyl ring and phenyl group, the shortcomings of existing USP7 inhibitors in inhibiting activity, solubility and stability are solved, and the effectiveness of USP7 is achieved Inhibition, providing improved treatment options for cancer and tumor diseases.
Patent Information
- Application Number
- CN202380027580.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-01-21
- Filing Date
- 2023-01-20
- Publication Date
- 2024-11-12
AI Technical Summary
The existing USP7 inhibitors have room for improvement in inhibiting activity, solubility and in vivo stability, and the pharmacokinetic characteristics are insufficient, making it difficult to effectively treat cancer and tumor diseases.
A novel compound, according to formula (I), which comprises a specific connection mode of the dangling morpholinyl ring to phenyl, significantly improves the properties of the USP7 inhibitor, including improved solubility and microsomal stability, by The specific binding site of USP7 significantly improves inhibitory activity.
This compound significantly improves the inhibitory effect on USP7, improves solubility and stability, and provides a more effective treatment plan with potential therapeutic and preventive applications for cancer and tumor diseases.
Smart Images

Figure CN118946566A_ABST
Abstract
Description
[0001] This application claims priority to GB application No. 2200753.8, filed on January 21, 2022, the contents and elements of which are incorporated herein by reference for all purposes. Technical Field
[0002] This invention relates to an inhibitor of ubiquitin-specific protease 7 (USP7) and its method of use. Background Technology
[0003] Over the past three decades, protein ubiquitination has become an important post-translational modification that plays a role in a wide range of cellular processes, including proteolysis, gene expression, DNA repair, immune responses, metabolism, and cell cycle regulation. Dysregulation of the ubiquitin-proteasome system (UPS) is also associated with the pathogenesis of a variety of human diseases, including (but not limited to): cancer (Hoeller et al., Nat. Rev. Cancer (2006), 6, 776-788), viral infections (Gao et al., Can. J. Physiol. Pharmacol. (2006), 84, 5-14), metabolic or neurodegenerative diseases (Loosdregt et al., Immunity (2013), 39, 259-271; Rubinsztein et al., Nature (2006), 443, 780-786), and immune and inflammatory-related medical disorders (Wang et al., Cell Mol. Immunol. (2006), 3, 255-261; Corn J. et al., Nat. Struct. Mol. Biol. (2014), 21, 297-300; Nicholson et al., Cell...). Biochem. Biophys. (2011), 60, 61-68).
[0004] The established and increasingly close links between USP7 and many proteins involved in human diseases suggest that small molecule inhibitors of USP7 may have broad therapeutic applications beneficial to human health. Small molecule USP7 inhibitors have been reported in the following patent applications: US2008 / 0103149 A1, WO 2010 / 114881A1, WO 2010 / 081783A1, WO 2011 / 086178A1, WO2013 / 030218A1, EP 2565186 A1, EP 1749822 A1, WO 2016 / 109515A1, WO 2016 / 109480 A1, WO 2016 / 126929 A1, WO2016 / 126926A1, WO 2016 / 126935 A1, WO 2016 / 150800 A1, WO2017 / 158381, WO2017 / 158388, WO2018 / 073602 and WO2021 / 161047.
[0005] However, there remains a need for improved USP7 inhibitors, such as inhibitors with improved inhibitory activity, improved solubility, improved in vivo stability, improved pharmacokinetic properties, or some or all of these properties. This application addresses this need. Summary of the Invention
[0006] The compounds described herein selectively inhibit USP7 activity. Therefore, the compounds provided herein are suitable for the treatment and prevention of diseases such as cancer and tumors. These compounds can be used as monotherapy or as combination therapy with radiation and / or other therapeutic agents.
[0007] Therefore, in the first aspect, compounds according to formula (I) are provided, including their stereoisomers:
[0008]
[0009] in:
[0010] “m” is 0, 1, or 2, and each R 1 Independently selected from: halogenated groups; C1-C6 alkyl groups optionally substituted with halogenated groups; and C3-C6 cycloalkyl groups;
[0011] “n” is 0, 1, or 2, and each of R is a finite number of 2. 2 The group is independently selected from optionally substituted C1-C6 alkyl groups, optionally substituted C3-C6 cycloalkyl groups, wherein each of one or more optional substituents is independently selected from C1-C6 alkyl groups, and a halogen group.
[0012] Or where "n" is 2 and each R 2They combine with one or more carbon ring atoms to form C3-C6 fused cycloalkyl rings, C3-C6 spirocycloalkyl rings, or C3-C4 bridges;
[0013] R 3 Selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted C7-C 10 arylalkyl, optionally substituted C8-C 10 Arylalkenyl and optionally substituted C3-C6 heteroaryl; wherein each of one or more optional substituents is independently selected from: a halogroup; a C1-C6 alkyl group optionally substituted with a halogroup; and a C3-C6 cycloalkyl group optionally substituted with a methyl group or CF3.
[0014] R 4 It is H, Cl, or C1-C6 alkyl;
[0015] One of X and Z is O and one of X and Z is NR', such that the ring containing X and Z is a morpholine ring, wherein R' is H or a C1-C6 alkyl group, optionally H;
[0016] Or its pharmaceutically acceptable salts or solvates.
[0017] In one specific embodiment, a compound according to formula (Ia) is provided, including its stereoisomers:
[0018]
[0019] in:
[0020] “m”, “n”, R 1 -R 4 And R' is as defined with respect to equation (I),
[0021] Or its pharmaceutically acceptable salts or solvates.
[0022] The compounds according to the invention are particularly advantageous because they exhibit improved properties compared to USP7 inhibitors described in the art.
[0023] WO2018 / 073602 describes a USP7 inhibitor with the following structure:
[0024]
[0025] (Comparative Example 226 in WO2018 / 073602).
[0026] The compounds of the present invention differ from those of the comparative embodiments in at least the fact that the pendant morpholinoyl ring in formula (I) is C-linked instead of N-linked, and is linked to a phenyl group at the 4 (para) position instead of the 3 (meta) position.
[0027] Compared to Comparative Example 226, the compounds according to the invention exhibit improved USP7 inhibition. This is especially true when USP7 involvement is used as a cellular target to determine USP7 inhibition (Table 1).
[0028] Table 1
[0029]
[0030]
[0031] Compared with existing USP7 compounds, the compounds of the present invention also exhibit improved solubility and microparticle stability (Table 2).
[0032] Table 2
[0033]
[0034] Therefore, the present invention provides novel USP7 inhibitor compounds with improved properties compared to compounds in the prior art.
[0035] This invention includes all the described aspects and preferred features in combination, unless such combination is expressly prohibited or explicitly avoided. Attached Figure Description
[0036] Schemes and experiments illustrating the principles of the invention will now be discussed with reference to the accompanying drawings, in which:
[0037] Figure 1 An electron density map is shown, determined by a crystal structure derived from USP7 and an inhibitor according to the invention, as illustrated in the examples below. Figure 1 (a) is the initial Fo-Fc differential electron density plot (outline at 3.0σ) of the model obtained after refining the initial model before modeling the compound using BUSTER. It shows the region of the compound binding site in chain B. For clarity, the final refined coordinates are also shown; Figure 1 (b) is the final 2Fo-Fc electron density map (outline of 1.5σ) obtained by refining the final model using BUSTER. It shows the region of the compound binding site.
[0038] Figure 2 The overall structure of USP7 combined with the inhibitor according to the present invention is shown. Detailed Implementation
[0039] Aspects and embodiments of the invention will now be discussed with reference to the accompanying drawings. Other aspects and embodiments will be apparent to those skilled in the art. All references herein are incorporated by way of citation.
[0040] Unless otherwise defined herein, scientific and technical terms used in conjunction with this invention shall have the meanings commonly understood by one of ordinary skill in the art. The meanings and scopes of terms should be clear; however, in the event of any potential ambiguity, the definitions provided herein shall prevail over any dictionary or external definitions.
[0041] As used in the specification and appended claims, unless otherwise stated, the following terms have indicative meanings:
[0042] The term "alkyl" (alone or in combination with other terms) refers to a straight-chain or branched saturated hydrocarbon substituent that typically contains 1 to 15 carbon atoms, such as 1 to 10, 1 to 8, 1 to 6, or 1 to 4 carbon atoms. "C n "Alkyl" refers to an aliphatic group containing n carbon atoms. For example, C1-C 10 Alkyl groups contain 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms. The connection to the alkyl group occurs through the carbon atom. Examples of such substituents include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, pentyl (branched or unbranched), hexyl (branched or unbranched), heptyl (branched or unbranched), octyl (branched or unbranched), nonyl (branched or unbranched), and decyl (branched or unbranched).
[0043] The term "alkenyl" (alone or in combination with other terms) refers to a substituent containing one or more double bonds and typically 2 to 15 carbon atoms; such as a straight-chain or branched hydrocarbon substituent with 2 to 10, 2 to 8, 2 to 6, or 2 to 4 carbon atoms. Examples of such substituents include ethenyl, 1-propenyl, 3-propenyl, 1,4-pentadienyl, 1,4-butadienyl, 1-butenyl, 2-butenyl, 3-butenyl, pentenyl, and hexenyl.
[0044] The term "alkynyl" (alone or in combination with other terms) refers to a substituent containing one or more triple bonds and typically 2 to 15 carbon atoms; such as a straight-chain or branched hydrocarbon substituent with 2 to 10, 2 to 8, 2 to 6, or 2 to 4 carbon atoms. Examples of such substituents include ethynyl, 1-propynyl, 3-propynyl, 1-butynyl, 3-butynyl, and 4-butynyl.
[0045] The term "cycloalkyl" (alone or in combination with other terms) refers to a saturated cyclic hydrocarbon substituent containing 3 to 14 carbon ring atoms. A cycloalkyl group can be a monocyclic ring, typically containing 3 to 8 carbon ring atoms, and more commonly 3 to 6 ring atoms. It should be understood that the ring atoms are linked to the cycloalkyl group via the cycloalkyl group. Examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl. Alternatively, a cycloalkyl group can be polycyclic or contain more than one ring. Polycyclic cycloalkyl groups include bridged cycloalkyl, fused cycloalkyl, and spirocycloalkyl groups.
[0046] The term "aryl" (alone or in combination with other terms) refers to an aromatic carbocyclic group containing 6 to 14 carbon ring atoms, optionally 6 to 8, 6 to 7, or optionally 6 carbon ring atoms. "C n "Aryl" refers to an aromatic group containing n carbon atoms. For example, C6-C 10 The aryl group contains 6, 7, 8, 9, or 10 carbon atoms. The linkage with the aryl group occurs through the carbon atoms. The aryl group can be monocyclic or polycyclic (i.e., containing more than one ring). In the case of polycyclic aromatic rings, only one ring in the polycyclic system is required to be unsaturated, while the remaining rings can be saturated, partially saturated, or unsaturated. The linkage with the aryl group occurs through the carbon atoms contained in the ring. Examples of aryl groups include phenyl, naphthyl, acridine, indenyl, indenyl, and tetrahydronaphthyl. Preferably, the aryl group is phenyl.
[0047] The term "arylalkyl" refers to an aryl substituent linked via an alkyl chain. Examples of arylalkyl substituents include phenethyl / ethylbenzyl, where the ethyl chain links the phenyl group to the linking point. In "C n "In arylalkyl groups, C n This includes carbon atoms in alkyl chains and aryl groups. For example, ethylbenzene is a C8 arylalkyl group.
[0048] The term "arylalinyl" refers to an aryl substituent linked via an alkenyl chain. Examples of arylalinyl substituents include phenylvinyl / vinylbenzyl, where the vinyl chain links the phenyl group to the linking point. In "C..." n "In arylalkyl groups, C n This includes carbon atoms in alkyl chains and aryl groups. For example, phenyl vinyl is a C8 aryl alkenyl group.
[0049] The term "heteroaryl" (alone or in combination with other terms) refers to an aromatic heterocyclic group containing 5 to 14 ring atoms. "C" n "Heteroaryl" refers to an aromatic group containing n carbon atoms and at least one heteroatom. For example, C2-C 10The aryl group contains 2, 3, 4, 5, 6, 7, 8, 9, or 10 carbon atoms in addition to at least one heteroatom. The connection to the heteroaryl group occurs through carbon atoms or through heteroatoms. The heteroaryl group can be monocyclic or polycyclic. It can be monocyclic or composed of two or three fused rings. Examples of monocyclic heteroaryl groups include 6-membered rings such as pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, and 1,3,5-triazinyl, 1,2,4-triazinyl, or 1,2,3-triazinyl; and 5-membered rings such as imidazolyl, furanyl, thiophene, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, or 1,3,4-oxadiazolyl and isothiazolyl. Polycyclic heteroaryl groups can be composed of two or three fused rings. Examples of polycyclic heteroaryl groups include 6 / 5-membered fused ring groups, such as benzothiofuranyl, benzoisoxazolyl, benzoxazolyl, and purine; and 6 / 6-membered fused ring groups, such as benzopyranyl, quinolinyl, isoquinolinyl, cenolinyl, quinazolinyl, and benzoxazinyl. In the case of polycyclic heteroaryl groups, only one ring in the polycyclic system is required to be unsaturated, while the remaining rings can be saturated, partially saturated, or unsaturated.
[0050] The term "amino" refers to the -NR'R" group. The amino group can be substituted or unsubstituted. In an unsubstituted amino group, R' and R" are hydrogen. In a substituted amino group, R' and R" can each independently be, but are not limited to, hydrogen, alkyl, heteroalkyl, cycloalkyl, heterocycloalkyl, alkylcycloalkyl, alkylheteroalkyl, alkoxy, sulfonyl, alkenyl, alkanoyl, aryl, arylalkyl, or heteroaryl, provided that R' and R" are not simultaneously hydrogen. In a substituted amino group, R' and R" can cyclize to form a heterocyclic group (e.g., a pyrrolidinyl group) comprising the nitrogen to which they are attached. The heterocyclic group formed by R' and R" may optionally include additional heteroatoms, such as nitrogen or oxygen (e.g., the NR'R" group can form morpholine or piperazine). The heterocyclic group formed by R' and R" can be monocyclic, polycyclic (e.g., bicyclic), spirocyclic, or bridged cyclic (e.g., a diazabicyclo[3.2.1]octyl group). This cyclic amino group can be optionally substituted, for example, by an amino, methyl, hydroxyl, or oxo group.
[0051] The term "hydroxyl group" refers to the -OH group.
[0052] The term "oxo group" refers to an O group, which is a substituent oxygen atom connected to another atom via a double bond. For example, a carbonyl group (-C(=O)-) is a carbon atom connected to an oxygen atom via a double bond, i.e., an oxo group attached to a carbon atom.
[0053] The term "halogen group" refers to a group selected from chlorine, fluorine, bromine, and iodine. Preferably, the halogen group is selected from chlorine and fluorine.
[0054] The term "optionally substituted" means that the group may be substituted by one or more identical or different substituents, or that the group may not have any substituents. The term "optionally monosubstituted" means that the group may have a single substituent or may be unsubstituted.
[0055] Substituents can be linked to carbon atoms and / or heteroatoms in alkyl, alkenyl, cycloalkyl, aryl, or other groups. The term "substituent" (or "radical") includes, but is not limited to, alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, alkenyl, substituted alkenyl, ynyl, substituted ynyl, halogen, hydroxyl, cyano, amino, amide, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, nitro, thio, alkanoyl, carboxyl, alkoxycarbonyl, and oxo.
[0056] In some respects, the substituents are alkyl, substituted alkyl, arylalkyl, substituted arylalkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, halogen, hydroxyl, cyano, amino, amide, cycloalkyl, substituted cycloalkyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, nitro, thio, alkylacyl, carboxyl, alkoxycarbonyl, and oxo.
[0057] In some embodiments, each of one or more substituents of any optionally substituted group is independently selected from OH, F, Cl, Br, I, CN, C1-C6 alkyl, CF3, CHF2, CH2F, CH2OH, C(O)CH3, CH2NHC(O)OCH2CH3, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, C1-C6 alkoxy, amino, C1-C6 alkylamine, C5-C6 aryl, C3-C6 heteroaryl, benzyl, oxo, and amide, or two adjacent substituents may together form a ring.
[0058] If a group is substituted by another optionally substituted group, it should be understood that the first substituted group itself can be unsubstituted or substituted.
[0059] For completeness, it should also be noted that some chemical formulas used herein define delocalized systems. This definition is known in the art as the definition of aromaticity and can indicate, for example, the existence of planar monocyclic, bicyclic, or tricyclic systems containing (4n+2) electrons (where n is an integer). In other words, these systems can exhibit Hückel aromaticity.
[0060] In any respect, the compounds of the present invention may possess a certain aspect of stereochemistry. For example, the compounds may have a chiral center and / or a planar and / or symmetry axis. Unless otherwise stated, the compounds according to the present invention cover all such stereoisomers. Therefore, unless otherwise stated, the compounds may be provided as a single stereoisomer, a single diastereomer, a mixture of stereoisomers, or as a racemic mixture. Stereoisomers known in the art are molecules having the same molecular formula and bonded atomic sequence but with different spatial orientations of their atoms and / or groups.
[0061] Furthermore, the compounds of the present invention can exhibit tautomerism. Each tautomer is intended to fall within the scope of the present invention.
[0062] In addition, the compounds of the present invention can be provided as prodrugs. Prodrugs are generally converted from one form to the active form of the drug described herein in vivo.
[0063] Furthermore, it should be understood that the elements described herein can be common isotopes or isotopes other than common isotopes. For example, a hydrogen atom can be... 1 H, 2 H (deuterium) or 3 H (tritium).
[0064] In addition, the compounds of the present invention may be provided in the form of their pharmaceutically acceptable salts or as cocrystals.
[0065] The term "pharmaceutically acceptable salt" refers to an ionic compound formed by the addition of an acid to a base. This term also refers to salts deemed suitable in the art for use in contact with patients, such as those that are pharmaceutically acceptable and are generally selected due to their non-toxic and non-irritating characteristics.
[0066] The term "eutectic" refers to a multicomponent molecular crystal that may contain nonionic interactions.
[0067] Pharmaceutically acceptable salts and cocrystals can be prepared by ion exchange chromatography, or by reacting the free base or acid form of the compound with a stoichiometric amount or an excess of the desired salt-forming inorganic or organic acid or base in one or more suitable solvents, or by mixing the compound with another pharmaceutically acceptable compound capable of forming a cocrystal.
[0068] Salts known in the art as generally suitable for use in patient contact include salts derived from inorganic and / or organic acids, including hydrobromides, hydrochlorides, sulfates, hydrogen sulfates, nitrates, acetates, oxalates, oleates, palmitates, stearates, laurates, benzoates, lactates, phosphates, toluenesulfonates, citrates, maleates, fumarates, succinates, and tartrates. These may include alkali metal and alkaline earth metal-based cations such as sodium, potassium, calcium, and magnesium, as well as ammonium, tetramethylammonium, and tetraethylammonium. Further reference has been made to numerous literature sources investigating suitable pharmaceutically acceptable salts, such as the Handbook of Medicinal Salts published by IUPAC.
[0069] In addition, the compounds of the present invention may sometimes exist as zwitterions, which is considered part of the present invention.
[0070] Therefore, in a first aspect of the invention, compounds according to formula (I) are provided, including their stereoisomers:
[0071]
[0072] in:
[0073] “m” is 0, 1, or 2, and each R 1 Independently selected from: halogenated groups; C1-C6 alkyl groups optionally substituted with halogenated groups; and C3-C6 cycloalkyl groups;
[0074] “n” is 0, 1, or 2, and each of R is a finite number of 2. 2 The group is independently selected from optionally substituted C1-C6 alkyl groups, optionally substituted C3-C6 cycloalkyl groups, wherein each of one or more optional substituents is independently selected from C1-C6 alkyl groups, and a halogen group.
[0075] Or where “n” is 2 and each R2 is combined with one or more carbon ring atoms to which they are connected to form a C3-C6 fused cycloalkyl ring, a C3-C6 spirocycloalkyl ring, or a C3-C4 bridge;
[0076] R' is H or a C1-C6 alkyl group, optionally H;
[0077] R 3 Selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted C7-C 10 arylalkyl, optionally substituted C8-C10 arylalenyl and optionally substituted C3-C6 heteroaryl; wherein each of one or more optional substituents is independently selected from: halogen; C1-C6 alkyl optionally substituted with halogen; and C3-C6 cycloalkyl optionally substituted with methyl or CF3;
[0078] R4 It is H, Cl, or C1-C6 alkyl;
[0079] One of X and Z is O and one of X and Z is NR', such that the ring containing X and Z is a morpholine ring, wherein R' is H or a C1-C6 alkyl group, optionally H;
[0080] Or its pharmaceutically acceptable salts or solvates.
[0081] According to equation (I), when it exists, each R 1 and R 2 Any carbon atom that can be attached to its corresponding ring.
[0082] According to equation (I), when “m” is 2, each R 1 The substituents are independently selected from the listed options and therefore can be the same as or different from each other. Similarly, when "n" is 2, each R 2 The substituents are independently selected from the listed options and therefore may be the same as or different from each other.
[0083] In a preferred embodiment, a compound according to formula (Ia) is provided, including its stereoisomers:
[0084]
[0085] in:
[0086] “m”, “n”, R 1 -R 4 R' is defined above with respect to equation (I),
[0087] Or its pharmaceutically acceptable salts or solvates.
[0088] In some embodiments of formula (I) or formula (Ia), R' is preferably H.
[0089] In an alternative implementation of equation (I), X is NR' and Z is O.
[0090] In some preferred embodiments of formula (I) or formula (Ia), "m" is zero or 1. In some such embodiments, "m" is zero – that is, the benzene ring is unsubstituted. In some alternative embodiments, "m" is 1 – that is, the benzene ring is monosubstituted.
[0091] In the implementation where "m" is 1, R 1 Selected from: halogenated groups; C1-C6 alkyl groups optionally substituted with halogenated groups; and C3-C6 cycloalkyl groups. In some such embodiments, R 1Selected from fluorine, chlorine, C3-C6 cycloalkyl, and optionally fluorine-substituted C1-C6 alkyl, such as methyl or CF3. In some preferred embodiments, R 1 Selected from: Cl; F; and methyl groups optionally substituted with F, optionally CF3. In some preferred embodiments, R 1 It is Cl or F. In some preferred embodiments, R 1 It is a methyl group optionally substituted with F. In some preferred embodiments, R 1 It's CF3.
[0092] In some preferred embodiments, when R 1 When present as a single substituent, it is located at the 3-position of the benzene ring. That is, preferably, the compound of the present invention is according to formula (Ib):
[0093]
[0094] Where “m” is 0 or 1, and the remaining integers are as defined with respect to equation (I).
[0095] In some embodiments, a preferred combination of features of formulas (Ia) and (Ib) is used such that Z is NH, X is O, and when R 1 When present as a single substituent, it is located at the 3-position of the benzene ring. That is, certain preferred compounds of the present invention are compounds according to formula (Ic):
[0096]
[0097] Where “m” is 0 or 1, and the remaining integers are as defined with respect to equation (I).
[0098] In certain preferred embodiments across all aspects (including formulas (I), (Ia), (Ib), (Ic), and (Id)), “n” is 1 or 2. Alternatively, in some embodiments, “n” is zero, and the morpholine ring has no R. 2 Substituents. In some preferred embodiments, "n" is 1. In some preferred embodiments, "n" is 2.
[0099] In some implementations, when "n" is 2, each R 2 The substituents are located at the same positions on the morpholino group ring. Alternatively, when "n" is 2, each R... 2 Substituents can be located at different positions on the morpholino group ring.
[0100] As those skilled in the art will understand, and in accordance with IUPAC convention, the ring atoms of the morpholine ring are always numbered starting with the oxygen atom. In the numbering used herein, the direction of numbering is such that the junction of the morpholine ring and the benzene ring has the lowest possible number. Therefore, for compounds where Z is NR' and X is O, the ring atom numbering is as follows:
[0101]
[0102] For compounds where Z is O and X is NR', the ring atom numbering is as follows:
[0103]
[0104] The references to substituents at certain positions on the morpholino group ring in this article can be explained accordingly.
[0105] In some preferred embodiments, when "n" is 1 or 2, at least one R 2 The substituent is located at the 6-position of the morpholino ring. In a preferred embodiment of this type, each R 2 The substituent is located at the 6 position of the morpholino group ring.
[0106] In some implementations, when "n" is 1 or 2, at least one R 2 The group is located at the 2 position of the morpholino ring. In some preferred embodiments of this type, each R 2 The substituent is located at the 2 position of the morpholino group ring.
[0107] In some implementations, when "n" is 1 or 2, at least one R 2 The group is located at the 5-position of the morpholino ring. In some preferred embodiments, each R 2 The substituent is located at the 5 position of the morpholino group ring.
[0108] In some implementations, "n" is two and each R 2 Connected to the same carbon ring atom. In some alternative embodiments, "n" is two and each R 2 It is attached to different carbon ring atoms, such as adjacent carbon ring atoms.
[0109] In certain preferred embodiments across all aspects, R 2 Independently selected from: methyl groups optionally substituted with F; ethyl groups; and cyclopropyl groups. In some such embodiments, R 2 Selected from methyl, CHF2, CF3, ethyl, and cyclopropyl. In some embodiments, R 2 It is methyl. In some embodiments, "n" is dimethyl and each R 2It is a methyl group. In some such embodiments, each methyl group is attached to the same carbocyclic atom. In some such embodiments, each methyl group is attached to the 6-position of the morpholine ring. Alternatively, each methyl group may be attached to a different carbocyclic atom.
[0110] Alternatively, in some implementations, "n" is one and R 2 It is a methyl group.
[0111] In certain implementations across all aspects (including formulas (I), (Ia), (Ib), (Ic), and (Id)), R 2 The presence of a substituent results in a chiral center at the carbon atom of the morpholino ring to which it is attached. In some preferred embodiments of this type, R 2 The substituent is located at the R position. In some alternative and preferred embodiments, R 2 The substituent is located at the S position.
[0112] For example, in some implementations of equation (Ic), where n is 1 and R 2 Located at position 6 of the morpholine ring, this invention covers the area according to formula (Ic). I (Ic) ii (Ic) iii Or (Ic) iv Compounds of any one of them:
[0113]
[0114] Where m, R 1 R 2 R 3 and R 4 As defined in equation (Ic); where R 2 Preferably, it is independently selected from: methyl, CHF2, CF3, ethyl, and cyclopropyl. In some such embodiments, R 2 Preferably, it is methyl, ethyl, or cyclopropyl. In some such embodiments, R 2 It is methyl. In some such embodiments, R 2 It is an ethyl group.
[0115] In some implementations, "n" is 2 and each R 2 They combine with one or more carbon ring atoms to form C3-C6 spirocyclic cycloalkyl rings. In some preferred embodiments, "n" is 2 and each R 2 They combine with the carbon ring atoms to which they are attached to form C3 or C4 spirocyclic cycloalkyl rings. In some preferred embodiments of this kind, "n" is 2 and each R 2 Combine to form:
[0116]
[0117] In some such implementations, Z is NR' and X is O. Or, X is NR' and Z is O.
[0118] In some preferred embodiments, "n" is 2 and each R 2 They combine with the carbon ring atoms to which they are attached to form C3-C6 fused cycloalkyl rings.
[0119] In some such implementations, two R 2 The substituent is located on an adjacent carbon ring atom.
[0120] In some implementations, "n" is 2 and each R 2 They combine with the carbon ring atoms to which they are attached to form C3, C5, or C6 fused cycloalkyl rings. In some such embodiments, each R 2 Combining to form a C3 fused cycloalkyl ring. In some such embodiments, each R 2 Combining to form a C5 fused cycloalkyl ring. In some such embodiments, each R 2 Combining to form a C6 fused cycloalkyl ring.
[0121] In some implementations, "n" is 2 and each R 2 Combine to form:
[0122]
[0123] In some such implementations, Z is NR' and X is O. Or, X is NR' and Z is O.
[0124] In some implementations, "n" is 2 and each R 2 Combine to form:
[0125]
[0126] In some such implementations, Z is NR' and X is O. Or, X is NR' and Z is O.
[0127] In some implementations, "n" is 2 and each R 2 Combine to form:
[0128]
[0129] In some such implementations, Z is NR' and X is O. Or, X is NR' and Z is O.
[0130] In some implementations, "n" is 2 and each R 2They combine with the carbon ring atoms to which they are attached to form C3 or C4 bridged rings. In some embodiments, "n" is 2 and each R 2 They combine with the carbon ring atoms they are attached to to form C4 bridged rings.
[0131] In some implementations, "n" is 2 and each R 2 They combine with the carbon ring atoms to form:
[0132]
[0133] According to all aspects (including equations (I), (Ia), (Ib), (Ic), and (Id)), R 3 Selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted C7-C 10 arylalkyl, optionally substituted C8-C 10 Aryl alkenyl and optionally substituted C3-C6 heteroaryl; wherein each of one or more optional substituents is independently selected from: halogen; C1-C6 alkyl optionally substituted with a halogen; and C3-C6 cycloalkyl optionally substituted with methyl or CF3.
[0134] In some implementation schemes (including formulas (I), (Ia), (Ib), (Ic), and (Id)), R 3 Selected from optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted C7-C 10 arylalkyl, optionally substituted C8-C 10 Aryl alkenyl and optionally substituted C3-C6 heteroaryl; wherein each of one or more optional substituents is independently selected from: halogen; C1-C6 alkyl optionally substituted with a halogen; and C3-C6 cycloalkyl optionally substituted with methyl or CF3.
[0135] In some implementations, R 3 It is an optionally substituted C3-C6 cycloalkyl group. In some such embodiments, each of one or more optional substituents is independently selected from: a halogen; a C1-C2 alkyl group optionally substituted with F; and a C3-C6 cycloalkyl group.
[0136] In some implementations, R 3 It is an optionally substituted cyclopropyl group. In some such embodiments, each of the one or more optional substituents is independently selected from methyl, CHF2, CF3, and cyclopropyl. In some embodiments, R 3 It is an optionally substituted cyclopropyl group, wherein one or more optional substituents are methyl. In some embodiments, R 3It is an optionally substituted cyclopropyl group, wherein one or more optional substituents are CHF2. In some embodiments, R 3 It is an optionally substituted cyclopropyl group, wherein one or more optional substituents are CF3. In some embodiments, R 3 It is an optionally substituted cyclopropyl group, wherein one or more of the optional substituents is cyclopropyl.
[0137] In some implementations, R 3 It is a optionally substituted cyclopropyl group, with the general formula:
[0138] Where R 5 and R 6 Each is independently selected from hydrogen, halogenated groups; C1-C2 alkyl groups optionally substituted with F; and C3-C6 cycloalkyl groups.
[0139] In other words, in some embodiments, the compound of the present invention may be according to formula (Id):
[0140]
[0141] Where R 5 and R 6 As defined now and the remaining integers as defined with respect to equations (I), (Ia), (Ib), or (Ic).
[0142] R 5 and R 6 These are substituents as defined above, and each is independently selected from hydrogen, halogroups; C1-C2 alkyl groups optionally substituted with F; and C3-C6 cycloalkyl groups. In some embodiments, R... 5 and R 6 Each is independently selected from hydrogen, methyl, CHF2, CF3 and cyclopropyl.
[0143] In some implementation schemes, R 5 Selected from hydrogen, methyl, CHF2, and CF3. In some embodiments, R 5 Selected from hydrogen, methyl, and CF3. In some embodiments, R 5 Selected from hydrogen and CF3. In some embodiments, R 5 It is hydrogen. In some implementations, R 5 It's CF3.
[0144] In some implementation schemes, R 6 Selected from hydrogen, methyl, CHF2, CF3, and cyclopropyl. In some embodiments, R 6 Selected from methyl and cyclopropyl. In some embodiments, R 6 It is a methyl group.
[0145] In compounds of formula (Id), R 5 and / or R 6 The presence of a substituent can lead to the formation of a chiral center at the relevant cyclopropyl ring carbon. In some such embodiments, R 5 The substituent is of the R configuration. In some alternative embodiments, R... 5 The substituent is of the S configuration. In some such embodiments, R 6 The substituent is of the R configuration. In some alternative embodiments, R... 6 The substituent is in the S configuration.
[0146] For example, in some embodiments of formula (Id), the compound may be according to formula (Id). i (Id) ii (Id) iii Or (Id) iv Compounds of any one of them:
[0147]
[0148] In some other implementations (i.e., implementations of formulas (I), (Ia), (Ib), or (Ic), R 3 It is an optionally substituted phenyl group. In some such embodiments, each of one or more optional substituents is independently selected from: a halogen; a C1-C2 alkyl group optionally substituted with F; and a C3-C6 cycloalkyl group optionally substituted with methyl or CF3.
[0149] In some implementations, R 3 It is an optionally substituted phenyl group, wherein each of one or more optional substituents is independently selected from Cl, F, methyl, CF3, CHF2, and a cyclopropyl group optionally substituted with methyl or CF3. In some embodiments, R 3 It is an optionally substituted phenyl group, wherein one or more optional substituents are Cl. In some embodiments, R 3 It is an optionally substituted phenyl group, wherein one or more optional substituents are F. In some embodiments, R 3 It is an optionally substituted phenyl group, wherein one or more optional substituents are methyl. In some embodiments, R 3 It is an optionally substituted phenyl group, wherein one or more optional substituents are CF3. In some embodiments, R 3 It is an optionally substituted phenyl group, wherein one or more optional substituents are CHF2. In some embodiments, R 3 It is an optionally substituted phenyl group, wherein one or more optional substituents are cyclopropyl groups optionally substituted with methyl groups. In some embodiments, R3 It is an optionally substituted phenyl group, wherein one or more of the optional substituents is a cyclopropyl group optionally substituted with CF3.
[0150] In some implementations, R 3 It is an optional replacement of C7-C 10 Arylalkyl. In some such embodiments, each of one or more optional substituents is independently selected from: a halogen; a C1-C6 alkyl group optionally substituted with a halogen; and a C3-C6 cycloalkyl group optionally substituted with a methyl group or CF3.
[0151] In some implementations, R 3 It is optionally substituted (CH2)2-phenyl. In some such embodiments, each of one or more optional substituents is independently selected from: a halogen; a C1-C6 alkyl group optionally substituted with a halogen; and a C3-C6 cycloalkyl group optionally substituted with a methyl or CF3 group. In some embodiments, R 3 R3 is an optionally substituted (CH2)2-phenyl, wherein one or more optional substituents are a halogen group. In some embodiments, R3 is an optionally substituted (CH2)2-phenyl, wherein one or more optional substituents are a C1-C6 alkyl group optionally substituted with a halogen group, such as CHF2 or CF3. In some embodiments, R... 3 It is an optionally substituted (CH2)2-phenyl, wherein one or more optional substituents are C3-C6 cycloalkyl groups (e.g., cyclopropyl) optionally substituted with methyl. In some embodiments, R 3 It is an optionally substituted (CH2)2-phenyl, wherein one or more optional substituents are C3-C6 cycloalkyl groups (e.g., cyclopropyl) optionally substituted with CF3.
[0152] In some implementations, R 3 It is an optionally substituted (CH2)2-phenyl, wherein one or more optional substituents are on the ethylene chain. In some such embodiments, the optional substituents on the ethylene chain are selected from: methyl or ethyl, optionally substituted with F.
[0153] In some implementations, R 3 It is an optionally substituted (CH2)2-phenyl, wherein one or more optional substituents are on the ethylene chain and are selected from methyl, CHF2, and CF3. In some such embodiments, the optional substituent is CHF2. In some such embodiments, the optional substituent is CF3.
[0154] In some preferred embodiments, when R 3When it is optionally substituted (CH2)2-phenyl, the optional substituent on the ethylene chain is located on the second methylene group – i.e., R 3 Yes: -CH2-CHR-Ph, where "R" is an optional substituent.
[0155] In some such implementations, R 3 Substituents on the ethylene chain result in a chiral center at the carbon atom of the chain. In some preferred embodiments, the compound is the R stereoisomer at this position. In some alternative embodiments, the compound is the S stereoisomer at this position.
[0156] Preferably, when R 3 When it is an arylalkyl group, each of one or more optional substituents of the arylalkyl group is independently selected from F, Cl, methyl, ethyl, CHF2 and CF3.
[0157] According to all aspects (including equations (I), (Ia), (Ib), (Ic), and (Id)), R 4 Selected from H, Cl and C1-C6 alkyl groups.
[0158] In some implementations, R 4 It is chlorine.
[0159] In some alternative implementations, R 4 It is a C1-C6 alkyl group. For example, R 4 It can be H or methyl.
[0160] In certain embodiments across all aspects (including formulas (I), (Ia), (Ib), (Ic), and (Id)), the chiral center of the morpholinyl ring carbon linked to the benzene ring is located at the R position. In embodiments across all aspects (including formulas (I), (Ia), (Ib), (Ic), and (Id)), the chiral center of the morpholinyl ring carbon linked to the benzene ring is located at the S position. That is, the present invention covers compounds with the general formula:
[0161]
[0162] According to the first aspect, a compound (or a pharmaceutically acceptable salt or solvate thereof) is also provided:
[0163] Racemic-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0164] Racemic-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,5S)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0165] 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(3-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0166] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0167] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0168] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2S,3S)-2-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0169] 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0170] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2R,3R)-2-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0171] Racemic-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6R)-6-(trifluoromethyl)morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0172] 6-Chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0173] 6-Chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0174] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0175] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0176] 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0177] 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0178] 6-Chloro-7-(4-(5,5-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0179] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(5,5-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0180] Racemic-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0181] 7-(4-(7-oxa-4-azaspiro[2.5]oct-5-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0182] 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0183] 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0184] 6-Chloro-3-((1-(2,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0185] (S)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0186] 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0187] 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0188] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,5S)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0189] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,5R)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0190] (S)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0191] (R)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0192] 6-Chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0193] 6-Chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0194] 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0195] 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0196] (R)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0197] 6-Chloro-3-((1-(3-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0198] 6-Chloro-3-((1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0199] 6-Chloro-3-((1-(3,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0200] 6-Chloro-3-((1-(3-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0201] 6-Chloro-3-((1-(2,3-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0202] (S)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0203] (R)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0204] 3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0205] 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0206] 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0207] 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0208] 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0209] 7-(4-((1R,2S,5S)-8-oxa-3-azabicyclo[3.2.1]oct-2-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0210] 7-(4-((1R,2S,5S)-8-oxa-3-azabicyclo[3.2.1]oct-2-yl)phenyl)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0211] 6-Chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0212] 6-Chloro-3-((1-(3-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0213] 6-Chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0214] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(octahydro-2H-benzo[b][1,4]oxazin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0215] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(octahydrocyclopenta[b][1,4]oxazin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0216] 6-Chloro-3-((4-hydroxy-1-(4-methylbenzoyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0217] 6-Chloro-3-((4-hydroxy-1-(4-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0218] 6-Chloro-3-((1-(2-chloro-4-methylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0219] 6-Chloro-3-((1-(2,4-dimethylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0220] 6-Chloro-3-((1-(2,4-dimethylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0221] 7-(4-(2-oxa-5-azabicyclo[4.1.0]hept-4-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0222] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-cyclopropylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0223] 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0224] 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0225] 6-Chloro-3-((1-cinnamyl-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0226] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-cyclopropylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0227] 6-Chloro-3-((4-hydroxy-1-(4-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0228] 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0229] 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0230] 6-Chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0231] 6-Chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0232] 6-Chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0233] 6-Chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0234] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0235] 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0236] (S)-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0237] (R)-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0238] 6-Chloro-7-(3-fluoro-4-(morpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0239] (S)-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0240] (R)-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0241] 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(4-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0242] (S)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0243] (R)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0244] 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0245] (S)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0246] (R)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0247] 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0248] 6-Chloro-3-((1-((R)-4,4-difluoro-3-phenylbutyryl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0249] 6-Chloro-3-((4-hydroxy-1-(1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0250] 6-Chloro-3-((4-hydroxy-1-(1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0251] 6-Chloro-3-((1-((R)-4,4-difluoro-3-phenylbutyryl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0252] 6-Chloro-7-(3-Chloro-4-((S)-morpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0253] 6-Chloro-7-(3-Chloro-4-((R)-morpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0254] 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)-3-(trifluoromethyl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0255] 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)-3-(trifluoromethyl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0256] 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(morpholin-2-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0257] 6-Chloro-3-((1-(4-chloro-2-methylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0258] 6-Chloro-3-((1-(4-chloro-2-methylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0259] 6-Chloro-3-((1-(4-(difluoromethyl)benzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0260] 6-Chloro-3-((1-(4-(difluoromethyl)benzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0261] 6-Chloro-3-((1-(4-cyclopropylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0262] 6-Chloro-3-((4-hydroxy-1-(4-(1-methylcyclopropyl)benzoyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0263] 6-Chloro-3-((1-((1S,2S)-1,2-dimethylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0264] 6-Chloro-3-((1-((1R,2R)-1,2-dimethylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0265] 7-(4-((1S,2R,5R)-8-oxa-3-azabicyclo[3.2.1]oct-2-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0266] (R)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0267] (S)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0268] 6-Chloro-3-((1-(2,2-dicyclopropylacetyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0269] 6-Chloro-7-(4-((3R,6S)-6-cyclopropylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0270] 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0271] 6-Chloro-3-((4-hydroxy-1-(1-methylcyclobutane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0272] 6-Chloro-3-((1-(3-cyclopropylpropionyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0273] 6-Chloro-7-(4-((3S,6R)-6-cyclopropylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0274] 6-Chloro-7-(4-((3S,6R)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0275] 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0276] 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0277] 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0278] 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0279] 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0280] 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0281] 6-Chloro-3-((1-((1S,2S)-2-(difluoromethyl)-1-methylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one,
[0282] and
[0283] 6-Chloro-3-((1-((1R,2R)-2-(difluoromethyl)-1-methylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one.
[0284] In some embodiments, the compounds of the present invention are effective against USP7 IC. 50 The values are from about 1 nM to about 10,000 nM, more preferably from about 1 nM to about 1,000 nM, or from about 100 nM to about 1,000 nM, or from about 100 nM to about 500 nM, or from about 100 nM to about 300 nM, or from about 100 nM to about 250 nM. In some preferred embodiments, the compounds of the present invention have an IC value of USP7. 50 The value is less than 500 nM, with an optimal value less than 250 nM. The following describes an IC50 assay for determining the susceptibility of a compound to USP7. 50 The method for setting values (see examples).
[0285] In some embodiments, a compound of formula (I), (Ia), (Ib), (Ic) or (Id) according to the first aspect is provided, or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.
[0286] Although the compounds of the present invention can be administered alone, they are preferably presented as pharmaceutical formulations (e.g., compositions, formulations, pharmaceutical preparations) comprising at least one USP7 inhibitor as described herein and one or more other pharmaceutically acceptable ingredients well known to those skilled in the art, including pharmaceutically acceptable carriers, diluents, excipients, adjuvants, fillers, buffers, preservatives, antioxidants, lubricants, stabilizers, solubilizers, surfactants (e.g., wetting agents), masking agents, colorants, flavoring agents, and sweeteners. Formulations may also contain other active agents, such as other therapeutic or preventative agents.
[0287] Therefore, in a second aspect, the present invention provides a pharmaceutical composition comprising a compound according to any embodiment of the first aspect, such as a compound of formula (I), (Ia), (Ib), (Ic) or (Id), or a pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.
[0288] Pharmaceutical compositions can be formulated, depending on their specific use and purpose, by mixing, for example, excipients, binders, lubricants, disintegrants, coating materials, emulsifiers, suspending agents, solvents, stabilizers, absorption enhancers, and / or ointment bases. The compositions are suitable for oral, injectable, rectal, topical buccal, sublingual, transmucosal, transdermal, intranasal, pulmonary, ocular, vaginal, or parenteral administration.
[0289] Suitable carriers, diluents, excipients, etc., can be found in standard drug descriptions, for example, Remington' sPharmaceuticalSciences , 18th edition, Mack Publishing Company, Easton, Pa., 1990; and Han dbookofPharmaceuticalExcipients , 5th edition, 2005.
[0290] Therefore, those skilled in the art know suitable pharmaceutically acceptable excipients, such as: fats, water, physiological saline, alcohol (e.g., ethanol), glycerol, polyols, aqueous glucose solutions, expanders, disintegrants, binders, lubricants, wetting agents, stabilizers, emulsifiers, dispersants, preservatives, sweeteners, colorants, flavorings or aromas, concentrates, diluents, buffers, solvents or solubilizers, chemicals for achieving storage effects, salts for altering osmotic pressure, coating agents or antioxidants, sugars such as lactose or glucose; starch from corn, wheat or rice; fatty acids such as stearic acid; inorganic salts such as magnesium aluminosilicate or anhydrous calcium phosphate; synthetic polymers such as polyvinylpyrrolidone or polyalkylene glycols; alcohols such as stearyl alcohol or benzyl alcohol; synthetic cellulose derivatives such as methylcellulose, carboxymethylcellulose, ethylcellulose or hydroxypropyl methylcellulose; and other conventionally used additives such as gelatin, talc, vegetable oils and gum arabic.
[0291] For example, the pharmaceutical composition can be administered orally, such as in the form of tablets, coated tablets, hard or soft gelatin capsules, solutions, emulsions, or suspensions. It can also be administered rectally, such as with suppositories, topically or transdermally, such as with ointments, creams, gels, or solutions, or parenterically, such as with injectable solutions.
[0292] Formulations can be prepared using any method well-known in the pharmaceutical field. These methods involve the step of binding a compound to a carrier that constitutes one or more auxiliary components. Generally, formulations are prepared by uniformly and tightly binding a compound to a carrier (e.g., a liquid carrier, a finely divided solid carrier, etc.), and then shaping the product if desired.
[0293] For the preparation of tablets, coated tablets, or hard gelatin capsules, the compounds of the present invention can be mixed with pharmaceutically inert, inorganic, or organic excipients. Examples of suitable excipients include lactose, corn starch or derivatives thereof, talc, or stearic acid or salts thereof. Suitable excipients for use with soft gelatin capsules include, for example, vegetable oils, waxes, fats, and semi-solid or liquid polyols.
[0294] For the preparation of solutions and syrups, excipients include, for example, water, polyols, sucrose, invert sugar, and glucose.
[0295] For injectable solutions, excipients include, for example, water, alcohol, polyol, glycerin, and vegetable oil.
[0296] For suppositories and for topical and transdermal applications, excipients include, for example, natural or hardened oils, waxes, fats, and semi-solid or liquid polyols.
[0297] The pharmaceutical composition may also contain preservatives, solubilizers, stabilizers, wetting agents, emulsifiers, sweeteners, colorants, flavor enhancers, buffers, coating agents, and / or antioxidants.
[0298] For combination therapy, the second drug may be provided in the form of the pharmaceutical composition of the present invention, or it may be provided alone.
[0299] Therefore, pharmaceutical preparations for oral administration can be, for example, granules, tablets, sugar-coated tablets, capsules, pills, suspensions, or emulsions. For parenteral injections intended for, for example, intravenous, intramuscular, or subcutaneous use, a sterile aqueous solution containing other substances, such as saline and / or glucose, can be provided to make the solution isotonic. Anticancer agents can also be administered in the form of suppositories or vaginal suppositories, or topically in the form of lotions, solutions, creams, ointments, or powders.
[0300] In a third aspect, the present invention provides a compound or pharmaceutical composition for treatment, preferably for treating and / or preventing cancer, according to any embodiment of the first or second aspect.
[0301] In a fourth aspect, the present invention provides a method for treating or preventing cancer, comprising administering to a subject a compound according to any embodiment of the first aspect of the invention or a pharmaceutical composition according to any embodiment of the second aspect of the invention.
[0302] As used herein, the term "treatment" in the context of treating a condition generally refers to the treatment of a person or animal (e.g., in veterinary applications) to achieve some desired therapeutic effect, such as inhibiting the progression of the condition, and includes reducing the rate of progression, stopping the rate of progression, alleviating symptoms, improving the condition, and curing the condition. It also includes treatment as a preventative measure (i.e., prevention). For example, the term "treatment" includes use with patients who have not yet developed the condition but are at risk of developing it. For example, treatment includes preventing cancer, reducing cancer incidence, alleviating cancer symptoms, etc.
[0303] Subjects / patients can be mammals, chordates, vertebrates, placental mammals, marsupials (e.g., kangaroos, wombats), monotremes (platypuses), rodents (e.g., guinea pigs, hamsters, rats, mice), murines (e.g., mice), lagomorphs (e.g., rabbits), birds (e.g., birds), canines (e.g., dogs), felines (e.g., cats), equines (e.g., horses), suidae (e.g., pigs), oviidae (e.g., sheep), bovids (e.g., cattle), primates, apes (e.g., monkeys or apes), monkeys (e.g., marmosets, baboons), apes (e.g., gorillas, chimpanzees, orangutans, gibbons), or humans. Furthermore, subjects / patients can be in any developmental stage, such as a fetus.
[0304] In the preferred embodiment, the subject / patient is a human being.
[0305] Cancers or neoplasms suitable for treatment or prevention using these methods include, for example, prostate cancer, colon cancer, breast cancer, lung cancer, kidney cancer, skin cancer (e.g., melanoma), liver cancer, pancreatic cancer, central nervous system cancers (e.g., neuroblastoma, glioblastoma), osteosarcoma, and hematologic malignancies (e.g., leukemia, multiple myeloma, and mantle cell lymphoma). In some preferred embodiments, the cancer is associated with p53 dysregulation. In some preferred embodiments, the cancer is selected from hematologic malignancies (e.g., mantle cell lymphoma, multiple myeloma), prostate cancer, neuroblastoma, or glioblastoma.
[0306] Cancers or tumors suitable for treatment with the compounds or compositions according to the present invention include, for example: prostate cancer, colon cancer, breast cancer, lung cancer, kidney cancer, skin cancer (e.g., melanoma), liver cancer, pancreatic cancer, central nervous system cancers (e.g., neuroblastoma, glioblastoma), osteosarcoma, and hematologic malignancies (e.g., leukemia, multiple myeloma, and mantle cell lymphoma). In some preferred embodiments, the cancer is associated with p53 dysregulation. In some preferred embodiments, the cancer is selected from hematologic malignancies (e.g., mantle cell lymphoma, multiple myeloma), prostate cancer, neuroblastoma, or glioblastoma.
[0307] WO2021 / 161047 demonstrates that USP7 inhibitors can treat cancer by influencing the tumor microenvironment (TME), for example, by inhibiting USP7 in fibroblasts. The contents and publication of WO2021 / 161047 are explicitly incorporated herein by reference.
[0308] Therefore, this article provides a method for treating cancer by inhibiting USP7 activity in fibroblasts, the method comprising administering to a subject in need a composition comprising the compound provided herein or a pharmaceutically acceptable salt or solvate thereof.
[0309] In some embodiments, administration of the compounds provided herein or their pharmaceutically acceptable salts or solvates thereof treats cancer by inhibiting USP7 activity in cancer-associated fibroblasts (CAFs).
[0310] In some embodiments, administration of the compounds provided herein or pharmaceutically acceptable salts or solvates thereof treats cancer by reducing VEGF levels in the serum of a subject. In some embodiments, administration of the compounds provided herein or pharmaceutically acceptable salts or solvates thereof treats cancer by reducing VEGF levels in the tumor microenvironment.
[0311] In some embodiments, administration of the compounds provided herein or their pharmaceutically acceptable salts or solvates treats cancer by inhibiting VEGF production by cancer-associated fibroblasts (CAFs).
[0312] On the other hand, a method for treating cancer by modulating the tumor immune environment is provided, the method comprising administering to a subject in need a compound provided herein or a pharmaceutically acceptable salt or solvate thereof, wherein the administration of the compound modulates the tumor immune environment.
[0313] On the other hand, a method for treating cancer by increasing tumor-infiltrating lymphocytes (TILs) is provided, the method comprising administering to a subject in need a compound provided herein or a pharmaceutically acceptable salt or solvate thereof, wherein the administration of the compound increases the number of TILs, preferably CD8+TILs.
[0314] On the other hand, a method for treating cancer by reducing the ratio of Treg cells to CD8+ T cells in the TME is provided, the method comprising administering to a subject in need a compound provided herein or a pharmaceutically acceptable salt or solvate thereof, wherein the administration of the compound reduces the ratio of Treg cells to CD8+ T cells in the TME.
[0315] On the other hand, a method for treating cancer by reducing the number of macrophages in the TME is provided, the method comprising administering to a subject in need a compound provided herein or a pharmaceutically acceptable salt or solvate thereof, wherein the administration of the compound reduces the number of macrophages in the TME.
[0316] WO2021 / 161047 also demonstrates the beneficial efficacy (e.g., synergistic effect) of combining USP7 inhibitors with immune checkpoint inhibitors in cancer treatment. The contents and publication of WO2021 / 161047 are explicitly incorporated herein by reference.
[0317] On the other hand, a method is provided for treating cancer by administering a combination therapy to a subject in need, said combination therapy comprising a composition containing a compound provided herein or a pharmaceutically acceptable salt or solvate thereof, and a composition containing an immune checkpoint inhibitor.
[0318] On the other hand, a method for treating cancer is provided using the compounds provided herein or pharmaceutically acceptable salts or solvates thereof, the method comprising administering a combination therapy to a subject in need, the combination therapy comprising a composition containing the compounds provided herein or pharmaceutically acceptable salts or solvates thereof, and a composition containing an immune checkpoint inhibitor.
[0319] On the other hand, an immune checkpoint inhibitor is provided as a method for treating cancer, the method comprising administering a combination therapy to a subject in need, the combination therapy comprising a composition containing a compound provided herein or a pharmaceutically acceptable salt or solvate thereof, and a composition containing an immune checkpoint inhibitor.
[0320] On the other hand, a combination therapy is provided for treating cancer, the method comprising administering the combination therapy to a subject in need, the combination therapy comprising a composition containing a compound provided herein or a pharmaceutically acceptable salt or solvate thereof, and a composition containing an immune checkpoint inhibitor.
[0321] In some embodiments, administration of the compounds provided herein or their pharmaceutically acceptable salts or solvates treats cancer by inhibiting extracellular matrix (ECM) remodeling of cancer-associated fibroblasts. In such embodiments, the ECM is the ECM of the tumor microenvironment.
[0322] In some embodiments, administration of the compounds provided herein or their pharmaceutically acceptable salts or solvates treats cancer by inhibiting the degradation of the basement membrane (optionally inhibiting the degradation of tubular basement membranes).
[0323] In some embodiments, administration of the compounds provided herein or their pharmaceutically acceptable salts or solvates treats cancer by inhibiting angiogenesis (optionally inhibiting new blood vessel formation). In such embodiments, angiogenesis in the tumor microenvironment is inhibited.
[0324] In some embodiments, administration of the compounds provided herein or their pharmaceutically acceptable salts or solvates treats cancer by modulating the tumor immune environment (e.g., by promoting the infiltration of CD8 T cells).
[0325] In some embodiments, the treated cancer is formed from cancer cells, and the cancer cells are resistant to the applied compound (or a pharmaceutically acceptable salt or solvate). In some embodiments, the cancer treated by the method is formed from cancer cells, and the cancer cells are resistant to USP7 inhibitors in vitro.
[0326] The compounds or compositions of the present invention can be used for monotherapy and / or combination therapy.
[0327] As already described, in some aspects, the compounds provided herein (or their pharmaceutically acceptable salts or solvates) may be administered in combination with immune checkpoint inhibitors. In some embodiments, the checkpoint inhibitor is selected from inhibitors of PD1, PD-L1, CTLA4, TIGIT, 41BB, OX40, and GITR. In some embodiments, the checkpoint inhibitor is selected from anti-PD1 antibodies, anti-PD-L1 antibodies, anti-CTLA4 antibodies, anti-41BB antibodies, anti-OX40 antibodies, anti-GITR antibodies, and anti-ICOS antibodies. In some embodiments, the checkpoint inhibitor is selected from anti-PD1 antibodies, anti-PD-L1 antibodies, and anti-CTLA4 antibodies. In some embodiments, the checkpoint inhibitor is selected from anti-PD1 antibodies and anti-PD-L1 antibodies. In some embodiments, the checkpoint inhibitor is an anti-CTLA4 antibody. In some embodiments, the checkpoint inhibitor is selected from: pembrolizumab (Keytruda). TM ), nivolumab (Opdivo) TM ), cimiprilmab (Libtayo) TM Atezolizumab (Tecentriq) TM Avelumab (Bavencio) TM Durvalumab (Imfinzi) TM ) and ipilimumab (Yervoy TM ).
[0328] Other suitable agents that can be used in combination with the compounds or compositions according to the invention include one or more anticancer agents, anti-inflammatory agents, immunomodulators, immunosuppressants, neuromodulators, antidiabetic agents, antiviral agents, antibacterial agents, and / or radiotherapy agents.
[0329] Agents used in combination with the compounds of the present invention may target the same or similar biological pathways as the compounds of the present invention, or may act on different or unrelated pathways.
[0330] Depending on the disease to be treated, multiple combination partners may be co-administered with the compounds of this invention. The second active ingredient may include, but is not limited to: alkylating agents, including cyclophosphamide, ifosfamide, thiotepa, melphalan, chloroethylnitrosourea, and bendamustine; platinum derivatives, including cisplatin, oxaliplatin, carboplatin, and saline; and antimitotic agents, including vinblastine alkaloids (vincristine, vinorelbine, and vinblastine), taxanes (paclitaxel, docetaxel), and epoetomycin. iodilone and mitotic kinase inhibitors, including aurora kinase and polo kinase; topoisomerase inhibitors, including anthracyclines, epipodophyllotoxin, camptothecin and camptothecin analogs; antimetabolites, including 5-fluorouracil, capecitabine, cytarabine, gemcitabine, 6-mercaptopurine, 6-thioguanine, fludarabine, methotrexate and pemetrexed. Exed); protein kinase inhibitors, including imatinib, gefitinib, sorafenib, sunitinib, erlotinib, dasatinib, and lapatinib; proteasome inhibitors, including bortezomib; histone deacetylase inhibitors, including valproic acid and SAHA; anti-angiogenic drugs, including bevacizumab; monoclonal antibodies, including trastuzumab, rituximab, alemtuzumab, tositumomab, cetuximab, and panitumumab; monoclonal antibody conjugates, including gestuzumab-oczomidin. ozogamicin), tiemomumab; hormone therapy, including anti-estrogens (tamoxifen, raloxifen, anastrozole, letrozole, examestane), anti-androgens (flutamide, biclutamide) and luteinizing hormone analogs or antagonists.
[0331] Those skilled in the art will understand that the appropriate dosage of the compounds of the present invention and compositions comprising said compounds may vary from patient to patient. Determining the optimal dosage will generally involve a balance between the level of therapeutic benefit and any risks or harmful side effects. The dosage for therapeutic effect may differ from the dosage required for diagnostic effect. The selected dosage level will depend on a variety of factors, including the activity of the specific compound, route of administration, time of administration, rate of excretion of the compound, duration of treatment, other drugs, compounds and / or materials used in combination, severity of the condition, and the patient's species, sex, age, weight, condition, general health status, and medical history. The amount of the compound and the route of administration will ultimately be determined by a physician, veterinarian, or clinician, but generally a dosage will be chosen to achieve a local concentration at the site of action to achieve the desired effect without causing substantial harmful side effects.
[0332] Throughout the treatment, a single dose may be administered continuously or intermittently (e.g., divided into doses at appropriate time intervals). Methods for determining the most effective manner of administration and dosage are well known to those skilled in the art and will vary depending on the formulation used for treatment, the purpose of treatment, the target cells being treated, and the subject being treated. Dosage levels and patterns may be selected by the treating physician, veterinarian, or clinician for single or multiple administrations.
[0333] Regarding aspects of the invention concerning the therapeutic use of compounds according to the invention, the compounds may be administered to a subject requiring treatment in an "effective amount." The term "effective amount" refers to the quantity or dose of a compound that provides therapeutic efficacy for a disease when administered to a subject in a single dose or multiple doses. Therapeutic effective amounts of compounds according to the invention may range from about 0.1 mg / kg to about 20 mg / kg per single dose. Healthcare professionals can determine the therapeutic effective amount for any individual patient using methods understood by those skilled in the art. The amount of compound administered at any given point in time may vary such that the optimal amount of the compound administered during the course of treatment, whether used alone or in combination with any other therapeutic agent, is considered. It is also contemplated to administer compounds according to the invention, or pharmaceutical compositions comprising such compounds, in combination with any other cancer treatment as a combination therapy.
[0334] The features expressed in the foregoing description or in the following claims or drawings, in their particular form or by means of performing the disclosed functions or by methods or processes for obtaining the disclosed results, may, where appropriate, be used alone or in any combination of such features to implement the invention in its various forms.
[0335] While the invention has been described in conjunction with the exemplary embodiments described above, many equivalent modifications and variations will be apparent to those skilled in the art when this disclosure is given. Therefore, the exemplary embodiments of the invention set forth above are to be considered illustrative rather than restrictive. Various changes may be made to the described embodiments without departing from the spirit and scope of the invention.
[0336] To avoid any doubt, any theoretical explanations provided herein are intended to enhance the reader's understanding. The inventor does not wish to be bound by any of these theoretical explanations.
[0337] Any chapter headings used in this article are for organizational purposes only and should not be construed as limiting the subject matter described.
[0338] Throughout the specification, including the appended claims, unless the context otherwise requires, the words “comprising” and “including”, as well as variations such as “containing” and “covering”, shall be understood to implicitly include the indicated integer or step or group of steps, but not exclude any other integer or step or group of steps.
[0339] It must be noted that, unless the context clearly indicates otherwise, the singular forms “a,” “an,” and “the” used in this specification and the appended claims include a plural referent. A range may be expressed herein as “about” a particular value and / or “about” another particular value. When such a range is expressed, another embodiment includes a range from one particular value and / or to another particular value. Similarly, when a value is expressed as an approximation using the antecedent “about,” it should be understood that the particular value forms another embodiment. The term “about” in relation to numerical values is optional and means, for example, + / - 10%.
[0340] Example
[0341] The invention will now be described through several embodiments.
[0342] The examples shown below were synthesized according to the methods described subsequently. Biochemical inhibition IC 50 The values are determined as described below and are represented in the table below.
[0343]
[0344]
[0345] Table 3a. Inhibition of USP7 by the exemplified compounds.
[0346]
[0347] Table 3a (continued). Examples of the inhibitory effects of compounds on USP7.
[0348] The USP7 inhibitory activity is categorized as follows in Table 3a:
[0349]
[0350] Table 3b. Examples of the inhibitory effects of compounds on USP7.
[0351]
[0352] Table 3b (continued). Examples of the inhibitory effects of compounds on USP7.
[0353] Experimental Section
[0354] Abbreviations and Acronyms
[0355] B2Pin2: bis(pinacolyl)diboron; Boc: tert-butyloxycarbonyl; Boc2O: ditert-butyl dicarbonate; br: broad; ca: catalytic amount; Cu(OTf)2: copper(II) trifluoromethanesulfonate; DCM: dichloromethane; d: bimodal (spectral); DIPEA: diisopropylethylamine; DMAP: 4-dimethylaminopyridine; DMF: N,N-dimethylformamide; DMSO: dimethyl sulfoxide; dp: data point; Pd(dppf)Cl2·CH2Cl2: [1,1'-bis(diphenylphosphine)ferrocene]palladium(II) dichloride complex with dichloromethane; EDC: N-(3-dimethylaminopropyl)-N'-ethylcarbodiimide hydrochloride; ee: enantiomeric excess; equiv.: equivalent; EtOAc: ethyl acetate; Ex.: example; h: hour; HATU: N-[(dimethylaminopropyl)-cobalamin]-dichloromethane-cobalamin (amino)-1H-1,2,3-triazolo-[4,5-b]pyridin-1-ylmethylene]-N-methylmethylammonium hexafluorophosphate N-oxide; hept: septet (spectral); HFIP: hexafluoroisopropanol; HPLC: high-performance liquid chromatography; IPA: 2-propanol; KOAc: potassium acetate; LC: liquid chromatography; LCMS: liquid chromatography-mass spectrometry; M: molar concentration; m / z: mass-to-charge ratio; m-CPBA: 3-chloroperbenzoic acid; MeCN: acetonitrile; MeOH: methanol; min: minutes; MS: mass spectrometry; m: multiplet (spectral); MTBE: methyl tert-butyl ether; NMR: nuclear magnetic resonance; p: quintet (spectral); Ph: phenyl; ppm: parts per million; prep: preparative; q: quartet (spectral); quint: quintet (spectral); RBF: round-bottom flask; R T Retention time; rt: room temperature; s: singlet; TFA: trifluoroacetic acid; THF: tetrahydrofuran; t: triplet (spectral); UV: ultraviolet light; v / v: volume per unit volume; w / w: weight per unit weight.
[0356] General experimental conditions
[0357] Solvents and reagents
[0358] Common organic solvents used in the reaction (such as THF, DMF, DCM, and MeOH) are all derived from... Purchase and install in Sure / Seal TM In a bottle, in an anhydrous form, and appropriately treated under nitrogen. Water was deionized using Elga PURELABOption-Q. All other solvents used (i.e., those used for post-processing and purification) were generally HPLC grade and used in forms supplied from various commercial sources. Unless otherwise specified, all starting materials used were purchased from commercial suppliers and used in the form supplied.
[0359] Microwave Synthesis
[0360] Using Biotage Initiator TM Eight instruments were used for microwave experiments. The system provides good reproducibility and controllability over a temperature range of 60-250°C and a maximum pressure of 20 bar.
[0361] Rapid chromatography
[0362] Unless otherwise specified, the compounds are purified by rapid chromatography using the Biotage Isolera Four system, which employs... Silica D Duo 60μm cassette column (10-340 g), GraceGraceResolv cassette column (4-330 g), SILICYCLESiliaSep TM Cuing column (4-12 g) or SILICYCLESiliaSep PREMIUM cushion column (25-40 g). Depending on the polarity of the compound, use an appropriate gradient of cyclohexane, EtOAc, DCM, and MeOH. For compounds with stronger polarity and basicity, use... KP-Amino D cassette column (11-28 g). NMR spectrum.
[0363] Recordings were performed at ambient temperature using a Bruker Avance (300 MHz), Bruker Avance III (400 MHz), or Bruker Ascend (500 MHz) spectrometer. 11H NMR spectra. All chemical shifts (δ) are expressed in ppm. Residual solvent signals were used as internal standards, and characteristic solvent peaks were corrected to the reference data listed in J. Org. Chem., 1997, 62, pp. 7512-7515; otherwise, the NMR solvent contained tetramethylsilane used as an internal standard.
[0364] Liquid chromatography-mass spectrometry (LCMS)
[0365] The following methods were used to perform liquid chromatography-mass spectrometry (LCMS) experiments to determine the retention time (R). T and related mass ions:
[0366] Method A The system comprises an Agilent Technologies 6130 quadrupole mass spectrometer with a UV diode array detector and an autosampler connected to an Agilent Technologies 1290 Infinity LC system. The spectrometer consists of an electrospray ionization source operating in both positive and negative ion modes. LCMS experiments were performed on each submitted sample under the following conditions: LC column: Agilent Eclipse Plus C18 RRHD, 1.8 μm, 50 x 2.1 mm, maintained at 40 °C. Mobile phase: A) 0.1% (v / v) aqueous formic acid; B) 0.1% (v / v) formic acid acetonitrile solution.
[0367]
[0368] Method B The system consisted of an Agilent Technologies 6140 single quadrupole mass spectrometer connected to an Agilent Technologies 1290 Infinity LC system, equipped with a UV diode array detector and an autosampler. The spectrometer consisted of a multi-mode ionization source (electrospray and atmospheric pressure chemical ionization) operating in both positive and negative ion modes. LCMS experiments were performed on each submitted sample under the following conditions: LC column: Zorbax Eclipse Plus C18 RRHD, 1.8 μm, 50 x 2.1 mm, maintained at 40 °C. Mobile phase: A) 0.1% (v / v) aqueous formic acid; B) 0.1% (v / v) formic acid acetonitrile solution.
[0369]
[0370] Method CThe system consisted of either an Agilent Technologies 1100 series LC / MSD system with a UV diode array detector and an evaporative light scattering detector (DAD / ELSD) and an Agilent LC / MSD VL (G1956A) or SL (G1956B) mass spectrometer, or an Agilent 1200 series LC / MSD system with a DAD / ELSD and an Agilent LC / MSD SL (G6130A) or SL (G6140A) mass spectrometer. All LCMS data were obtained using atmospheric pressure chemical ionization mode, positive / negative ion mode switching, and a scan range of m / z 80-1000. LCMS experiments were performed on each submitted sample under the following conditions: LC column: Zorbax SB-C18RRHD, 1.8 μm, 4.6 x 15 mm; Mobile phase: A) 0.1% (v / v) formic acid aqueous solution; B) 0.1% (v / v) formic acid acetonitrile solution.
[0371]
[0372] Method D The system consists of a Waters QDa mass spectrometer connected to a Waters iClass UPLC system with a TUV detector. The spectrometer consists of an electrospray ionization source operating in both positive and negative ion modes. LCMS experiments were performed on each submitted sample under the following conditions: LC column: Zorbax Eclipse Plus C18RRHD, 1.8 μm, 50 x 2.1 mm, maintained at 40 °C. Mobile phase: A) 0.1% (v / v) aqueous formic acid; B) 0.1% (v / v) formic acid acetonitrile solution.
[0373]
[0374] Preparative high-performance liquid chromatography
[0375] Basic conditions : LC column: Waters XBridge TM Prep C18 5μm OBD TM A 19x50mm column was used at room temperature with the following mobile phase gradients: A) 0.1% (v / v) ammonium hydroxide aqueous solution, B) 0.1% (v / v) ammonium hydroxide in a 95:5 acetonitrile / aqueous solution.
[0376] Chiral separation of stereoisomers by supercritical fluid chromatography (SFC)
[0377] The stereoisomer mixture was separated using the following general procedure. The stereoisomer mixture was dissolved in methanol to a concentration of 50 mg / mL and purified by SFC under specified conditions. The combined fractions of each stereoisomer were evaporated to near dryness using a rotary evaporator, transferred to a final container using DCM, the DCM was removed under a compressed air stream at 40 °C, and then stored in a vacuum oven at 40 °C and 5 mbar for 16 h.
[0378] Chiral separation of stereoisomers by HPLC
[0379] The stereoisomer mixture was separated using the following general procedure. The stereoisomer mixture was dissolved in methanol to a concentration of 66 mg / mL and purified by HPLC under specified conditions. The combined fractions of each stereoisomer were evaporated to near dryness using a rotary evaporator, transferred to a final container with MeOH, and the MeOH was removed under a compressed air stream at 35 °C. The mixture was then stored in a vacuum oven at 35 °C and 5 mbar for 16 h.
[0380] Chiral purity analysis
[0381] After chiral separation of the mixture of stereoisomers, each stereoisomer is analyzed under specified conditions using the following analytical methods (SFC or HPLC) to determine its chiral purity.
[0382] Method A (HPLC) :
[0383]
[0384]
[0385] Method B (HPLC) :
[0386]
[0387] Method C (SFC) :
[0388]
[0389] Method D (HPLC) :
[0390]
[0391] Method E (SFC) :
[0392]
[0393] Method F (SFC) :
[0394]
[0395] Method G (SFC) :
[0396]
[0397] Method H (SFC) :
[0398]
[0399] Method I (SFC) :
[0400]
[0401] Method J (SFC) :
[0402]
[0403]
[0404] Method K (SFC) :
[0405]
[0406] Method L (SFC) :
[0407]
[0408] Nomenclature and Stereochemistry
[0409] Unless otherwise specified, the naming of the structures was determined using the 'Convert Structure to Name' function of ChemDraw Professional 20.1 (CambridgeSoft / PerkinElmer). The relative stereochemistry of the morpholine substituents has been specified based on literature precedents (Org. Lett. 2014, 16, 1236–1239; J. Am. Chem. Soc. 2019, 141, 9739–9745) and NMR studies. In the cases of Examples 26, 27, 61, 64, 68, and 69, these are single non-racemic diastereomers with known relative stereochemistry, but their absolute stereochemistry is unknown and has been arbitrarily specified, and therefore may be contrary to that described.
[0410] In the cases of Examples 32, 33, 62, and 66, these are single non-racemic diastereomers in which the absolute stereochemistry of the morpholine substituent is known, but the absolute stereochemistry of the cyclopropyl substituent is unknown. In the case of Example 67, this is a single non-racemic diastereomer in which the absolute stereochemistry of all three stereocenters is unknown. In the cases of Examples 32, 33, 62, 66, and 67, the relative stereochemistry of the cyclopropyl substituent is specified based on NOE experiments. Subsequently, the absolute stereochemistry of the substituents on the cyclopropane ring in Example 62 was determined by X-ray analysis of the cocrystal of Example 62 in combination with USP7. Therefore, the absolute stereochemistry of the substituents on the cyclopropane ring in the relevant Examples 32, 33, 62, 66, and 67 was determined via the cocrystal structure of Example 62 / USP7 (see Examples below). The relative stereochemistry of the more reactive cyclopropane isomers is also consistent with Examples 95 and 96. Similarly, the stereochemistry of Examples 108, 109, and 110 of the same series was determined. In the cases of Examples 23, 28, 29, 34, 40, 41, 70, 71, 73, 74, 76, 77, 79, and 80, these are single enantiomers with unknown absolute configurations, where the stereochemistry has been arbitrarily assigned and may therefore be contrary to what has been stated. In the cases of Examples 1, 2, 9, and 17, these are racemic diastereomers with known relative stereochemistry. In the cases of Examples 10, 86, and 87, these are each a 1:1 mixture of two diastereomers. In the cases of Examples 53, 54, and 60, these are unknown mixtures of diastereomers. In the cases of Examples 78, 81, 82, and 85, these are single non-racemic diastereomers, where the absolute stereochemistry of the stereocenter in the morpholine ring is unknown and has been arbitrarily assigned and may therefore be contrary to what has been stated. In the cases of Examples 83 and 84, these are diastereomeric 4:4:1:1 mixtures, wherein the absolute stereochemistry of the stereocenter in the morpholine ring is unknown and has been arbitrarily assigned, and therefore may be contrary to what has been said.
[0411] Examples 111 and 112 are named based on their respective activities.
[0412] General Procedure
[0413] General Procedure 1: HATU Coupling
[0414] Dissolve the appropriate amine or amine hydrochloride (1 equiv.), carboxylic acid (1 equiv.), and HATU (1 equiv.) in DCM, then add DIPEA (3 equiv.). Stir the reaction for the prescribed time, then quench it by adding a saturated aqueous solution of sodium bicarbonate. The resulting mixture was extracted using a phase separator and DCM (x 3). The combined organic phases were concentrated under reduced pressure, and the remaining residue was purified by rapid chromatography to obtain the product.
[0415] General Procedure 2: m-CPBA Oxidation
[0416] At room temperature or 0°C, a solution of m-CPBA (<77% w / w) (1.2 equiv.) in DCM (0.2 M) was added dropwise to a stirred solution of olefin (1 equiv.) in DCM (0.2 M) using a syringe or dropping funnel. After the addition was complete, the reaction mixture was stirred at room temperature for a specified time. Excess m-CPBA was quenched by adding a saturated aqueous sodium thiosulfate solution (approximately 0.4 mL / g m-CPBA), and the resulting mixture was then transferred to a separatory funnel containing a saturated aqueous sodium bicarbonate solution. The resulting phase mixture was extracted with DCM (x 3), and the combined organic layers were strained through... The phase separator was used, and the product was concentrated under reduced pressure. The remaining residue was purified by rapid chromatography to obtain the product.
[0417] General Procedure 3: Boration of Miyaura
[0418] A suspension of appropriate amounts of aryl bromide (1 equiv.), B2Pin2 (1.5 equiv.), Pd(dppf)Cl2·CH2Cl2 (0.1 equiv.), and KOAc (3 equiv.) in 1,4-dioxane (0.1 M) was heated and stirred for a specified time using a prescribed method. Post-treatment A: After cooling to room temperature, the reaction mixture was filtered through diatomaceous earth and the solids were washed with EtOAc. The resulting solution was concentrated under reduced pressure, and the residue was purified by rapid chromatography to obtain the product. Post-treatment B: After cooling to room temperature, the reaction mixture was concentrated under reduced pressure, and the residue was suspended in DCM. The resulting suspension was filtered through diatomaceous earth and the solids were washed with DCM. The combined filtrates were then concentrated under reduced pressure. The resulting residue was purified by rapid chromatography to obtain the product.
[0419] General Procedure 4: Chan-Lam Coupling
[0420] A suspension of appropriate NH-heterocyclic compounds (1-1.5 equiv.), appropriate arylboronic esters (1-2 equiv.), appropriate copper(II) salts (2 equiv.), 1,10-phenanthroline (2 equiv.), and boric acid (2-4 equiv.) in DMF was stirred in air at a specified temperature for a specified time. Post-treatment A: After cooling to room temperature, the reaction mixture was diluted with a 1:1 brine / water solution and extracted with EtOAc. The organic layer was washed with a 1:1 brine / water solution, dried (MgSO4), filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography to obtain the product. Post-treatment B: After cooling to room temperature, the reaction mixture was diluted with a 10% aqueous ammonium hydroxide solution and extracted with... The resulting suspension was extracted using a phase separator with DCM (x 3). The combined organic phases were concentrated under reduced pressure, and the residue was purified by rapid chromatography to obtain the product.
[0421] General Procedure 5: Hydrolysis of Chlorpyrimethamine
[0422] A mixture of chlorpyrifos (1 equiv.), aqueous sodium hydroxide solution (10-20 equiv.), and 1,4-dioxane was heated at 100 °C for a specified time. After cooling to room temperature, the reaction mixture was acidified to approximately pH 4-5 by adding a specified acid, and the product was extracted into DCM (x 3). The resulting solution was then subjected to… The phase is separated and concentrated under reduced pressure to obtain the product, which is used in the next step without further purification.
[0423] General Procedure 6: Ring-opening of the epoxide with pyrimidinone
[0424] Suspend appropriate amounts of pyrimidinone (1 equiv.), epoxide (1-1.5 equiv.), and Cs₂CO₃ (1-3 equiv.) in DMF, and heat the reaction mixture at 80 °C for a specified time. Cool the reaction to room temperature, add a saturated aqueous solution of ammonium chloride or water, and extract the resulting mixture using DCM or EtOAc (x 3). Dry the combined organic phases. The product is obtained by using a phase separator (or MgSO4), concentrating under reduced pressure, and purifying the remaining residue by rapid chromatography.
[0425] General procedure 7: Deprotection of Boc to free base
[0426] A Boc-protected amine (1 equiv.) was dissolved in DCM and TFA was added. The reaction was stirred at room temperature for a specified time, and then concentrated under reduced pressure. The remaining residue was dissolved in a mixture of MeOH and DCM and loaded onto a pre-equilibrated SCX-2 filter cartridge. The filter cartridge was washed with a 4:1 mixture of DCM / MeOH, and basic compounds were eluted with a 4:1 mixture of DCM / 7M NH3 in MeOH. The ammonia-containing fraction was concentrated to give the desired product.
[0427] General Procedure 8: Synthesis of Saturated Heterocycles Using SnAP Reagents
[0428] Add the corresponding aldehyde (1 equiv.) to the SnAP reagent (1 equiv.) solution in DCM at room temperature. Molecular sieve (approximately 100 mg / mmol). The reaction mixture was stirred at room temperature for 2 h and filtered through a short-layer diatomaceous earth filter. The resulting filtrate was concentrated under reduced pressure to obtain imines.
[0429] Separately, 2,6-dimethylpyridine (1 equiv.) was added once to a suspension of HFIP (0.25 M) and anhydrous Cu(OTf)₂ (1 equiv.). The resulting mixture was stirred at room temperature for 1 h, during which time a homogeneous suspension was formed. Imine (1 equiv.) was added once to a solution of DCM (0.0625 M), and the resulting mixture was stirred at room temperature for 12 h. The reaction was quenched with a 10% ammonium hydroxide aqueous solution at room temperature and stirred vigorously for 15 min. The layers were separated and the aqueous layer was extracted with DCM (x 3). The combined organic layers were washed with water (x 3) and brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography to obtain the product.
[0430] General Procedure 9: Boc Protection
[0431] Boc₂O (1.2 equiv.) was added to a solution of substituted morpholine (1 equiv.) in DCM. After stirring at room temperature for 18 h, the reaction mixture was concentrated under reduced pressure and the residue was purified by rapid chromatography to obtain the desired product.
[0432] General Procedure 10: Boc Protection
[0433] Boc₂O (2 equiv.) was added to a solution of substituted morpholine (1 equiv.) in MeCN. After stirring at room temperature for 18 h, the reaction mixture was concentrated under reduced pressure and the residue was purified by rapid chromatography to obtain the desired product.
[0434] General Procedure 11: EDC Coupling
[0435] EDC (1.2 equiv.) was added to a solution of the corresponding carboxylic acid (1 equiv.) in DCM (0.1 M), and the resulting mixture was stirred at room temperature for 15 min. Then, 4,5,6,7-tetrachloroisoindoline-1,3-dione (1 equiv.) and DMAP (0.1 equiv.) were added. The resulting mixture was stirred at room temperature for 18 h, and then the reaction mixture was directly purified by rapid chromatography to obtain the desired product.
[0436] Epoxide 1: (1-Methylcyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0437]
[0438] Step 1: 4-Methylenepiperidine hydrochloride: A solution of 1-N-boc-4-methylenepiperidine (1.97 g, 10 mmol) in DCM (10 mL) and a solution of 4 M hydrogen chloride in 1,4-dioxane (25 mL, 100 mmol) were stirred at room temperature for 100 min, and then concentrated under reduced pressure to give the title compound (1.34 g, quantified) as a white solid. 1 H NMR (500MHz, DMSO-d6) δ9.17 (s, 2H), 4.86 (s, 2H), 3.05 (t, J = 6.1 Hz, 4H), 2.41 (t, J = 6.1 Hz, 4H).
[0439] Step 2: (1-Methylcyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (1.34 g, 10 mmol), 1-methylcyclopropane-1-carboxylic acid (1.00 g, 10 mmol), HATU (3.80 g, 10 mmol), DIPEA (4.18 mL, 30 mmol) and DCM (100 mL), yielded the title compound (1.69 g, 94%) as a colorless oil after 1 h. 1 H NMR (500MHz, DMSO-d6) δ4.77(s,2H),3.53(t,J=6.0Hz,4H),2.15(t,J=5.9Hz,4H),1.23(s,3H),0.85–0.75(m,2H),0.59–0.49(m,2H).
[0440] Step 3: (1-Methylcyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (1-methylcyclopropyl)-(4-methylene-1-piperidinyl) methyl ketone (1.69 g, 9.43 mmol) in DCM (47 mL) at 0 °C and m-CPBA (<77% w / w) (2.54 g, 11.3 mmol) in DCM (47 mL), after 20 h at room temperature, yielded the title compound (1.51 g, 82%) as a pale yellow oil. 1 H NMR (500MHz, DMSO-d6) δ3.78–3.68(m,2H),3.62–3.47(m,2H),2.68(s,2H),1.69(ddd,J=13.1,8.6, 4.2Hz, 2H), 1.43 (ddd, J=13.3, 6.5, 3.9Hz, 2H), 1.23 (s, 3H), 0.83–0.77 (m, 2H), 0.58–0.50 (m, 2H).
[0441] Epoxide 2: (4-Chlorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0442]
[0443] Step 1: (4-Chlorophenyl)(4-Methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (267 mg, 2.00 mmol), 4-chlorobenzoic acid (313 mg, 2.00 mmol), HATU (760 mg, 2.00 mmol), DIPEA (1.05 mL, 6.00 mmol), and DCM (20 mL), yielded the title compound (405 mg, 85%) as a colorless oil after 1 h. LCMS (Method A): R T =1.41min, m / z = 236,238 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ 7.54–7.48 (m, 2H), 7.46–7.41 (m, 2H), 4.79 (s, 2H), 3.60 (br.s, 2H), 3.34 (br.s, 2H (signal overlaps with HDO)), 2.20 (br.s, 4H).
[0444] Step 2: (4-Chlorophenyl)(1-oxa-6-azaspiro[2.5]octyl-6-yl) methyl ketone: General procedure 2, using (4-chlorophenyl)-(4-methylene-1-piperidinyl) methyl ketone (405 mg, 1.72 mmol) in DCM (8.5 mL) at 0 °C and m-CPBA (<77% w / w) (462 mg, 2.06 mmol) in DCM (8.5 mL), after 20 h at room temperature, yielded the title compound (430 mg, 99%) as a colorless oil, which was cured after standing. LCMS (Method A): R T =0.99min, m / z = 252,254 [M+H] + . 1 HNMR(500MHz,DMSO-d6)δ7.54–7.48(m,2H),7.48–7.42(m,2H),3.85(br.s,1H), 3.58(br.s,1H),3.42(br.s,2H),2.69(s,2H),1.76(br.s,2H),1.47(br.s,2H).
[0445] Epoxide 3: (R)-4,4,4-trifluoro-3-phenyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)but-1- ketone
[0446]
[0447] Step 1: (R)-4,4,4-trifluoro-1-(4-methylenepiperidin-1-yl)-3-phenylbut-1-one: General procedure 1, using 4-methylenepiperidin hydrochloride (59.5 mg, 0.445 mmol), (R)-4,4,4-trifluoro-3-phenylbutyric acid (97.1 mg, 0.445 mmol), HATU (169 mg, 0.445 mmol), DIPEA (0.233 mL, 1.34 mmol), and DCM (4.5 mL), yielded the title compound (129.5 mg, 97%) as a colorless oil after 1 h at room temperature. LCMS (Method A): R T =1.54min, m / z = 298[M+H] + . 1H NMR(500MHz,DMSO-d6)δ7.45–7.39(m,2H),7.38–7.29(m,3H),4.75(s,1H),4.73(s,1H),4.16–4.07(m,1H),3.54–3.42(m,2H),3.42 –3.33(m,2H),3.20(dd,J=16.4,9.4Hz,1H),2.98(dd,J=16.4,4.2Hz,1H),2.20–2.13(m,1H),2.08–2.00(m,2H),1.98–1.91(m,1H).
[0448] Step 3: (R)-4,4,4-trifluoro-3-phenyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)but-1-one: General procedure 2, using (R)-4,4,4-trifluoro-1-(4-methylenepiperidin-1-yl)-3-phenylbut-1-one (130 mg, 0.436 mmol) in DCM (2.1 mL) at 0 °C and m-CPBA (<77% w / w) (117 mg, 0.523 mmol) in DCM (2.1 mL), after 20 h at room temperature, yielded the title compound (143 mg, 94%) as a colorless oil. LCMS (Method A): R T =1.23min, m / z = 314[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ7.46–7.40(m,2H),7.40–7.29(m,3H),4.18–4.07( m,1H),3.70–3.49(m,3H),3.44–3.34(m,1H),3.21(dd,J=16.4,9.4Hz,1H), 3.00(dd,J=16.4,4.2Hz,1H),2.70–2.59(m,2H),1.76–1.68(m,0.5H),1.6 2–1.52(m,1H),1.50–1.41(m,1H),1.36–1.29(m,1H),1.27–1.21(m,0.5H).
[0449] Epoxide 4: Phenyl(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0450]
[0451] Step 1: (4-Methylenepiperidin-1-yl)(phenyl) methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (165 mg, 1.23 mmol), benzoic acid (151 mg, 1.23 mmol), HATU (470 mg, 1.23 mmol), DIPEA (645 μL, 3.70 mmol), and DCM (11 mL), yielded the title compound (196 mg, 78%) as a white solid after 30 min. 1 HNMR (500MHz, chloroform-d) δ7.56–7.29(m,5H),4.80(s,2H),3.76(br.s,2H),3.40(br.s,2H),2.33(br.s,2H),2.18(br.s,2H).
[0452] Step 2: Phenylene(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (4-methylenepiperidin-1-yl)(phenyl) methyl ketone (196 mg, 0.974 mmol) in DCM (4.5 mL) at 0 °C and m-CPBA (<77% w / w) (164 mg, 0.733 mmol) in DCM (4.5 mL), after 20 h at room temperature, yielded the title compound (163 mg, 77%) as a colorless oil. 1 H NMR (500MHz, chloroform-d) δ 7.54–7.32 (m, 5H), 4.25 (br.s, 1H), 3.76–3.42 (br.m, 3H), 2.73 (s, 2H), 2.08–1.79 (br.m, 2H), 1.68–1.30 (br.m, 2H (signal overlaps with HDO)).
[0453] Epoxide 5: (4-Fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0454]
[0455] Step 1: (4-Fluorophenyl)(4-Methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (2.67 g, 20.0 mmol), 4-fluorobenzoic acid (2.80 g, 20.0 mmol), HATU (7.60 g, 20.0 mmol), DIPEA (10.5 mL, 60.0 mmol), and DCM (200 mL), yielded the title compound (4.31 g, 98%) as a colorless oil after 30 min. LCMS (Method A): R T =1.25min, m / z = 220[M+H] + . 1H NMR (500MHz, DMSO-d6) δ 7.51–7.45 (m, 2H), 7.31–7.24 (m, 2H), 4.79 (s, 2H), 3.59 (br.s, 2H), 3.33 (br.s, 2H (signal overlaps with HDO)), 2.20 (br.s, 4H).
[0456] Step 2: (4-Fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (4-fluorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (4.31 g, 19.7 mmol) in DCM (98 mL) at 0 °C and m-CPBA (<77% w / w) (5.29 g, 23.6 mmol) in DCM (98 mL), after 20 h at room temperature, yielded the title compound (3.74 g, 80%) as a colorless oil, which was cured after standing. LCMS (Method A): R T =0.82min, m / z = 236[M+H] + . 1 H NMR (500MHz, DMSO-d6) δ7.55–7.45(m,2H),7.31–7.24(m,2H),3.85(br.s,1H),3.70–3.33(br.m,3H),2.69(s,2H),1.76(br.s,2H),1.47(br.s,2H).
[0457] Epoxide 6: (2,4-Difluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0458]
[0459] Step 1: (2,4-Difluorophenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (134 mg, 1.00 mmol), 2,4-difluorobenzoic acid (158 mg, 1.00 mmol), HATU (380 mg, 1.00 mmol), DIPEA (523 μL, 3.00 mmol), and DCM (10 mL), yielded the title compound (146 mg, 61%) as a viscous, colorless oil after 75 min. LCMS (Method A): R T =1.31min, m / z = 238[M+H] + . 1H NMR(500MHz,DMSO-d6)δ7.54–7.46(m,1H),7.40–7.31(m,1H),7.22–7.14(m,1H),4.81(s,1 H),4.78(s,1H),3.64(br.s,2H),3.26–3.15(m,2H),2.30–2.19(m,2H),2.18–2.06(m,2H).
[0460] Step 2: (2,4-Difluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (2,4-difluorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (145 mg, 0.611 mmol) in DCM (2.7 mL) at room temperature and m-CPBA (<77% w / w) (164 mg, 0.733 mmol) in DCM (2.7 mL), after 22 h at room temperature, yielded the title compound (150 mg, 97%) as a viscous, colorless oil. LCMS (Method A): R T =0.89min, m / z = 254[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ7.58–7.48(m,1H),7.41–7.32(m,1H),7.24–7.14(m,1H),3.98–3.83(m,1H),3.69–3.56(m,1H),3.40–3.31 (m,2H),2.71(d,J=4.8Hz,1H),2.68(d,J=4.8Hz,1H),1.86–1.73(m,1H),1.73–1.62(m,1H),1.58–1.47(m,1H),1.47–1.34(m,1H).
[0461] Epoxide 7: (4-chloro-2-fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0462]
[0463] Step 1: (4-Chloro-2-fluorophenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (339 mg, 2.54 mmol), 4-chloro-2-fluorobenzoic acid (443 mg, 2.54 mmol), HATU (965 mg, 2.54 mmol), DIPEA (1.33 mL, 7.61 mmol), and DCM (20 mL), yielded the title compound (569 mg, 88%) as a colorless gel after 19 h. LCMS (Method A): R T =1.46min, m / z = 254, 256 [M+H] +.
[0464] Step 2: (4-Chloro-2-fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (4-chloro-2-fluorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (569 mg, 2.24 mmol) in DCM (22 mL) at 0 °C and m-CPBA (<77% w / w) (603 mg, 2.69 mmol) in DCM (22 mL), yielded the title compound (574 mg, 94%) as a colorless oil after 20 h at room temperature. LCMS (Method B): R T =1.06min, m / z = 270, 272 [M+H] + .
[0465] Epoxide 8: (2-Chlorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0466]
[0467] Step 1: (2-Chlorophenyl)(4-Methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (339 mg, 2.54 mmol), 2-chlorobenzoic acid (397 mg, 2.54 mmol), HATU (965 mg, 2.54 mmol), DIPEA (1.33 mL, 7.61 mmol), and DCM (20 mL), yielded the title compound (564 mg, 94%) as a colorless oil after 20 h. LCMS (Method A): R T =1.34min, m / z = 236,238 [M+H] + .
[0468] Step 2: (2-Chlorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (2-chlorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (564 mg, 2.39 mmol) in DCM (22 mL) at 0 °C and m-CPBA (<77% w / w) (644 mg, 2.87 mmol) in DCM (22 mL), yielded the title compound (530 mg, 88%) as a colorless oil after 20 h at room temperature. LCMS (Method B): R T =0.85min, m / z = 252, 254 [M+H] + .
[0469] Epoxide 9: ((1S*,2S*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(1-oxa-6-azaspiro[2.5] Oct-6-yl)methyl ketone
[0470]
[0471] Step 1: 4-Nitrophenyl(1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylate and 4-nitrophenyl(1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylate: Commercially available 1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylic acid (dr 82:18) was purified by rapid chromatography (5:95 THF in hexane) to obtain a single diastereomer. Based on NOE experiments, the major compound was designated as racemic-(1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylic acid. EDC (13.7 g, 71.4 mmol) was added to a solution of racemic-(1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylic acid (10 g, 59.5 mmol) in DMF (178.5 mL), and the resulting mixture was stirred at room temperature for 15 min. Then, 4-nitrophenol (9.93 g, 71.4 mmol) and DMAP (73 mg, 0.595 mmol) were added. The resulting mixture was stirred at room temperature for 19 h, then the reaction mixture was diluted with water and extracted with EtOAc (x3). The combined organic layers were washed with water, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography (0–20% EtOAc in hexane) to give racemic-4-nitrophenyl(1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylic acid ester (12.7 g, 74%). Racemic 4-nitrophenyl(1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylate (2 g) was resolved to a single stereoisomer by semi-preparative chiral HPLC using a Chiralpak AS-H (4.6 mm x 250 mm, 5 μm) column and isocratic solvent conditions: 95:5 hexane (0.1% v / v TFA) / IPA. The first eluted material was arbitrarily designated as 4-nitrophenyl(1S*,2S*)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylate (532 mg, recovery 26%). Chiral purity (Method A): R T = 17.06 min, 100% ee. [α] D 20 = +44.72 (c 0.25, MeOH). The second eluted material was arbitrarily designated as 4-nitrophenyl(1R*,2R*)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylate (449 mg, recovery 22%). Chiral purity (Method A): R T = 18.41 min, 97.7% ee. [α] D 20 = -43.92 (c 0.25, MeOH).
[0472] Step 2: ((1S*,2S*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone: A mixture of 4-nitrophenyl(1S*,2S*)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylate (142 mg, 0.491 mmol), 4-methylenepiperidin hydrochloride (98.4 mg, 0.737 mmol), DIPEA (257 μL, 1.47 mmol), and DMF (4.9 mL) was stirred at room temperature for 70 min. The reaction mixture was diluted with saturated sodium bicarbonate aqueous solution (30 mL) and then... The phase separator was used for extraction with DCM (3 x 20 mL). The combined organic phases were concentrated under reduced pressure and the residue was purified by rapid chromatography to give the title compound (94.6 mg, 77%) as a viscous, colorless oil. 1 H NMR (500MHz, DMSO-d6) δ4.79(s,2H),3.50(br.s,4H),2.34–2.06(m,5H),1.44–1.38(m,1H),1.38–1.32(m,3H),1.16–1.10(m,1H).
[0473] Step 3: ((1S*,2S*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using ((1S*,2S*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone (94.6 mg, 0.383 mmol) in DCM (1.9 mL) at room temperature and m-CPBA (<77% w / w) (103 mg, 0.459 mmol) in DCM (1.9 mL), after 22 h 30 min at room temperature, yielded the title compound (87 mg, 86%) as a viscous, colorless oil. LCMS (Method A, 220 nm): R T =0.99min, m / z = 264[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ3.78–3.64(m,2H),3.52(br.s,2H),2.69(s,2H),2.20–2.10( m,1H),1.72(br.s,2H),1.53–1.39(m,3H),1.38–1.35(m,3H),1.13(t,J=5.8Hz,1H).
[0474] Epoxide 10: ((1R*,2R*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(1-oxa-6-azaspiro[2.5] Oct-6-yl)methyl ketone
[0475]
[0476] Step 1: ((1R*,2R*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone: A mixture of 4-nitrophenyl(1R*,2R*)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylate (238 mg, 0.823 mmol), 4-methylenepiperidin hydrochloride (165 mg, 1.23 mmol), DIPEA (430 μL, 2.47 mmol), and DMF (8.2 mL) was stirred at room temperature for 80 min. The reaction mixture was diluted with saturated sodium bicarbonate aqueous solution (30 mL) and then... The phase separator was used for extraction with DCM (3 x 20 mL). The combined organic phases were concentrated under reduced pressure and the residue was purified by rapid chromatography to give the title compound (103 mg, 50%) as a viscous, colorless oil. 1 H NMR (500MHz, DMSO-d6) δ4.79 (s, 2H), 3.50 (s, 4H), 2.29–2.06 (m, 5H), 1.40 (dd, J = 9.5, 5.5Hz, 1H), 1.38–1.32 (m, 3H), 1.13 (t, J = 5.9Hz, 1H).
[0477] Step 2: ((1R*,2R*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using ((1R*,2R*)-1-methyl-2-(trifluoromethyl)cyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone (102 mg, 0.413 mmol) in DCM (2 mL) at room temperature and m-CPBA (<77% w / w) (111 mg, 0.495 mmol) in DCM (2 mL), after 22 h at room temperature, yielded the title compound (107.9 mg, 99%) as a viscous, colorless oil. LCMS (Method A, 220 nm): R T =1.00min(220nm),m / z=264[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ3.78–3.64(m,2H),3.53(br.s,2H),2.69(s,2H),2.20–2.10( m,1H),1.72(br.s,2H),1.56–1.38(m,3H),1.38–1.31(m,3H),1.13(t,J=5.9Hz,1H).
[0478] Epoxide 11: (3-Chlorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0479]
[0480] Step 1: (3-Chlorophenyl)(4-Methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (339 mg, 2.54 mmol), 3-chlorobenzoic acid (397 mg, 2.54 mmol), HATU (965 mg, 2.54 mmol), DIPEA (1.33 mL, 7.61 mmol), and DCM (20 mL), yielded the title compound (520 mg, 86%) as a colorless oil after 20 h. LCMS (Method B): R T =1.41min, m / z = 236,238 [M+H] + .
[0481] Step 2: (3-Chlorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (3-chlorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (520 mg, 2.21 mmol) in DCM (10 mL) at 0 °C and m-CPBA (<77% w / w) (593 mg, 2.65 mmol) in DCM (10 mL), yielded the title compound (445 mg, 80%) as a colorless oil after 20 h at room temperature. LCMS (Method B): R T =0.98min, m / z = 252,254[M+H] + .
[0482] Epoxide 12: (2-Fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0483]
[0484] Step 1: (2-Fluorophenyl)(4-Methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (339 mg, 2.54 mmol), 2-fluorobenzoic acid (355 mg, 2.54 mmol), HATU (965 mg, 2.54 mmol), DIPEA (1.33 mL, 7.61 mmol), and DCM (5 mL), yielded the title compound (501 mg, 90%) as a viscous, colorless oil after 20 h. LCMS (Method A): R T =1.24min, m / z = 220[M+H] + .
[0485] Step 2: (2-Fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (2-fluorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (501 mg, 2.29 mmol) in DCM (10 mL) at room temperature and m-CPBA (<77% w / w) (615 mg, 2.74 mmol) in DCM (10 mL), yielded the title compound (501 mg, 93%) as a colorless oil after 20 h at room temperature. LCMS (Method A): R T =0.80min, m / z = 236[M+H] + .
[0486] Epoxide 13: (3,4-Difluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0487]
[0488] Step 1: (3,4-Difluorophenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (339 mg, 2.54 mmol), 3,4-difluorobenzoic acid (401 mg, 2.54 mmol), HATU (965 mg, 2.54 mmol), DIPEA (1.33 mL, 7.61 mmol), and DCM (15 mL), yielded the title compound (533, 88%) as a colorless gel after 19 h. LCMS (Method A): R T =1.32min, m / z = 238[M+H] + .
[0489] Step 2: (3,4-Difluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (3,4-difluorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (533 mg, 2.25 mmol) in DCM (10 mL) at 0 °C and m-CPBA (<77% w / w) (604 mg, 2.70 mmol) in DCM (10 mL), after 20 h at room temperature, yielded the title compound (533 mg, 93%) as a colorless oil. LCMS (Method B): R T =0.91min, m / z = 254[M+H] + .
[0490] Epoxide 14: (3-Fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0491]
[0492] Step 1: (3-Fluorophenyl)(4-Methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (134 mg, 1.00 mmol), 3-fluorobenzoic acid (140 mg, 1.00 mmol), HATU (380 mg, 1.00 mmol), DIPEA (523 μL, 3.00 mmol), and DCM (10 mL), yielded the title compound (178 mg, 81%) as a viscous, colorless oil after 19 h. LCMS (Method A): R T =1.27min, m / z = 220[M+H] + .
[0493] Step 2: (3-Fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (3-fluorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (178 mg, 0.812 mmol) in DCM (4 mL) at room temperature and m-CPBA (<77% w / w) (218 mg, 0.974 mmol) in DCM (4 mL), yielded the title compound (183 mg, 95%) as a colorless solid after 18 h at room temperature. LCMS (Method A): R T =0.85min, m / z = 236[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ7.54–7.45(m,1H),7.41–7.09(m,3H),3.87(br.s,1H),3.59(br .s,1H),3.40(br.s,2H),2.69(s,2H),1.77(br.s,2H),1.50(br.s,1H),1.43(br.s,1H).
[0494] Epoxide 15: (2,3-Difluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0495]
[0496] Step 1: (2,3-Difluorophenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (339 mg, 2.54 mmol), 2,3-difluorobenzoic acid (401 mg, 2.54 mmol), HATU (965 mg, 2.54 mmol), DIPEA (1.33 mL, 7.61 mmol), and DCM (15 mL), yielded the title compound (504 mg, 83%) as a white solid after 19 h. LCMS (Method A): R T =1.31min, m / z = 238[M+H] + .
[0497] Step 2: (2,3-Difluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (2,3-difluorophenyl)(4-methylenepiperidin-1-yl) methyl ketone (504 mg, 2.12 mmol) in DCM (10 mL) at 0 °C and m-CPBA (<77% w / w) (571 mg, 2.55 mmol) in DCM (10 mL), after 20 h at room temperature, yielded the title compound (501 mg, 93%) as a colorless oil. LCMS (Method B): R T =0.89min, m / z = 254[M+H] + .
[0498] Epoxide 16: [1,1'-bi(cyclopropane)]-1-yl(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0499]
[0500] Step 1: [1,1'-Bi(cyclopropane)]-1-yl(4-methylenepiperidin-1-yl) methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (267 mg, 2.00 mmol), [1,1'-Bi(cyclopropane)]-1-carboxylic acid (252 mg, 2.00 mmol), DIPEA (1.05 mL, 6.00 mmol), HATU (760 mg, 2.00 mmol), and DCM (20 mL), yielded the title compound (392 mg, 95%) as a colorless oil after 19 h at room temperature. 1 H NMR(500MHz,DMSO-d6)δ4.78(s,2H),3.57(br.s,4H),1.16(tt,J=8.3,5.1Hz,1H),2.25– 2.07(m,4H),0.73–0.65(m,2H),0.52–0.42(m,2H),0.42–0.34(m,2H),0.15–0.05(m,2H).
[0501] Step 2: [1,1'-Bi(cyclopropane)]-1-yl(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using [1,1'-bi(cyclopropane)]-1-yl(4-methylenepiperidin-1-yl) methyl ketone (392 mg, 1.91 mmol) in DCM (9.5 mL) at 0 °C and m-CPBA (<77% w / w) (514 mg, 2.29 mmol) in DCM (9.5 mL), after 20 h at room temperature, yielded the title compound (421 mg, 90%) as a colorless oil. LCMS (Method A): R T =0.79min, m / z = 222[M+H] + .1 H NMR(500MHz,DMSO-d6)δ3.78(br.s,2H),3.59(br.s,2H),2.68(s,2H),1.80–1.60(m,2H),1.51–1.38( m,2H),1.20–1.13(m,1H),0.74–0.69(m,2H),0.50–0.44(m,2H),0.43–0.35(m,2H),0.17–0.08(m,2H).
[0502] Epoxide 17: (1-oxa-6-azaspiro[2.5]oct-6-yl)(p-tolyl) methyl ketone
[0503]
[0504] Step 1: (4-Methylenepiperidin-1-yl)(p-Tolyl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (668 mg, 5.00 mmol), 4-methylbenzoic acid (681 mg, 5.00 mmol), HATU (1.90 g, 5.00 mmol), DIPEA (2.61 mL, 15.0 mmol), and DCM (50 mL), yielded the title compound (940 mg, 87%) as a colorless oil after 1 h. LCMS (Method A): R T =1.36min, m / z = 216[M+H] + . 1 H NMR (500MHz, DMSO-d6) δ 7.30 (d, J = 8.0Hz, 2H), 7.25 (d, J = 7.8Hz, 2H), 4.78 (s, 2H), 3.58 (br.s, 2H), 3.34 (br.s, 2H (signal overlaps with HDO)), 2.34 (s, 3H), 2.19 (br.s, 4H).
[0505] Step 2: (1-oxa-6-azaspiro[2.5]oct-6-yl)(p-tolyl) methyl ketone: General procedure 2, using (4-methylenepiperidin-1-yl)(p-tolyl) methyl ketone (940 mg, 4.37 mmol) in DCM (22 mL) at 0 °C and m-CPBA (<77% w / w) (1.17 g, 5.24 mmol) in DCM (22 mL), after 19 h at room temperature, yielded a colorless oily title compound (984 mg, 97%), which was cured after standing. LCMS (Method A): R T =0.93min, m / z = 232[M+H] + . 1H NMR (500MHz, DMSO-d6) δ7.33–7.30(m,2H),7.25(d,J=7.8Hz,2H),3.98–3.33(br.m,4H),2.68(s,2H),2.34(s,3H),1.73(br.s,2H),1.46(br.s,2H).
[0506] Epoxide 18: (1-oxa-6-azaspiro[2.5]oct-6-yl)(4-(trifluoromethyl)phenyl) ketone
[0507]
[0508] Step 1: (4-Methylenepiperidin-1-yl)(4-(trifluoromethyl)phenyl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (668 mg, 5.00 mmol), 4-(trifluoromethyl)benzoic acid (951 mg, 5.00 mmol), HATU (1.90 g, 5.00 mmol), DIPEA (2.61 mL, 15.0 mmol), and DCM (50 mL), yielded the title compound (1.31 g, 97%) as a white crystalline solid after 1 h. LCMS (Method A): R T =1.48min, m / z = 270[M+H] + . 1 H NMR (500MHz, DMSO-d6) δ7.82(d,J=8.0Hz,2H),7.64(d,J=8.0Hz,2H),4.86–4.73(m,2H),3.64(s,2H),3.26(s,2H),2.27(s,2H),2.16(s,2H).
[0509] Step 2: (1-oxa-6-azaspiro[2.5]oct-6-yl)(4-(trifluoromethyl)phenyl) ketone: General procedure 2, using (4-methylenepiperidin-1-yl)(4-(trifluoromethyl)phenyl) ketone (1.31 g, 4.87 mmol) in DCM (24 mL) at 0 °C and m-CPBA (<77% w / w) (1.31 g, 5.84 mmol) in DCM (24 mL), after 19 h at room temperature, yielded the title compound (1.29 g, 92%) as a white solid. LCMS (Method A): R T =1.12min, m / z = 286[M+H] + . 1HNMR(500MHz,DMSO-d6)δ7.82(d,J=8.0Hz,2H),7.65(d,J=7.9Hz,2H),3.99–3.82(m,1H),3.69–3.53(m,1H), 3.37(s,2H),2.76–2.65(m,2H),1.90–1.78(m,1H),1.78–1.67(m,1H),1.60–1.48(m,1H),1.48–1.35(m,1H).
[0510] Epoxide 19: (2-chloro-4-methylphenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0511]
[0512] Step 1: (2-Chloro-4-methylphenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (668 mg, 5.00 mmol), 2-chloro-4-methylbenzoic acid (853 mg, 5.00 mmol), HATU (1.90 g, 5.00 mmol), DIPEA (2.61 mL, 15.0 mmol), and DCM (50 mL), yielded the title compound (1.21 g, 96%) as a colorless oil after 1 h. LCMS (Method A): R T =1.48min, m / z = 250, 252[M+H] + . 1 HNMR(500MHz,DMSO-d6)δ7.37–7.35(m,1H),7.27(d,J=7.7Hz,1H),7.22(ddd,J=7.8,1.5,0.7Hz,1H),4.83–4.79(m,1H),4.7 8–4.74(m,1H),3.73–3.66(m,1H),3.65–3.54(m,1H),3.18–3.08(m,2H),2.33(s,3H),2.28–2.19(m,2H),2.19–2.04(m,2H).
[0513] Step 2: (2-Chloro-4-fluorophenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (2-chloro-4-methylphenyl)(4-methylenepiperidin-1-yl) methyl ketone (1.21 g, 4.85 mmol) in DCM (24 mL) at 0 °C and m-CPBA (<77% w / w) (1.30 g, 5.81 mmol) in DCM (24 mL), yielded the title compound (1.29 g, 92%) as a white solid after 19 h at room temperature. LCMS (Method A): R T=1.16min, m / z = 266,268 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ7.36(s,1H),7.29(t,J=7.1Hz,1H),7.22(d,J=7.8Hz,1H),3.97–3.89 (m,0.5H),3.89–3.81(m,0.5H),3.67(ddd,J=13.0,8.5,4.0Hz,0.5H),3.58(ddd,J=12.8,8.9, 3.8Hz,0.5H),3.30–3.16(m,2H),2.74–2.68(m,1H),2.68–2.62(m,1H),2.33(s,3H),1.83(dd d, J=13.4, 8.8, 4.1Hz, 0.5H), 1.78–1.63 (m, 1.5H), 1.58–1.51 (m, 0.5H), 1.51–1.34 (m, 1.5H).
[0514] Epoxide 20: (2,4-Dimethylphenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0515]
[0516] Step 1: (2,4-Dimethylphenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (339 mg, 2.54 mmol), 2,4-dimethylbenzoic acid (401 mg, 2.54 mmol), HATU (965 mg, 2.54 mmol), DIPEA (1.33 mL, 7.61 mmol), and DCM (15 mL), yielded the title compound (572 mg, 98%) as a white solid after 19 h. LCMS (Method B): R T =1.31min, m / z = 230[M+H] + .
[0517] Step 2: (2,4-Dimethylphenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (2,4-dimethylphenyl)(4-methylenepiperidin-1-yl) methyl ketone (572 mg, 2.49 mmol) in DCM (10 mL) at 0 °C and m-CPBA (<77% w / w) (671 mg, 2.99 mmol) in DCM (10 mL), after 20 h at room temperature, yielded the title compound (519 mg, 84%) as a colorless oil. LCMS (Method A): R T =1.00min, m / z = 246[M+H] + .
[0518] Epoxide 21: 6-((4-nitrophenyl)sulfonyl)-1-oxa-6-azaspiro[2.5]octane
[0519]
[0520] Step 1: 4-Methylene-1-((4-nitrophenyl)sulfonyl)piperidine: A mixture of 4-nitrobenzenesulfonyl chloride (1.12 g, 5.07 mmol), 4-methylenepiperidine hydrochloride (678 mg, 5.074 mmol), DIPEA (2.65 mL, 15.2 mmol), and THF (50 mL) was stirred overnight at room temperature. The reaction mixture was diluted with saturated sodium bicarbonate aqueous solution (100 mL) and extracted with DCM (3 x 100 mL). The combined organic phases were concentrated under reduced pressure, and the residue was purified by rapid chromatography to give the title compound (1.43 mg, 99%) as a white solid. LCMS (Method B): R T =1.34 min, no mass ions were observed. 1 ¹H NMR (500MHz, chloroform-d) δ 8.43–8.32 (m, 2H), 8.00–7.88 (m, 2H), 4.80–4.69 (m, 2H), 3.20–3.06 (m, 4H), 2.39–2.26 (m, 4H).
[0521] Step 2: 6-((4-nitrophenyl)sulfonyl)-1-oxa-6-azaspiro[2.5]octane: General procedure 2, using 4-methylene-1-((4-nitrophenyl)sulfonyl)piperidine (1.43 g, 5.07 mmol) in DCM (50 mL) at 0 °C and m-CPBA (<77% w / w) (1.36 g, 6.08 mmol) in DCM (50 mL) for 20 h at room temperature to obtain the title compound. LCMS (Method B): R T =1.07 min, no mass ions were observed. 1 ¹H NMR (500MHz, chloroform-d) δ 8.48–8.34 (m, 2H), 8.04–7.91 (m, 2H), 3.72–3.57 (m, 2H), 2.92 (td, J = 11.3, 3.2 Hz, 2H), 2.68 (s, 2H), 2.17–2.01 (m, 2H), 1.51–1.41 (m, 2H).
[0522] Epoxide 22: (R)4,4-difluoro-3-phenyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)but-1-one
[0523]
[0524] Step 1: (R)-4,4-difluoro-1-(4-methylenepiperidin-1-yl)-3-phenylbut-1-one: General procedure 1, using 4-methylenepiperidin hydrochloride (138 mg, 1.03 mmol), (R)-4,4-difluoro-3-phenylbutyric acid (207 mg, 1.03 mmol), HATU (393 mg, 1.03 mmol), DIPEA (0.540 mL, 3.10 mmol), and DCM (10.3 mL), yielded the title compound (255 mg, 88%) as a colorless oil after 3 days. LCMS (Method A): R T =1.46min, m / z = 280[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ7.36–7.24(m,5H),6.24(td,J=56.5,3.9H,1H),4.74(d,J=6.2Hz,2H),3.71–3.59(m,1H),3 .47–3.33(m,4H),2.95(dd,J=16.2,8.2Hz,1H),2.87(dd,J=16.2,5.8Hz,1H),2.18–2.10(m,1H),2.09–1.92(m,3H).
[0525] Step 2: (R)-4,4-difluoro-3-phenyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)but-1-one: General procedure 2, using (R)-4,4-difluoro-1-(4-methylenepiperidin-1-yl)-3-phenylbut-1-one (250 mg, 0.895 mmol) in DCM (4.5 mL) at 0 °C and m-CPBA (<77% w / w) (241 mg, 1.074 mmol) in DCM (4.5 mL), after 20 h at room temperature, yielded the title compound (245 mg, 92%) as a colorless oil. LCMS (Method A): R T =1.08min, m / z = 296[M+H] + .
[0526] Epoxide 23: (1-Methyl-2-(trifluoromethyl)cyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl)methyl ketone
[0527]
[0528] Step 1: (1-Methyl-2-(trifluoromethyl)cyclopropyl)(4-methylenepiperidin-1-yl)methyl ketone: HATU (11.3 g, 29.8 mmol) and DIPEA (18.1 mL, 104 mmol) were sequentially added to a stirred solution of 1-methyl-2-(trifluoromethyl)cyclopropane-1-carboxylic acid (4:1 diastereomer mixture, 5.00 g, 29.8 mmol) in DMF (25 mL) at room temperature. After stirring for 3 min at room temperature, 4-methylenepiperidin hydrochloride (3.97 g, 29.8 mmol) was added in a single addition, and the resulting mixture was stirred overnight at room temperature. The reaction mixture was poured into 150 mL of water and extracted with EtOAc (3 x 100 mL). The combined organic layers were washed with water and brine. The organic layer was dried over Na2SO4, filtered, concentrated under reduced pressure, and the product was dried (0.1 mbar / 50 °C, 5 h) to give the title compound (6.69 g, 91%). This material was used in the next step without purification.
[0529] Step 2: (1-Methyl-2-(trifluoromethyl)cyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (1-methyl-2-(trifluoromethyl)cyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone (4:1 mixed diastereomers, 6.69 g, 27.1 mmol) in DCM (200 mL) at 0 °C, and adding solid m-CPBA (<70% w / w) (7.84 g, 3.5 mmol), yielded the title compound (4.42 g, 62%) as a yellow oil after 1 h at room temperature. LCMS (Method C): R T =0.95min, m / z = 264[M+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 1.08 (t, J = 5.9 Hz, 1H), 1.40–1.54 (m, 6H), 1.79–1.93 (m, 3H), 2.72 (s, 2H), 3.27–3.74 (m, 2H), 3.89–4.09 (m, 2H).
[0530] Epoxide 24: (4-chloro-2-methylphenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0531]
[0532] Step 1: (4-Chloro-2-methylphenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (356 mg, 2.66 mmol), 4-chloro-2-methylbenzoic acid (455 mg, 2.66 mmol), HATU (1.01 g, 2.66 mmol), DIPEA (1.39 mL, 7.99 mmol), and DCM (20 mL), yielded the title compound (548 mg, 82%) as a white solid after 20 h. LCMS (Method A): R T =1.34min, m / z = 250, 252 [M+H] + .
[0533] Step 2: (4-Chloro-2-methylphenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (4-chloro-2-methylphenyl)(4-methylenepiperidin-1-yl) methyl ketone (545 mg, 2.18 mmol) in DCM (10 mL) at 0 °C and m-CPBA (<77% w / w) (587 mg, 2.62 mmol) in DCM (10 mL), yielded the title compound (554 mg, 95%) as a colorless oil after 20 h at room temperature. LCMS (Method B): R T =1.04min, m / z = 266,268 [M+H] + .
[0534] Epoxide 25: (4-(difluoromethyl)phenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0535]
[0536] Step 1: (4-(difluoromethyl)phenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (372 mg, 2.78 mmol), 4-(difluoromethyl)benzoic acid (479 mg, 2.78 mmol), HATU (1.06 g, 2.78 mmol), DIPEA (1.45 mL, 8.35 mmol), and DCM (20 mL), yielded the title compound (595 mg, 85%) as a white solid after 20 h. LCMS (Method A): R T =1.20min, m / z = 252[M+H] + .
[0537] Step 2: (4-(difluoromethyl)phenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (4-(difluoromethyl)phenyl)(4-methylenepiperidin-1-yl) methyl ketone (595 mg, 2.37 mmol) in DCM (10 mL) at 0 °C and m-CPBA (<77% w / w) (637 mg, 2.84 mmol) in DCM (10 mL), yielded the title compound (581 mg, 91%) as a colorless oil after 20 h at room temperature. LCMS (Method B): R T =0.91min, m / z = 268[M+H] + .
[0538] Epoxide 26: (4-Cyclopropylphenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone
[0539]
[0540] Step 1: (4-Cyclopropylphenyl)(4-Methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (1.00 g, 7.49 mmol), 4-cyclopropylbenzoic acid (1.26 g, 7.77 mmol), HATU (2.85 g, 7.49 mmol), DIPEA (3.91 mL, 22.5 mmol), and DMF (12 mL), yielded the title compound (1.33 g, 71%) as a pale yellow oil after 20 h. LCMS (Method C): R T =1.26min, m / z = 242[M+H] + . 1 H NMR (400MHz, chloroform-d) δ7.31(d,J=7.4Hz,2H),7.09(d,J=7.2Hz,2H),4.79(s,2H),3.72(br.s,2H),3. 45(br.s,2H),2.25(br.s,4H),1.91(tt,J=8.6,4.9Hz,1H),1.09–0.93(m,2H),0.81–0.61(m,2H).
[0541] Step 2: (4-Cyclopropylphenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (4-cyclopropylphenyl)(4-methylenepiperidin-1-yl) methyl ketone (1.33 g, 5.52 mmol) in DCM (50 mL) at 0 °C and m-CPBA (<70% w / w) (1.50 g, 6.08 mmol) in DCM (50 mL), after 20 h at room temperature, yielded the title compound (653 mg, 46%) as a pale yellow oil. LCMS (Method C): R T=1.21min, m / z = 258[M+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.32 (d, J = 7.8Hz, 2H), 7.09 (d, J = 7.8Hz, 2H), 4.35–4.07 (m, 1H), 3.81–3.45 (m, 3H), 2.73 (s, 2H), 2.07–1.76 (m, 3H), 1.53–1.32 (m, 2H), 1.08–0.91 (m, 2H), 0.79–0.62 (m, 2H).
[0542] Epoxide 27: (4-(1-methylcyclopropyl)phenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0543]
[0544] Step 1: (4-(1-Methylcyclopropyl)phenyl)(4-methylenepiperidin-1-yl)methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (1.63 g, 12.2 mmol), 4-(1-methylcyclopropyl)benzoic acid (2.16 g, 12.2 mmol), HATU (4.64 g, 12.2 mmol), DIPEA (5.10 mL, 36.6 mmol), and DMF (18 mL), yielded the title compound (2.31 g, 74%) as a pale yellow oil after 20 h. LCMS (Method C): R T =1.34min, m / z = 256[M+H] + . 1 H NMR (400MHz, chloroform-d) δ7.33(d,J=7.9Hz,2H),7.26(d,J=7.7Hz,2H),4.79(s,2H),3.68(br.s ,2H),3.49(br.s,2H),2.25(br.s,4H),1.41(s,3H),0.99–0.82(m,2H),0.82–0.63(m,2H).
[0545] Step 2: (4-(1-methylcyclopropyl)phenyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (4-(1-methylcyclopropyl)phenyl)(4-methylenepiperidin-1-yl) methyl ketone (2.31 g, 9.06 mmol) in DCM (50 mL) at 0 °C and m-CPBA (<70% w / w) (1.50 g, 6.08 mmol) in DCM (50 mL), after 20 h at room temperature, yielded the title compound (1.19 g, 49%) as a pale yellow oil. LCMS (Method C): R T =1.16min, m / z = 272[M+H] +. 1 ¹H NMR (400MHz, chloroform-d) δ 7.31 (d, J = 8.5Hz, 2H), 7.24 (d, J = 8.5Hz, 2H), 4.35–4.04 (m, 1H), 3.79–3.46 (m, 3H), 2.71 (s, 2H), 2.03–1.72 (m, 2H), 1.62–1.32 (m, 5H), 0.90–0.83 (m, 2H), 0.78–0.72 (m, 2H). 1 H NMR (400MHz, chloroform-d) δ7.34(d,J=8.3Hz,2H),7.26(d,J=8.1Hz,2H),4.22(br.s,1H),3.65(br.s,1H),3.60–3. 36(m,2H),2.73(s,2H),1.89(br.s,2H),1.49(br.s,2H),1.41(s,3H),0.99–0.83(m,2H),0.83–0.65(m,2H).
[0546] Epoxide 28: ((1S,2S)-1,2-dimethylcyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl)methyl ketone
[0547]
[0548] Step 1: 4-Nitrophenyl (1S,2S)-1,2-dimethylcyclopropane-1-carboxylate: EDC (814 mg, 4.25 mmol) was added to a solution of (1S,2S)-1,2-dimethylcyclopropane-1-carboxylic acid (404 mg, 3.54 mmol) in DMF (10.6 mL), and the resulting mixture was stirred at room temperature for 15 min. Then, 4-nitrophenol (542 mg, 3.89 mmol) and DMAP (43 mg, 0.354 mmol) were added. The resulting mixture was stirred at room temperature for 19 h, then the reaction mixture was diluted with water and extracted with EtOAc (x3). The combined organic layers were washed with water, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography (0-20% EtOAc in hexane) to give the title compound (633 mg, 76%) as a pale yellow oil. 1 ¹H NMR (500MHz, chloroform-d) δ 8.26 (d, J = 9.1Hz, 2H), 7.25 (d, J = 9.1Hz, 2H), 1.76–1.66 (m, 1H), 1.61 (dd, J = 9.3, 4.1Hz, 1H), 1.40 (s, 3H), 1.22 (d, J = 6.3Hz, 3H), 0.58 (dd, J = 6.9, 4.1Hz, 1H).
[0549] Step 2: ((1S,2S)-1,2-dimethylcyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone: A solution of 1-N-boc-4-methylenepiperidine (796 mg, 4.04 mmol) in 4 M HCl, 1,4-dioxane (3.36 mL, 13.5 mmol), and DCM (2.3 mL) was stirred at room temperature for 1 h, and then concentrated under reduced pressure. A solution of 4-nitrophenyl(1S,2S)-1,2-dimethylcyclopropane-1-carboxylate (633 mg, 2.69 mmol) in DMF (15.6 mL) and DIPEA (1.41 mL, 8.07 mmol) was added to the resulting solid. The resulting mixture was stirred at room temperature for 90 min, and then diluted with saturated aqueous sodium bicarbonate solution (30 mL). The resulting mixture was extracted with EtOAc (x3), and the combined organic layers were washed with 1:1 water / salt water (x4), passed through a phase separator, and concentrated under reduced pressure. The residue was purified by rapid chromatography to give the title compound (456 mg, 87%) as a yellow oil. LCMS (Method B): R T =1.12min(220nm),m / z=194[M+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 4.78 (s, 2H), 3.61–3.51 (m, 4H), 2.21 (t, J = 5.8 Hz, 4H), 1.25 (s, 3H), 1.17–1.05 (m, 5H), 0.19 (dd, J = 5.4, 4.4 Hz, 1H).
[0550] Step 3: ((1S,2S)-1,2-dimethylcyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using ((1S,2S)-1,2-dimethylcyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone (455 mg, 2.35 mmol) in DCM (11.7 mL) at 0 °C and m-CPBA (<77% w / w) (633 mg, 2.82 mmol) in DCM (11.7 mL), after 20 h at room temperature, yielded the title compound (413 mg, 83%) as a viscous, colorless oil. LCMS (Method B): R T =0.79min(220nm),m / z=210[M+H] + . 1 ¹H NMR (500MHz, chloroform-d)δ 1¹H NMR (500MHz, chloroform-d) δ 4.01–3.86 (m, 2H), 3.61–3.42 (m, 2H), 2.72 (s, 2H), 1.84 (ddd, J = 14.0, 9.8, 4.5Hz, 2H), 1.49 (ddd, J = 5.2, 3.6, 1.3Hz, 1H), 1.46 (ddd, J = 5.1, 3.8, 1.4Hz, 1H), 1.26 (s, 3H), 1.19–1.05 (m, 5H), 0.21 (t, J = 4.8Hz, 1H).
[0551] Epoxide 29: ((1R,2R)-1,2-dimethylcyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl)methyl ketone
[0552]
[0553] Step 1: 4-Nitrophenyl (1R,2R)-1,2-dimethylcyclopropane-1-carboxylate: EDC (1.21 g, 6.29 mmol) was added to a solution of (1R,2R)-1,2-dimethylcyclopropane-1-carboxylic acid (598 mg, 5.24 mmol) in DMF (15.7 mL), and the resulting mixture was stirred at room temperature for 15 min. Then, 4-nitrophenol (802 mg, 5.76 mmol) and DMAP (64 mg, 0.524 mmol) were added. The resulting mixture was stirred at room temperature for 19 h, then the reaction mixture was diluted with water and extracted with EtOAc (x3). The combined organic layers were washed with water, dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography (0-20% EtOAc in hexane) to give the title compound (912 mg, 74%) as a pale yellow oil. 1 ¹H NMR (500MHz, chloroform-d) δ 8.26 (d, J = 9.1Hz, 2H), 7.25 (d, J = 9.1Hz, 2H), 1.76–1.66 (m, 1H), 1.61 (dd, J = 9.3, 4.1Hz, 1H), 1.40 (s, 3H), 1.22 (d, J = 6.3Hz, 3H), 0.58 (dd, J = 6.9, 4.1Hz, 1H).
[0554] Step 2: ((1R,2R)-1,2-dimethylcyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone: A solution of 1-N-boc-4-methylenepiperidine (1.15 g, 5.82 mmol) in 4 M HCl, 1,4-dioxane (4.85 mL, 19.4 mmol), and DCM (3.7 mL) was stirred at room temperature for 1 h, and then concentrated under reduced pressure. A solution of 4-nitrophenyl(1R,2R)-1,2-dimethylcyclopropane-1-carboxylate (912 mg, 3.88 mmol) in DMF (22.5 mL) and DIPEA (2.03 mL, 11.6 mmol) was added to the resulting solid. The resulting mixture was stirred at room temperature for 90 min, and then diluted with saturated sodium bicarbonate aqueous solution (30 mL). The resulting mixture was extracted with EtOAc (x3), and the combined organic layers were washed with 1:1 water / salt water (x4), passed through a phase separator, and concentrated under reduced pressure. The residue was purified by rapid chromatography to give the title compound (722 mg, 96%) as a yellow oil. LCMS (Method B): R T =1.12min(220nm),m / z=194[M+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 4.78 (s, 2H), 3.61–3.51 (m, 4H), 2.21 (t, J = 5.8 Hz, 4H), 1.25 (s, 3H), 1.17–1.05 (m, 5H), 0.19 (dd, J = 5.4, 4.4 Hz, 1H).
[0555] Step 3: ((1R,2R)-1,2-dimethylcyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using ((1R,2R)-1,2-dimethylcyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone (722 mg, 3.74 mmol) in DCM (18.7 mL) at 0 °C and m-CPBA (<77% w / w) (1.00 g, 4.48 mmol) in DCM (18.7 mL), after 20 h at room temperature, yielded the title compound (618 mg, 79%) as a viscous, colorless oil. LCMS (Method B): R T =0.79min(220nm),m / z=210[M+H] + . 1 ¹H NMR (500MHz, chloroform-d)δ 1¹H NMR (500MHz, chloroform-d) δ 4.01–3.86 (m, 2H), 3.61–3.42 (m, 2H), 2.72 (s, 2H), 1.84 (ddd, J = 14.0, 9.8, 4.5Hz, 2H), 1.49 (ddd, J = 5.2, 3.6, 1.3Hz, 1H), 1.46 (ddd, J = 5.1, 3.8, 1.4Hz, 1H), 1.26 (s, 3H), 1.19–1.05 (m, 5H), 0.21 (t, J = 4.8Hz, 1H).
[0556] Epoxide 30: 2,2-Dicyclopropyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)acet-1-one
[0557]
[0558] Step 1: 2,2-Dicyclopropyl-1-(4-methylenepiperidin-1-yl)ethyl-1-one: General procedure 1, using 4-methylenepiperidin hydrochloride (159 mg, 1.19 mmol), 2,2-cyclopropylacetic acid (167 mg, 1.19 mmol), HATU (452 mg, 1.19 mmol), DIPEA (0.622 mL, 3.57 mmol), and DCM (21 mL), yielded the title compound (180 mg, 69%) as a colorless oil after 19 h. LCMS (Method B): R T =1.22min, m / z = 220[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ4.77(s,2H),3.49(br s,2H),3.42(br s,2H),2.11(br s,4H),1.70(t,J=8.8Hz,1H),1.07–0.98(m,2H),0.49–0.42(m,2H),0.35–0.23(m,4H),0.11–0.04(m,2H).
[0559] Step 2: 2,2-Dicyclopropyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)ethyl-1-one: General procedure 2, using 2,2-dicyclopropyl-1-(4-methylenepiperidin-1-yl)ethyl-1-one (180 mg, 0.821 mmol) in DCM (4.1 mL) at 0 °C and m-CPBA (<77% w / w) (221 mg, 0.985 mmol) in DCM (4.1 mL), after 20 h at room temperature, yielded the title compound (187 mg, 97%) as a colorless oil. LCMS (Method B): R T =0.90min, m / z = 236[M+H] + . 1HNMR(500MHz,DMSO-d6)δ3.77–3.64(m,1H),3.64–3.54(m,1H),3.54–3.45(m,2H),2.67(s,2H),1.71(t,J=8.8Hz,1H ),1.68–1.58(m,2H),1.44–1.33(m,2H),1.08–0.98(m,2H),0.50–0.41(m,2H),0.37–0.23(m,4H),0.13–0.03(m,2H).
[0560] Epoxide 31: (1-Methylcyclobutyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) ketone
[0561]
[0562] Step 1: (1-Methylcyclobutyl)(4-methylenepiperidin-1-yl) methyl ketone: General procedure 1, using 4-methylenepiperidin hydrochloride (97 mg, 0.726 mmol), 1-methylcyclobutane-1-carboxylic acid (83 mg, 0.726 mmol), HATU (276 mg, 0.726 mmol), DIPEA (0.379 mL, 2.18 mmol), and DCM (7.2 mL), yielded the title compound (131 mg, 93%) as a colorless oil after 1 h. 1 H NMR(500MHz,DMSO-d6)δ4.76(s,2H),3.54–3.33(m,2H),3.28–3.12(m,2H),2.46–2.37(m,2H) ),2.21–2.04(m,4H),1.98–1.85(m,1H),1.83–1.73(m,2H),1.69–1.55(m,1H),1.35(s,3H).
[0563] Step 2: (1-Methylcyclobutyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using (1-methylcyclobutyl)(4-methylenepiperidin-1-yl) methyl ketone (129 mg, 0.667 mmol) in DCM (3.5 mL) at 0 °C and m-CPBA (<77% w / w) (179 mg, 0.801 mmol) in DCM (3.5 mL), after 22.5 h at room temperature, yielded the title compound (133 mg, 95%) as a pale yellow oil. 1H NMR(500MHz,DMSO-d6)δ3.74–3.59(m,1H),3.48–3.32(m,3H),2.67(s,2H),2.46–2.38(m,2H) ),1.97–1.86(m,1H),1.83–1.76(m,2H),1.74–1.57(m,3H),1.46–1.37(m,2H),1.36(s,3H).
[0564] Epoxide 32: 3-Cyclopropyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)prop-1-one
[0565]
[0566] Step 1: 3-Cyclopropyl-1-(4-Methylenepiperidin-1-yl)prop-1-one: General procedure 1, using 4-methylenepiperidin hydrochloride (356 mg, 2.66 mmol), 3-cyclopropylpropionic acid (304 mg, 2.66 mmol), HATU (1.01 g, 2.66 mmol), DIPEA (1.39 mL, 7.99 mmol), and DCM (20 mL), yielded the title compound (269 mg, 52%) as a colorless gel after 19 h. 1 H NMR (500MHz, chloroform-d) δ4.79–4.76(m,2H),3.60(t,J=5.9Hz,2H),3.50–3.44(m,2H),2.50–2.42(m,2H),2. 22(dt,J=16.3,5.9Hz,4H),1.58–1.50(m,2H),0.78–0.67(m,1H),0.49–0.38(m,2H),0.11–0.02(m,2H).
[0567] Step 2: 3-Cyclopropyl-1-(1-oxa-6-azaspiro[2.5]oct-6-yl)prop-1-one: General procedure 2, using 3-cyclopropyl-1-(4-methylenepiperidin-1-yl)prop-1-one (269 mg, 1.39 mmol) in DCM (6 mL) at 0 °C and m-CPBA (<77% w / w) (374 mg, 1.67 mmol) in DCM (6 mL), yielded the title compound (200 mg, 68%) as a colorless oil after 20 h at room temperature. 1¹H NMR (500MHz, chloroform-d) δ 4.15–4.07 (m, 1H), 3.75–3.67 (m, 1H), 3.56 (ddd, J = 13.5, 9.9, 3.5 Hz, 1H), 3.42 (ddd, J = 13.4, 9.9, 3.6 Hz, 1H), 2.72 (s, 2H), 2.53–2.41 (m, 2H), 1.90–1.79 (m, 2H), 1.58–1.52 (m, 2H), 1.52–1.41 (m, 2H), 0.78–0.68 (m, 1H), 0.49–0.39 (m, 2H), 0.12–0.03 (m, 2H).
[0568] Epoxide 33: Racemic-((1R,2R)-2-(difluoromethyl)-1-methylcyclopropyl)(1-oxa-6-azaspiro) [2.5] Oct-6-yl)methyl ketone
[0569]
[0570] Step 1: Racemic-(1R,2R)-2-(dimethoxymethyl)-1-methylcyclopropane-1-carboxylic acid ethyl ester: To a solution of ethyl 2-(diethoxyphosphoryl)propionate (6.67 mL, 31.1 mmol) and 2-(dimethoxymethyl)ethylene oxide (5.00 g, 42.3 mmol) in 1,2-dimethoxyethane (60 mL), n-butyllithium (2.4 M, 13 mL, 0.0311 mol) in hexane was added dropwise. The reaction mixture was heated to room temperature and stirred for 15 min. The reaction mixture was transferred to an autoclave pressure reactor and heated at 145 °C for 18 h. After cooling to room temperature, the reaction mixture was quenched with saturated ammonium chloride aqueous solution (200 mL) and the product was extracted with MTBE (3 x 200 mL). The combined organic extracts were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (6.80 g, 108%) as a pale yellow oil. This material was used in the next step without purification. 1 ¹H NMR (400MHz, chloroform-d) δ 4.28 (d, J = 7.1Hz, 1H), 4.09 (q, J = 7.1Hz, 2H), 3.39 (s, 6H), 1.84 (dt, J = 9.5, 6.8Hz, 1H), 1.41 (dd, J = 9.5, 4.2Hz, 1H), 1.33 (s, 3H), 1.28–1.11 (m, 3H), 0.74 (dd, J = 6.6, 4.3Hz, 1H).
[0571] Step 2: Racemic-(1R,2R)-2-formyl-1-methylcyclopropane-1-carboxylic acid ethyl ester: Concentrated hydrochloric acid aqueous solution (8 mL) was added to a solution of crude racemic-(1R,2R)-2-(dimethoxymethyl)-1-methylcyclopropane-1-carboxylic acid ethyl ester (6.80 g, 31.1 mmol) in THF (100 mL) and water (32 mL). The resulting mixture was stirred at room temperature for 2 h, and then the volatiles were removed under reduced pressure. The residue was diluted with brine (200 mL) and the product was extracted into DCM (3 x 100 mL). The combined organic layers were washed with saturated sodium bicarbonate aqueous solution and brine. The organic layers were dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (4.60 g, 94% (step 2)) as a yellow oil. This material was used without further purification. 1 ¹H NMR (500 MHz, chloroform-d) δ 9.51 (d, J = 4.3 Hz, 1H), 4.18–4.11 (m, 2H), 2.55–2.48 (m, 1H), 1.72 (dd, J = 8.7, 4.4 Hz, 1H), 1.53–1.48 (m, 1H), 1.44 (s, 3H), 1.26 (t, J = 7.2 Hz, 3H).
[0572] Step 3: Racemic-(1R,2R)-2-(difluoromethyl)-1-methylcyclopropane-1-carboxylate: Add thiomorpholine trifluoride (7.65 g, 43.7 mmol) to a stirred solution of crude racemic-ethyl(1R,2R)-2-formyl-1-methylcyclopropane-1-carboxylate (4.60 g, 29.5 mmol) in DCM (80 mL). Stir the reaction at room temperature for 19 h, then slowly pour the mixture into a vigorously stirred mixture of saturated sodium bicarbonate aqueous solution and crushed ice. After the ice melted, transfer the resulting mixture to a separatory funnel, separate the layers, and further extract the aqueous layer with DCM (2 x 50 mL). Dry the combined organic layers with sodium sulfate, filter, and concentrate under reduced pressure to give the title compound (5.14 g, 97%) as a yellow oil. This material was used without further purification. 1 ¹H NMR (500MHz, chloroform-d) δ 5.60 (td, J = 55.9, 6.1 Hz, 1H), 4.13 (q, J = 7.1 Hz, 2H), 2.07–1.97 (m, 1H), 1.54–1.48 (m, 1H), 1.39 (s, 3H), 1.26 (t, J = 7.1 Hz, 3H), 0.94–0.88 (m, 1H). 19 F NMR (proton uncoupling, 376 MHz, chloroform-d) δ-109.20 (d, 2 J F-F =289.2Hz), -113.89(d,2 J F-F =289.2Hz).
[0573] Step 4: Racemic-(1R,2R)-2-(difluoromethyl)-1-methylcyclopropane-1-carboxylic acid: A solution of sodium hydroxide (2.62 g, 0.0655 mmol) in water (10 mL) was added to a stirred solution of racemic-ethyl(1R,2R)-2-(difluoromethyl)-1-methylcyclopropane-1-carboxylic acid ester (5.14 g, 28.8 mmol) in MeOH (40 mL). The resulting mixture was stirred at room temperature for 19 h, and then the volatiles were removed under reduced pressure. The residue was diluted with water (100 mL) and acidified to pH 3-4 by adding concentrated hydrochloric acid aqueous solution, and then the product was extracted into DCM (3 x 50 mL). The combined organic layers were dried over sodium sulfate, filtered, concentrated under reduced pressure, and the residue was purified by rapid chromatography (SiO2, 2-5% THF in hexane) to give the title compound (1.77 g, 40%) as a pale gray crystalline solid. 1 ¹H NMR (600MHz, chloroform-d) δ 11.38 (br.s, 1H), 5.63 (td, J=55.8, 5.8Hz, 1H), 2.15–2.05 (m, 1H), 1.62–1.55 (m, 1H), 1.41 (s, 3H), 1.06–0.99 (m, 1H). 19 F NMR (proton uncoupling, 376 MHz, chloroform-d) δ -109.84 (d, J = 289.7 Hz), -114.24 (d, J = 289.7 Hz). Based on NOE experiments, the product was identified as racemic-(1R,2R)-2-(difluoromethyl)-1-methylcyclopropane-1-carboxylic acid.
[0574] Step 5: Racemic-((1R,2R)-2-(difluoromethyl)-1-methylcyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone: Under a nitrogen atmosphere at 0°C, oxaloyl chloride (2M, 3.00 mL, 6.00 mmol in DCM) was added dropwise to a stirred solution of racemic-(1R,2R)-2-(difluoromethyl)-1-methylcyclopropane-1-carboxylic acid (751 mg, 5.00 mmol) and DMF (19.36 μL, 0.250 mmol) in DCM (5 mL). The reaction mixture was heated to room temperature and stirred for another 2 h, and then 4-methylenepiperidin hydrochloride (802 mg, 6.00 mmol) was added to a stirred solution of DCM (5 mL) under a nitrogen atmosphere via syringe. The resulting solution was cooled to 0°C and triethylamine (2.09 mL, 15.0 mmol) was added dropwise. After the addition was complete, the ice bath was removed, and the reaction mixture was stirred at room temperature for 1 h, followed by the addition of a saturated aqueous solution of sodium bicarbonate (60 mL). The resulting mixture was extracted with DCM (3 x 20 mL) using a phase separator, and the combined organic layers were concentrated under reduced pressure to give the title compound (1.25 g, 109%) as a yellow oil. This material was used without further purification. 1 H NMR(500MHz,DMSO-d6)δ5.94(ddd,J=56.2,54.5,7.2Hz,1H),4.81–4.73(m,2H),3.70–3.36(m, 4H),2.26–2.07(m,4H),1.72–1.61(m,1H),1.33(s,3H),1.25–1.18(m,1H),0.95–0.91(m,1H).
[0575] Step 6: Racemic-((1R,2R)-2-(difluoromethyl)-1-methylcyclopropyl)(1-oxa-6-azaspiro[2.5]oct-6-yl) methyl ketone: General procedure 2, using crude racemic-((1R,2R)-2-(difluoromethyl)-1-methylcyclopropyl)(4-methylenepiperidin-1-yl) methyl ketone (1.25 g, 5.00 mmol) in DCM (25 mL) at room temperature and m-CPBA (<77% w / w) (1.46 g, 6.50 mmol) in DCM (25 mL), after 19 h at room temperature, yielded the title compound (1.16 g, 94% (step 2)) as a yellow oil. 1H NMR(500MHz,DMSO-d6)δ5.94(ddd,J=56.2,54.6,7.2Hz,1H),3.94–3.63(m,2H),3.53(br.s,2H),2.71– 2.65(m,2H),1.83–1.61(m,3H),1.54–1.38(m,2H),1.34(s,3H),1.25–1.20(m,1H),0.96–0.90(m,1H).
[0576] Example 1: Racemic-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl 3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0577]
[0578] Step 1: Racemic-(2R,5S)-5-(4-bromophenyl)-2-methylmorpholine: General procedure 8, using 4-bromobenzaldehyde (1.85 g, 10.0 mmol), 2-((tributyltinyl)methoxy)prop-1-amine (3.78 g, 10.0 mmol), Cu(OTf)2 (3.62 g, 10 mmol), 2,6-dimethylpyridine (1.07 g, 10.0 mmol), HFIP (40 mL). Molecular sieve (approximately 1 g) and DCM (160 mL) yielded the title compound (1 g, 39%). 1 ¹H NMR (400MHz, chloroform-d) δ 7.43 (d, J = 8.4 Hz, 2H), 7.34–7.18 (m, 2H), 3.92–3.73 (m, 2H), 3.65 (ddd, J = 10.2, 6.2, 2.4 Hz, 1H), 3.37 (t, J = 9.8 Hz, 1H), 3.01 (dd, J = 11.7, 2.4 Hz, 1H), 2.70 (dd, J = 11.6, 10.1 Hz, 1H), 1.17 (d, J = 6.2 Hz, 3H).
[0579] Step 2: Racemic-(2R,5S)-5-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 9, using racemic-(2R,5S)-5-(4-bromophenyl)-2-methylmorpholine (1 g, 3.90 mmol) and Boc2O (1.02 g, 4.68 mmol) to give the title compound (1.39 g, quantitative). LCMS (Method C), R T =1.47min,m / z=256,258[M-Boc+H] + . 1H NMR (500MHz, chloroform-d) δ7.46(d,J=8.5Hz,2H),7.26(d,J=8.5Hz,2H),4.77(t,J=5.4Hz,1H),4.02(dd,J=12.3,4.6Hz,1H),3.99–3.92(m ,1H),3.72(dd,J=12.3,5.8Hz,1H),3.51(dd,J=13.5,4.0Hz,1H),3.37(dd,J=13.5,4.8Hz,1H),1.35(s,9H),1.29(d,J=6.5Hz,3H).
[0580] Step 3: Racemic (2R,5S)-2-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using racemic (2R,5S)-5-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (600 mg, 1.68 mmol), B2Pin2 (642 mg, 2.53 mmol), Pd(dppf)Cl2·CH2Cl2 (143 mg, 0.168 mmol), KOAc (496 mg, 5.05 mmol) and 1,4-dioxane (17 mL), stirred at 120 °C (microwave irradiation) for 30 min to obtain the title compound (648 mg, 95%) as a yellow oil. LCMS (Method A): R T =1.97min, m / z = 404[M+H] + .
[0581] Step 4: Racemic-(2R,5S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (80 mg, 0.426 mmol), racemic-(2R,5S)-2-methyl-5-(4-(4,4,5,5-tetramethyl) tert-butyl 1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylate (343 mg, 0.851 mmol), copper(II) acetate (155 mg, 0.851 mmol), 1,10-phenanthroline (153 mg, 0.851 mmol), boric acid (105 mg, 1.70 mmol), and DMF (8 mL) were added. After 3 days, the title compound (98 mg, 49%) was obtained as a colorless, glassy substance. LCMS (Method A): R T =1.90min, m / z = 463,465 [M+H] + .
[0582] Step 5: Racemic-(2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate tert-butyl ester: General procedure 5, using racemic-(2R,5S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate tert-butyl ester (98 mg, 0.212 mmol), aqueous sodium hydroxide solution (4 M, 1.06 mL, 4.23 mmol), and 1,4-dioxane (1.1 mL), acidified with AcOH after 18 h at 100 °C to give the title compound (95 mg, quantitative) as a yellow oil. LCMS (Method B): R T =1.22min, m / z = 445[M+H] + .
[0583] Step 6: Racemic-(2R,5S)-5-(4-(6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using racemic-(2R,5S)-5-(4-(6-chloro-4-oxo-3-) 4-Dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (94 mg, 0.211 mmol), epoxide 1 (42 mg, 0.211 mmol), Cs2CO3 (207 mg, 0.634 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (31 mg, 22%) as a colorless glassy substance. LCMS (Method A): R T =1.42min, m / z = 640, 642[M+H] + .
[0584] Step 7: Racemic-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using racemic-(2R,5S)-5-(4-(6-chloro-3-((4-hydroxy- 1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (31 mg, 0.0484 mmol), TFA (1 mL), and DCM (2 mL) were freeze-dried to give the title compound (14 mg, 53%) as a white solid. LCMS (Method B): R T =0.71min, m / z = 540,542 [M+H] + . 1 H NMR (500MHz, DMSO-d6) δ8.07(s,1H),7.61(d,J=8.4Hz,2H),7.40(d,J=8.4Hz,2H),6.81(s,1H),4.91(s, 1H),4.01(s,2H),3.99–3.90(m,2H),3.85(dd,J=10.0,3.2Hz,1H),3.81(dd,J=10.6,3.2Hz,1H),3.61–3. 51(m,1H),3.26(t,J=10.3Hz,1H),3.16(s,2H),2.96(dd,J=11.7,2.3Hz,1H),2.94–2.85(m,1H),2.58–2 .54(m,1H),1.59–1.36(m,4H),1.21(s,3H),1.10(d,J=6.2Hz,3H),0.80–0.73(m,2H),0.55–0.49(m,2H).
[0585] Example 2: Racemic-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl 3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0586]
[0587] Step 1: Racemic-(3R,5S)-3-(4-bromophenyl)-5-methylmorpholine: General procedure 8, using 4-bromobenzaldehyde (2.83 g, 15.3 mmol), 1-((tributyltinyl)methoxy)prop-2-amine (5.78 g, 15.3 mmol), Cu(OTf)2 (5.51 g, 15.3 mmol), 2,6-dimethylpyridine (1.63 g, 15.3 mmol), HFIP (61 mL). Molecular sieve (approximately 1.5 g) and DCM (243 mL) yielded the title compound (737 mg, 19%). LCMS (Method C): R T =0.68min, m / z = 256, 258 [M+H] + .
[0588] Step 2: Racemic-(3R,5S)-3-(4-bromophenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 9, using racemic-(3R,5S)-3-(4-bromophenyl)-5-methylmorpholine (737 mg, 2.88 mmol) and Boc2O (754 mg, 3.45 mmol) to give the title compound (820 mg, 80%). LCMS (Method C), R T =1.50min, 256, 258[M-Boc+H] + . 1 HNMR (500MHz, chloroform-d) δ7.48(d,J=8.6Hz,2H),7.43(d,J=8.7Hz,2H),5.07(d,J=3.9Hz,1H),4.54–4.46(m,1H),4.1 1(dt,J=7.1,2.5Hz,1H),3.77(dd,J=12.2,4.0Hz,1H),3.71(d,J=2.5Hz,2H),1.50(s,9H),0.91(d,J=7.1Hz,3H).
[0589] Step 3: Racemic (3R,5S)-3-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using racemic (3R,5S)-3-(4-bromophenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester (600 mg, 1.68 mmol), B2Pin2 (642 mg, 2.53 mmol), Pd(dppf)Cl2·CH2Cl2 (143 mg, 0.168 mmol), KOAc (496 mg, 5.05 mmol) and 1,4-dioxane (17 mL), stirred at 120 °C (microwave irradiation) for 60 min to obtain the title compound (588 mg, 86%) as a colorless oil. LCMS (Method B): R T =1.74min, m / z = 304[M - Boc + H] + .
[0590] Step 4: Racemic-(3R,5S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (548 mg, 2.91 mmol), racemic-(3R,5S)-3-methyl-5-(4-(4,4,5,5-tetramethyl-1 tert-butyl 3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylate (1.76 mg, 4.37 mmol), copper(II) trifluoroacetate hydrate (1.69 g, 5.83 mmol), 1,10-phenanthroline (1.05 g, 5.83 mmol), boric acid (721 mg, 11.7 mmol), and DMF (55 mL) were added. After 3 days, the title compound (882 mg, 65%) was obtained as a colorless, glassy substance. LCMS (Method B): R T =1.69min, m / z = 463,465 [M+H] + . 1 H NMR (500MHz, chloroform-d) δ8.62(s,1H),7.89–7.77(m,2H),7.41–7.33(m,2H),6.74(s,1H),5.22(d,J=3.6Hz,1H),4.59(dd,J=1 2.3,1.2Hz,1H),4.23–4.14(m,1H),3.85(dd,J=12.3,4.0Hz,1H),3.80–3.74(m,2H),1.53(s,9H),1.01(d,J=7.1Hz,3H).
[0591] Step 5: Racemic (3R,5S)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylic acid tert-butyl ester: General procedure 5, using racemic (3R,5S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylic acid tert-butyl ester (145 mg, 0.313 mmol), aqueous sodium hydroxide solution (2 M, 2.35 mL, 4.69 mmol), and 1,4-dioxane (2.5 mL), at 100 °C for 18 h to give the title compound (140 mg, quantitative) as a white solid. LCMS (Method B): R T =1.22min, m / z = 445, 446 [M+H] + .
[0592] Step 6: Racemic-(3R,5S)-3-(4-(6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using racemic-(3R,5S)-3-(4-(6-chloro-4-oxo-3,4-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester: Dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholino-4-carboxylic acid tert-butyl ester (140 mg, 0.315 mmol), epoxide 1 (62 mg, 0.315 mmol), Cs2CO3 (205 mg, 0.629 mmol), and DMF (2.5 mL) were reacted at 80 °C for 18 h to give the title compound (120 mg, 59%) as a white solid. LCMS (Method B): R T =1.33 min, m / z = 584,586 [M-Butene + H] + ,540,542[M-Boc+H] + .
[0593] Step 7: Racemic-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,5S)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using racemic-(3R,5S)-3-(4-(6-chloro-3-((4-hydroxy-1-( 1-Methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester (10 mg, 0.0156 mmol), TFA (0.25 mL), and DCM (0.5 mL) were freeze-dried to give the title compound (7.1 mg, 78%) as a white solid. LCMS (Method B): R T =0.68min, m / z = 540,542 [M+H] + . 1H NMR (500MHz, DMSO-d6) δ8.07(s,1H),7.62(d,J=8.1Hz,2H),7.40(d,J=7.9Hz,2H),6. 81(s,1H),4.91(s,1H),4.01(s,2H),3.95(dt,J=13.0,4.6Hz,3H),3.75(dd,J=36.0, 10.4Hz,2H),3.25–3.07(m,3H),2.97(s,3H),1.50(d,J=12.0Hz,2H),1.39(d,J=13.3 Hz, 2H), 1.21 (s, 3H), 0.96 (d, J = 5.9Hz, 3H), 0.77 (q, J = 4.1Hz, 2H), 0.53–0.50 (m, 2H).
[0594] Example 3: 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4- (3-Methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0595]
[0596] Step 1: N-(2-(4-bromophenyl)-1-hydroxypropyl-2-yl)-2-chloroacetamide: Triethylamine (7.96 mL, 57.1 mmol) was added to a suspension of 2-amino-2-(4-bromophenyl)prop-1-ol hydrochloride (7.25 g, 27.2 mmol) in DCM. The resulting solution was cooled to -30 °C and chloroacetyl chloride (2.16 mL, 27.2 mmol) was added dropwise. The resulting mixture was stirred overnight at room temperature and then diluted with water. The resulting phase was separated and the organic layer was concentrated under reduced pressure. The residue was purified by rapid chromatography to give the title compound (5.00 g, 60%). LCMS (Method C): R T =1.12min, m / z = 306, 308 [M+H] + . 1 HNMR (500MHz, chloroform-d) δ7.47(d,J=8.5Hz,2H),7.20(d,J=8.5Hz,2H),7.13(br.s,1H),4.06(d, J=2.3Hz,2H),3.87(d,J=11.8Hz,1H),3.68(d,J=11.8Hz,1H),3.45(br.s,1H),1.68(s,3H).
[0597] Step 2: 5-(4-bromophenyl)-5-methylmorpholin-3-one: Sodium hydride (1.53 g, 35.1 mmol, a 55% dispersion in mineral oil) was added to a solution of N-(2-(4-bromophenyl)-1-hydroxypropyl-2-yl)-2-chloroacetamide (5.00 g, 16.3 mmol) in THF (100 mL) at 0 °C. The resulting mixture was stirred at room temperature for 18 h, then saturated sodium bicarbonate aqueous solution (70 mL) was added, and the mixture was extracted with EtOAc (3 × 100 mL). The combined organic layers were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced pressure. The crude product was purified by rapid chromatography to give the title compound (3.35 g, 76%). LCMS (Method C): R T =1.11min, m / z = 270, 272[M+H] + . 1 ¹H NMR (400MHz, chloroform-d) δ 7.49 (d, J = 7.2Hz, 2H), 7.25 (d, J = 7.2Hz, 2H), 4.17 (s, 2H), 3.78 (d, J = 11.9Hz, 1H), 3.69 (d, J = 11.9Hz, 1H), 1.62 (s, 3H), 0.84 (br.s, 1H).
[0598] Step 3: 3-(4-Bromophenyl)-3-methylmorpholine: Borane dimethyl sulfide complex (5.88 mL, 62.0 mmol) was added to a solution of 5-(4-bromophenyl)-5-methylmorpholine-3-one (3.35 g, 12.4 mmol) in THF (50 mL) under a nitrogen atmosphere at 0 °C. The resulting mixture was heated to room temperature and stirred for 16 h. To quench excess borane, MeOH (120 mL) was added dropwise and the resulting mixture was stirred at 70 °C for 1 h. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure, and 5% hydrochloric acid aqueous solution was added to the residue. The resulting mixture (pH 1) was extracted with EtOAc (2 x 30 mL) to remove byproducts. The pH of the aqueous layer was adjusted to pH 10 by adding Na2CO3, and the product was then extracted into EtOAc (3 x 40 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, filtered, and concentrated under reduced pressure to give the title compound (700 mg, 22%). LCMS (Method C): R T =1.36min, m / z = 256, 258 [M+H] + . 1H NMR (400MHz, chloroform-d) δ7.49(d,J=8.6Hz,2H),7.42(d,J=8.6Hz,2H),4.06(d,J=11.9Hz,1H),3 .69(m,2H),3.55(d,J=11.9Hz,1H),2.88(m,1H),2.80(m,1H),1.67(br.s,1H),1.34(s,3H).
[0599] Step 4: 3-(4-bromophenyl)-3-methylmorpholine-4-carboxylic acid tert-butyl ester: Triethylamine (0.457 mL, 3.28 mmol), Boc₂O (0.691 mL, 3.01 mmol), and DMAP (ca) were added to a solution of 3-(4-bromophenyl)-3-methylmorpholine (700 mg, 2.73 mmol) in THF (10 mL). The resulting solution was stirred at room temperature for 16 h, and then Boc₂O (0.457 mL, 3.28 mmol) was added. After the starting material was consumed, trifluoroethanol (0.43 mL) was added to decompose the excess Boc₂O. After 5 h, the reaction mixture was concentrated under reduced pressure and the residue was purified by rapid chromatography to give the title compound (800 mg, 82%). LCMS (Method C): R T =1.61min,m / z=300,302[M-butene+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.43 (d, J = 7.2Hz, 2H), 7.26 (d, J = 7.2Hz, 2H), 4.02 (m, 1H), 3.74 (m, 2H), 3.43 (m, 3H), 1.70 (s, 3H), 1.14 (s, 9H).
[0600] Step 5: 3-Methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using 3-(4-bromophenyl)-3-methylmorpholine-4-carboxylic acid tert-butyl ester (180 mg, 0.505 mmol), B2Pin2 (192 mg, 0.758 mmol), Pd(dppf)Cl2·CH2Cl2 (43 mg, 0.0505 mmol), KOAc (149 mg, 1.52 mmol), and 1,4-dioxane (4 mL), stirred at 120 °C (microwave irradiation) for 30 min, yielded the title compound (171 mg, 84%) as a yellow oil. LCMS (Method A): R T =1.97min, m / z = 404,406 [M+H] + .
[0601] Step 6: 3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (40 mg, 0.213 mmol), 3-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester (171 mg, 0.426 mmol), copper(II) acetate (77.3 mg, 0.426 mmol), 1,10-phenanthroline (76.7 mg, 0.426 mmol), boric acid (78.9 mg, 1.28 mmol), and DMF (2 mL), yielded the title compound (32 mg, 32%) as a colorless thin film after 3 days. LCMS (Method B): R T =1.65min, m / z = 463,465[M+H] + .
[0602] Step 4: 3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3-methylmorpholin-4-carboxylate tert-butyl ester: General procedure 5, using 3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3-methylmorpholin-4-carboxylate tert-butyl ester (32.0 mg, 0.0691 mmol), sodium hydroxide aqueous solution (2 M, 0.52 mL, 1.04 mmol), and 1,4-dioxane (1 mL), at 100 °C for 18 h, yielded the title compound (31 mg, quantitative) as a white solid. LCMS (Method B): R T =1.19min, m / z = 445,447 [M+H] + .
[0603] Step 7: 3-(4-(6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using 3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3-methylmorpholine-4-carboxylic acid tert-butyl ester (31 mg, 0.0697 mmol), epoxide 1 (13.6 mg, 0.0697 mmol), Cs2CO3 (45 mg, 0.139 mmol) and DMF (0.7 mL), at 80 °C for 3 h, yielded the title compound (25.4 mg, 56%) as a white solid. LCMS (Method B): R T=1.30 min, m / z = 584,586 [M-Butene + H] + ;540,542[M-Boc+H] + .
[0604] Step 8: 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(3-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using tert-butyl 3-(4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3-methylmorpholin-4-carboxylic acid (25 mg, 0.0391 mmol), TFA (0.5 mL), and DCM (1 mL), lyophilized to give the title compound (11.3 mg, 51%) as a grayish-white solid. LCMS (Method B): R T =0.674min,m / z=540,542[M+H] + . 1 HNMR(500MHz,DMSO-d6)δ8.08(s,1H),7.76–7.72(m,2H),7.41(d,J=8.5Hz,2H),6.81(s, 1H),4.91(s,1H),4.08(d,J=11.3Hz,1H),4.01(s,2H),3.95(dt,J=12.9,4.2Hz,2H),3.5 8–3.49(m,3H),3.16(br.s,2H),2.71(dd,J=53.7,7.1Hz,3H),1.50(d,J=12.7Hz,2H),1. 40(d,J=13.4Hz,2H),1.27(s,3H),1.21(s,3H),0.77(q,J=4.1Hz,2H),0.53–0.50(m,2H).
[0605] Example 4: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0606]
[0607] Step 1: (2S,5R)-5-(4-bromophenyl)-2-methylmorpholine: General procedure 8, using 4-bromobenzaldehyde (1.85 g, 10.0 mmol), (S)-2-((tributyltinyl)methoxy)prop-1-amine (prepared from (S)-1-aminoprop-2-ol according to the procedure outlined in Org. Lett. 2014, 16(4), 1236–1239) (3.78 g, 10.0 mmol), Cu(OTf)2 (3.62 g, 10.0 mmol), 2,6-dimethylpyridine (1.07 g, 10.0 mmol), HFIP (40 mL), Molecular sieve (approximately 1 g) and DCM (160 mL) yielded the title compound (1.37 g, 53%). LCMS (Method C): R T =0.63min, m / z = 256, 258 [M+H] + . 1 H NMR (500MHz, chloroform-d) δ7.58–7.39(m,2H),7.32–7.19(m,2H),3.94–3.76(m,2H),3.66(td,J=7.4,6.8,3.3Hz,1H),3 .38(t,J=10.1Hz,1H),3.02(dd,J=11.7,2.6Hz,1H),2.71(t,J=10.8Hz,1H),1.92(s,1H),1.18(d,J=6.2Hz,3H).
[0608] Step 2: (2S,5R)-5-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 9, using (2S,5R)-5-(4-bromophenyl)-2-methylmorpholine (1.37 g, 5.37 mmol) and Boc2O (1.4 g, 6.42 mmol) to obtain the title compound (1.7 g, 89%). LCMS (Method C): R T =1.32min,m / z=256,258[M-Boc+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.45 (d, J = 8.4Hz, 2H), 7.24 (d, J = 8.8Hz, 2H), 4.76 (t, J = 5.2Hz, 1H), 4.01 (dd, J = 12.3, 4.6Hz, 1H), 3.98–3.92 (m, 1H), 3.71 (dd, J = 12.3, 5.8Hz, 1H), 3.51 (dd, J = 13.5, 3.8Hz, 1H), 3.36 (dd, J = 13.5, 4.8Hz, 1H), 1.34 (s, 9H), 1.28 (d, J = 6.4Hz, 3H). Chiral purity (Method B): RT =11.32min,>98%ee.
[0609] Step 3: (2S,5R)-2-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using (2S,5R)-5-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (2 g, 5.61 mmol), B2Pin2 (2.14 g, 8.42 mmol), Pd(dppf)Cl2·CH2Cl2 (475 mg, 0.561 mmol), KOAc (1.65 g, 16.8 mmol) and 1,4-dioxane (55 mL), stirred at 100 °C (heat) for 2 h to give the title compound (2.10 g, 92%) as a pale yellow oil. LCMS (Method B): R T =1.71min, m / z = 304[M - Boc + H] + .
[0610] Step 4: (2S,5R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (652 mg, 3.48 mmol), (2S,5R)-2-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoborylpentyl) tert-butyl cyclo-2-yl)phenyl)morpholine-4-carboxylate (2.10 g, 5.20 mmol), copper(II) trifluoroacetate hydrate (2.01 g, 6.94 mmol), 1,10-phenanthroline (1.25 g, 6.94 mmol), boric acid (858 mg, 13.9 mmol), and DMF (65 mL) were reacted at 75–80 °C for 24 hours to give the title compound (1.07 g, 66%) as a colorless, glassy substance. LCMS (Method B): R T =1.68min, m / z = 463,465 [M+H] + .
[0611] Step 5: (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylate tert-butyl ester: General procedure 5, using (2S,5R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylate tert-butyl ester (1.07 g, 2.30 mmol), aqueous sodium hydroxide solution (4 M, 17.2 mL, 69.0 mmol), and 1,4-dioxane (17.3 mL), acidified with 1 M potassium hydrogen sulfate solution after 18 h at 100 °C to give the title compound (1.08 g, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.30min, m / z = 445,447 [M+H] + .
[0612] Step 6: (2S,5R)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H) -Pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (442 mg, 0.994 mmol), epoxide 2 (375 mg, 1.49 mmol), Cs2CO3 (971 mg, 2.98 mmol), and DMF (10 mL) were reacted at 80 °C for 18 h to give the title compound (498 mg, 72%) as a colorless glassy substance. LCMS (Method B): R T =1.50 min, m / z = 640, 642 [M-Butene + H] + .
[0613] Step 7: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (498 mg, 0.715 mmol), TFA (5 mL), and DCM (10 mL), lyophilized to give the title compound (385 mg, 90%) as a white solid. LCMS (Method B): R T =0.83min, m / z = 596,598 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.65–7.55(m,2H),7.55–7.48(m,2H),7.47–7.34(m,4H),6. 79(s,1H),4.95(s,1H),4.31–4.08(m,1H),4.02(s,2H),3.85(dd,J=10.1,3.3Hz,1H),3.80(dd,J =10.6, 3.2Hz, 1H), 3.62–3.49(m, 1H), 3.48–3.33(m, 1H), 3.29–3.20(m, 2H), 3.20–3.05(m, 1H), 3.04–2.77(m, 2H), 2.58–2.52(m, 1H), 1.69–1.53(m, 2H), 1.53–1.25(m, 2H), 1.09(d, J = 6.2Hz, 3H). Chiral purity (Method C): R T =2.98min, 99.8%ee.
[0614] Example 5: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-yl) ((3R,6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0615]
[0616] Step 1: (2S,5R)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine: General procedure 8, using 4-bromo-2-methylbenzaldehyde (1.99 g, 10.0 mmol), (S)-2-((tributyltinyl)methoxy)prop-1-amine (prepared from (S)-1-aminoprop-2-ol according to the procedure outlined in Org. Lett. 2014, 16(4), 1236–1239) (3.78 g, 10.0 mmol), Cu(OTf)2 (3.62 g, 10.0 mmol), 2,6-dimethylpyridine (1.07 g, 10.0 mmol), HFIP (40 mL), Molecular sieve (approximately 1 g) and DCM (160 mL) yielded the title compound (1.45 g, 53%). LCMS (Method C): R T =0.63min, m / z = 270, 272 [M+H] + .
[0617] Step 2: (2S,5R)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 9, using (2S,5R)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine (1.45 g, 5.37 mmol) and Boc2O (1.4 g, 6.42 mmol) to obtain the title compound (1.77 g, 89%). LCMS (Method C, 5 min gradient): R T =3.54min,m / z=270,272[M-Boc+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.36–7.12 (m, 3H), 4.72 (dd, J = 9.1, 4.9Hz, 1H), 3.92 (td, J = 7.2, 6.8, 4.1Hz, 1H), 3.84 (dd, J = 12.3, 4.7Hz, 1H), 3.76 (dd, J = 13.5, 3.8Hz, 1H), 3.45 (dd, J = 12.3, 8.8Hz, 1H), 3.23 (dd, J = 13.5, 6.5Hz, 1H), 2.31 (s, 3H), 1.25 (d, J = 5.9Hz, 3H), 1.19 (s, 9H). Chiral purity (Method D): R T =5.371min,>98%ee.
[0618] Step 3: (2S,5R)-2-methyl-5-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using (2S,5R)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (600 mg, 1.62 mmol), B2Pin2 (617 mg, 2.43 mmol), Pd(dppf)Cl2·CH2Cl2 (137 mg, 0.162 mmol), KOAc (477 mg, 4.86 mmol), and 1,4-dioxane (17 mL), stirred at 120 °C (microwave irradiation) for 30 min to obtain the title compound (432 mg, 63%) as a pale yellow oil. LCMS (Method B): R T =1.83min, m / z = 318[M - Boc + H] + .
[0619] Step 4: (2S,5R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (97 mg, 0.516 mmol), (2S,5R)-2-methyl-5-(2-methyl-4-(4,4,5,5-tetramethyl- 1,3,2-Dioxoboropentane-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester (431 mg, 1.03 mmol), copper(II) acetate (187 mg, 1.03 mmol), 1,10-phenanthroline (186 mg, 1.03 mmol), boric acid (128 mg, 2.06 mmol), and DMF (10 mL) were reacted at 50 °C for 6 days to give the title compound (107 mg, 43%) as a colorless, glassy substance. LCMS (Method B): R T =1.76min, m / z = 477,479 [M+H] + .
[0620] Step 5: (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylate tert-butyl ester: General procedure 5, using (2S,5R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylate tert-butyl ester (107 mg, 0.224 mmol), aqueous sodium hydroxide solution (4 M, 1.12 mL, 4.48 mmol), and 1,4-dioxane (1.12 mL), acidified with AcOH at 100 °C for 18 h to give the title compound (104 mg, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.28min, m / z = 459,461 [M+H] + .
[0621] Step 6: (2S,5R)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H) -Pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (52 mg, 0.113 mmol), epoxide 2 (42.8 mg, 0.170 mmol), Cs2CO3 (111 mg, 0.340 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (33 mg, 41%) as a colorless glassy substance. LCMS (Method B): R T =1.55 min, m / z = 654,656 [M-Butene + H] + .
[0622] Step 7: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (33 mg, 0.0464 mmol), TFA (1 mL) and DCM (2 mL), freeze-dried to give the title compound (26 mg, 91%) as a white solid. LCMS (Method B): R T =0.87min, m / z = 610,612[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.05(s,1H),7.73(d,J=7.9Hz,1H),7.54–7.47(m,2H),7.42(d,J=8.4Hz,2H),7.27–7 .19(m,2H),6.77(s,1H),4.95(s,1H),4.22–4.09(m,1H),4.01(s,2H),3.98(dd,J=10.0,3.0Hz,1H),3.79(dd, J=10.9,3.0Hz,1H),3.61–3.53(m,1H),3.43–3.33(m,1H),3.28–3.07(m,3H),2.97(dd,J=11.6,2.3Hz,1H),2. 84–2.71(m,1H),2.61–2.52(m,1H),2.41(s,3H),1.68–1.52(m,2H),1.52–1.29(m,2H),1.10(d,J=6.2Hz,3H).
[0623] Example 6: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2S, 3S)-2-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0624]
[0625] Step 1: 4-(tert-butyl)-3-(4,5,6,7-tetrachloro-1,3-dioxoisoindoline-2-yl)(2S,3R)-2-methylmorpholine-3,4-dicarboxylate: General procedure 11, using (2S,3R)-4-(tert-butyloxycarbonyl)-2-methylmorpholine-3-carboxylic acid (1.11 g, 4.54 mmol), 4,5,6,7-tetrachloro-2-hydroxyisoindoline-1,3-dione (1.37 g, 4.54 mmol), EDC (1.04 g, 5.45 mmol), and DMAP (55 mg, 0.454 mmol), yielded the title compound (1.10 g, 46%) as a yellow solid. 1 ¹H NMR (400MHz, chloroform-d) δ 4.60–4.15 (m, 2H), 3.95–3.86 (m, 1H), 3.73–3.61 (m, 1H), 3.60–3.35 (m, 2H), 1.61–1.43 (m, 12H).
[0626] Step 2: (2S,3S)-3-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: Under nitrogen atmosphere, 1,4-dioxane (26 mL) was added to 100 mL of RBF containing 4-(tert-butyl)-3-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)(2S,3R)-2-methylmorpholine-3,4-dicarboxylic acid ester (363 mg, 0.687 mmol) and (4-bromophenyl)boronic acid (414 mg, 2.06 mmol). The reaction mixture was heated to 75 °C (internal temperature), and then triethylamine (958 μL, 6.87 mmol) and NiCl₂⁶H₂O: phenanthroline complex in DMF (0.05 M, 2.6 mL, 0.130 mmol (Angew. Chem. Int. Ed. 2016, 55, 9676–9679)) were added sequentially. The resulting mixture was stirred overnight at 75 °C. After cooling to room temperature, the reaction mixture was diluted with EtOAc (40 mL) and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography to give the title compound (103 mg, 42%) as a colorless, glassy substance. LCMS (Method B): R T =1.61min,m / z=256,258[M-Boc+H] + .
[0627] Step 3: (2S,3S)-2-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using (2S,3S)-3-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (243 mg, 0.682 mmol), B2Pin2 (346 mg, 1.36 mmol), Pd(dppf)Cl2·CH2Cl2 (58 mg, 0.0682 mmol), KOAc (201 mg, 2.046 mmol), and 1,4-dioxane (7 mL), stirred at 120 °C (microwave irradiation) for 30 min to obtain the title compound (133 mg, 48%) as a colorless glassy substance. LCMS (Method B): R T =1.73min, m / z = 304[M - Boc + H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.81–7.74 (m, 2H), 7.46–7.38 (m, 2H), 4.68 (d, J = 4.1 Hz, 1H), 4.29–4.16 (m, 1H), 3.97 (td, J = 10.9, 4.1 Hz, 1H), 3.84–3.75 (m, 1H), 3.74–3.62 (m, 1H), 3.34–3.19 (m, 1H), 1.38 (s, 9H), 1.34 (s, 12H), 1.31 (d, J = 6.4 Hz, 3H).
[0628] Step 4: (2S,3S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (62 mg, 0.330 mmol), (2S,3S)-2-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-) Dioxoborane-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester (133 mg, 0.330 mmol), copper(II) acetate (120 mg, 0.660 mmol), 1,10-phenanthroline (119 mg, 0.660 mmol), boric acid (82 mg, 1.32 mmol), and DMF (6.2 mL) were reacted at 50 °C for 5 days to give the title compound (40 mg, 26%) as a colorless, glassy substance. LCMS (Method B): R T =1.68min, m / z = 463,465 [M+H] + .
[0629] Step 5: (2S,3S)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester: General procedure 5, using (2S,3S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (40 mg, 0.0863 mmol), sodium hydroxide aqueous solution (4 M, 0.43 mL, 1.73 mmol), and 1,4-dioxane (0.43 mL), acidified with AcOH at 100 °C for 18 h to give the title compound (38 mg, 98%) as a yellow glassy substance. LCMS (Method B): R T =1.22min, m / z = 445, 447 [M+H] + .
[0630] Step 6: (2S,3S)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,3S)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H- 39 mg (0.0877 mmol) of pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester, epoxide 2 (33.1 mg, 0.132 mmol), Cs2CO3 (85.7 mg, 0.263 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (14 mg, 22%) as a colorless glassy substance. LCMS (Method B): R T =1.48 min, m / z = 640, 642 [M-Butene + H] + .
[0631] Step 7: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2S,3S)-2-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,3S)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (14 mg, 0.0201 mmol), TFA (1 mL) and DCM (2 mL), freeze-dried to give the title compound (11 mg, 91%) as a white solid. LCMS (Method B): RT =0.85min, m / z = 596,598 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.61–7.54(m,2H),7.54–7.48(m,2H),7.45–7.41(m,2H),7.41– 7.36(m,2H),6.79(s,1H),4.95(s,1H),4.22–4.11(m,1H),4.02(s,2H),3.80(dd,J=10.7,1.9Hz,1H) ,3.62(td,J=11.0,3.0Hz,1H),3.44(d,J=8.7Hz,1H),3.39(dq,J=8.6,6.0Hz,2H),3.28–3.21(m,1H) ,3.19–3.07(m,1H),2.93–2.75(m,3H),1.67–1.52(m,2H),1.52–1.27(m,2H),0.86(d,J=6.0Hz,3H).
[0632] Example 7: 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl 3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0633]
[0634] Step 1: (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4) Dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (41 mg, 0.0922 mmol), epoxide 3 (43.3 mg, 0.138 mmol), Cs2CO3 (90.1 mg, 0.277 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (15 mg, 21%) as a colorless glassy substance. LCMS (Method B): R T =1.58 min, m / z = 702, 704 [M-Butene + H] + .
[0635] Step 2: 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-(( R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (15 mg, 0.0198 mmol), TFA (1 mL), and DCM (2 mL) were freeze-dried to give the title compound (12 mg, 92%) as a white solid. LCMS (Method B): R T =0.89min, m / z = 658,660 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.05(s,0.5H),8.03(s,0.5H),7.64–7.56(m,2H) ,7.46–7.26(m,7H),6.79(s,0.5H),6.79(s,0.5H),4.88(s,1H),4.18–4.0 4(m,1H),4.03–3.68(m,6H),3.62–3.50(m,1H),3.30–3.09(m,3H),3.01– 2.78(m,3H),2.57–2.52(m,2H),1.68–1.16(m,4H),1.09(d,J=6.2Hz,3H).
[0636] Example 8: 6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2R, 3R)-2-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0637]
[0638] Step 1: 4-(tert-butyl)-3-(4,5,6,7-tetrachloro-1,3-dioxoisoindoline-2-yl)(2R,3S)-2-methylmorpholine-3,4-dicarboxylate: General procedure 11, using (2R,3S)-4-(tert-butyloxycarbonyl)-2-methylmorpholine-3-carboxylic acid (581 mg, 2.37 mmol), 4,5,6,7-tetrachloro-2-hydroxyisoindoline-1,3-dione (713 mg, 2.37 mmol), EDC (546 mg, 2.84 mmol), and DMAP (29 mg, 0.237 mmol) to obtain the title compound (513 mg, 41%) as a yellow solid. 1¹H NMR (400MHz, chloroform-d) δ 4.60–4.15 (m, 2H), 3.95–3.86 (m, 1H), 3.73–3.61 (m, 1H), 3.60–3.35 (m, 2H), 1.61–1.43 (m, 12H).
[0639] Step 2: (2R,3R)-3-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: Under nitrogen atmosphere, 1,4-dioxane (37 mL) was added to 100 mL of RBF containing 4-(tert-butyl)-3-(4,5,6,7-tetrachloro-1,3-dioxoisoindolin-2-yl)(2R,3S)-2-methylmorpholine-3,4-dicarboxylic acid ester (513 mg, 0.971 mmol) and (4-bromophenyl)boronic acid (585 mg, 2.91 mmol). The reaction mixture was heated to 75 °C (internal temperature), and then triethylamine (1.35 mL, 9.71 mmol) and NiCl₂₆H₂O: phenanthroline complex in DMF (0.05 M, 3.7 mL, 0.185 mmol, (Angew. Chem. Int. Ed. 2016, 55, 9676–9679)) were added sequentially. The resulting mixture was stirred overnight at 75 °C. After cooling to room temperature, the reaction mixture was diluted with EtOAc (40 mL) and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography to give the title compound (118 mg, 34%) as a colorless, glassy substance. LCMS (Method B): R T =1.61min,m / z=256,258[M-Boc+H] + .
[0640] Step 3: (2R,3R)-2-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using (2R,3R)-3-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (118 mg, 0.331 mmol), B2Pin2 (168 mg, 0.663 mmol), Pd(dppf)Cl2·CH2Cl2 (28.1 mg, 0.0331 mmol), KOAc (97.5 mg, 0.994 mmol) and 1,4-dioxane (4 mL), stirred at 120 °C (microwave irradiation) for 1 h to obtain the title compound (65 mg, 48%) as a white solid. LCMS (Method B): R T =1.76min, m / z = 304[M - Boc + H] + .
[0641] Step 4: (2R,3R)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (30 mg, 0.160 mmol), (2R,3R)-2-methyl-3-(4-(4,4,5,5-tetramethyl-1,3,2-di) Tert-butyl oxoboropentane-2-yl)phenyl)morpholine-4-carboxylate (64.4 mg, 0.160 mmol), copper(II) acetate (58 mg, 0.319 mmol), 1,10-phenanthroline (57.5 mg, 0.319 mmol), boric acid (39.5 mg, 0.638 mmol), and DMF (3 mL) were reacted at 50 °C for 6 days to yield the title compound (24 mg, 32%) as a colorless, glassy substance. LCMS (Method A): R T =1.89min, m / z = 463,465 [M+H] + .
[0642] Step 5: (2R,3R)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester: General procedure 5, using (2R,3R)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (24 mg, 0.0518 mmol), aqueous sodium hydroxide solution (4 M, 0.39 mL, 1.55 mmol), and 1,4-dioxane (0.4 mL), acidified with AcOH at 100 °C for 18 h to give the title compound (24 mg, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.22min, m / z = 445, 447 [M+H] + .
[0643] Step 6: (2R,3R)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2R,3R)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H- 24 mg (0.0539 mmol) of pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester, epoxide 2 (20.4 mg, 0.0809 mmol), Cs2CO3 (52.7 mg, 0.162 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (12 mg, 31%) as a colorless glassy substance. LCMS (Method B): R T =1.48 min, m / z = 640, 642 [M-Butene + H] + .
[0644] Step 7: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2R,3R)-2-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2R,3R)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (12 mg, 0.0172 mmol), TFA (1 mL) and DCM (2 mL), freeze-dried to give the title compound (10 mg, 97%) as a grayish-white solid. LCMS (Method B): R T =0.94min, m / z = 596,598 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.08(s,1H),7.63–7.55(m,2H),7.56–7.48(m,2H),7.46–7.35(m,4H ),6.80(s,1H),4.96(s,1H),4.28–4.09(m,1H),4.03(s,2H),3.88–3.72(m,1H),3.63(td,J=1 1.0,3.0Hz,1H),3.45(d,J=8.7Hz,1H),3.40(dq,J=8.7,6.0Hz,2H),3.30–3.20(m,1H),3.20– 3.05(m,1H),2.93–2.75(m,3H),1.75–1.54(m,2H),1.53–1.25(m,2H),0.86(d,J=6.0Hz,3H).
[0645] Example 9: Racemic-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4- ((3R,6R)-6-(trifluoromethyl)morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0646]
[0647] Step 1: Racemic-(2R,5R)-5-(4-bromophenyl)-2-(trifluoromethyl)morpholine: General procedure 8, using 4-bromobenzaldehyde (5.55 g, 30.0 mmol), 3,3,3-trifluoro-2-((tributyltinyl)methoxy)prop-1-amine (prepared according to the procedure outlined in Org. Lett. 2014, 16(4), 1236–1239, starting with 3-amino-1,1,1-aminoprop-2-ol (13.0 g, 30.0 mmol), Cu(OTf)2 (10.9 g, 30.0 mmol), 2,6-dimethylpyridine (3.21 g, 30.0 mmol), HFIP (120 mL), Molecular sieves (approximately 3 g) and DCM (480 mL) yielded the title compound, which was used in the next step without further purification.
[0648] Step 2: Racemic-(2R,5R)-5-(4-bromophenyl)-2-(trifluoromethyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 10, using racemic-(2R,5R)-5-(4-bromophenyl)-2-(trifluoromethyl)morpholine (1 g, 3.9 mmol) and Boc2O (10.9 g, 50 mmol) to give the title compound (150 mg, 1% (2 steps)). LCMS (Method C): R T =1.63 min, no mass ions observed. This material was used without further purification.
[0649] Step 3: Racemic-(2R,5R)-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)-2-(trifluoromethyl)morpholine-4-carboxylate tert-butyl ester: General procedure 3 (post-treatment A), using racemic-(2R,5R)-5-(4-bromophenyl)-2-(trifluoromethyl)morpholine-4-carboxylate tert-butyl ester (150 mg, 0.366 mmol), B2Pin2 (139 mg, 0.549 mmol), Pd(dppf)Cl2·CH2Cl2 (31 mg, 0.0366 mmol), KOAc (108 mg, 1.10 mmol), and 1,4-dioxane (4 mL), stirred at 120 °C (microwave irradiation) for 1 h to obtain the title compound (135 mg, 80%) as a colorless glassy substance. LCMS (Method B): R T =1.75min, m / z=402 [M-Butene + H] + .
[0650] Step 4: Racemic-(2R,5R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-(trifluoromethyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (55 mg, 0.293 mmol), racemic-(2R,5R)-5-(4-(4,4,5,5-tetramethyl-1,3,2-di) Tert-butyl oxoboropentane-2-yl)phenyl)-2-(trifluoromethyl)morpholine-4-carboxylate (134 mg, 0.293 mmol), copper(II) acetate (106 mg, 0.585 mmol), 1,10-phenanthroline (105 mg, 0.585 mmol), boric acid (72 mg, 1.17 mmol), and DMF (5.5 mL) were reacted at 50 °C for 6 days to give the title compound (17 mg, 11%) as a colorless, glassy substance. LCMS (Method A): R T =1.71 min, m / z = 517,519 [M+H] + .
[0651] Step 5: Racemic-(2R,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-(trifluoromethyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 5, using racemic-(2R,5R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-(trifluoromethyl)morpholine-4-carboxylic acid tert-butyl ester (17 mg, 0.0329 mmol), aqueous sodium hydroxide solution (4 M, 0.25 mL, 1.00 mmol), and 1,4-dioxane (0.25 mL), acidified with AcOH after 18 h at 100 °C to give the title compound (17 mg, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.33min, m / z = 499,501 [M+H] + .
[0652] Step 6: Racemic-(2R,5R)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-(trifluoromethyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using racemic-(2R,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro) 7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-(trifluoromethyl)morpholine-4-carboxylic acid tert-butyl ester (17 mg, 0.0341 mmol), epoxide 2 (12.9 mg, 0.0511 mmol), Cs2CO3 (33.3 mg, 0.102 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (12 mg, 46%) as a colorless glassy substance. LCMS (Method B): R T =1.55min, m / z=694,696[M-Butene + H] + .
[0653] Step 7: Racemic-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6R)-6-(trifluoromethyl)morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using racemic-(2R,5R)-5-(4-(6-chloro-3-((1-(4- 12 mg (0.0160 mmol), TFA (1 mL), and DCM (2 mL) were lyophilized to give the title compound (7 mg, 67%) as a grayish-white solid. LCMS (Method B): R T =1.00min, m / z = 650, 652[M+H] + . 1 H NMR (500MHz, DMSO-d6) δ8.07(s,1H),7.64(d,J=8.1Hz,2H),7.54–7.49(m,2H),7.46(d,J=8.0Hz,2H),7.45–7.39(m,2H),6.81(s,1H),4.96( s,1H),4.31–4.12(m,2H),4.14–3.92(m,4H),3.59–3.45(m,1H),3.45– 3.34(m,2H),3.29–3.04(m,3H),3.03–2.83(m,1H),1.69–1.27(m,4H).
[0654] Example 10: 6-chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)- 4,4,4-Trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and 6-Chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenyl) (Butyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (1:1)
[0655]
[0656] Step 1: 5-(4-bromophenyl)-2,2-dimethylmorpholine: General procedure 8, using 4-bromobenzaldehyde (1.85 g, 10.0 mmol), 2-methyl-2-((tributyltinyl)methoxy)prop-1-amine (prepared from 1-amino-2-methylprop-2-ol according to the procedure outlined in Org. Lett. 2014, 16(4), 1236–1239) (3.92 g, 10.0 mmol), Cu(OTf)2 (3.62 g, 10.0 mmol), 2,6-dimethylpyridine (1.07 g, 10.0 mmol), HFIP (40 mL), Molecular sieve (approximately 1 g) and DCM (160 mL) yielded the title compound (1.74 g, 64%). LCMS (Method C): R T =0.75min, m / z = 270, 272 [M+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.45 (d, J = 7.6Hz, 2H), 7.30 (d, J = 7.6Hz, 2H), 3.86–3.76 (m, 1H), 3.64–3.51 (m, 2H), 2.90–2.79 (m, 2H), 1.43 (s, 3H), 1.22 (s, 3H).
[0657] Step 2: tert-butyl 5-(4-bromophenyl)-2,2-dimethylmorpholine-4-carboxylate: General procedure 9, using 5-(4-bromophenyl)-2,2-dimethylmorpholine (1.74 g, 6.44 mmol) and Boc2O (1.69 g, 7.73 mmol) to give the title compound (2.10 g, 88%). LCMS (Method C): R T =1.64min,m / z=270,272[M-Boc+H] + . 1 H NMR (500MHz, chloroform-d) δ7.46(d,J=8.9Hz,2H),7.33(d,J=8.1Hz,2H),5.04(s,1H),4.14–3.96(m ,2H),3.65(d,J=13.6Hz,1H),2.79(d,J=13.6Hz,1H),1.46(s,9H),1.27(s,3H),1.17(s,3H).
[0658] Step 3: 2,2-Dimethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using 5-(4-bromophenyl)-2,2-dimethylmorpholine (1.40 g, 3.78 mmol), B2Pin2 (1.44 mg, 5.67 mmol), Pd(dppf)Cl2·CH2Cl2 (320 mg, 0.378 mmol), KOAc (1.11 g, 11.3 mmol), and 1,4-dioxane (36 mL), stirred at 100 °C (heat) for 2 h to give the title compound (1.52 g, 96%) as a colorless, glassy substance. LCMS (Method B): R T =1.78min, m / z = 318[M - Boc + H] + .
[0659] Step 4: 5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (457 mg, 2.43 mmol), 2,2-dimethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-) 1,10-Phenanthroline (1.52 g, 3.65 mmol), copper(II) trifluoroacetate hydrate (1.41 mg, 4.86 mmol), 1,10-phenanthroline (876 mg, 4.86 mmol), boric acid (601 mg, 9.72 mmol), and DMF (46 mL) were reacted at 50 °C for 4 days to give the title compound (772 mg, 66%) as a colorless, glassy substance. LCMS (Method B): R T =1.74min, m / z = 477,479 [M+H] + .
[0660] Step 5: 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylate tert-butyl ester: General procedure 5, using 5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylate tert-butyl ester (97 mg, 0.203 mmol), aqueous sodium hydroxide solution (4 M, 1.52 mL, 6.09 mmol), and 1,4-dioxane (1.6 mL), acidified with AcOH at 100 °C for 18 h to give the title compound (94 mg, quantitative) as a yellow glassy substance. LCMS (Method B): R T =1.30min, m / z = 459,461 [M+H] + .
[0661] Step 6: (S)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester and (R)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl) tert-butyl 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylate (1:1): General procedure 6, using tert-butyl 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylate (47 mg, 0.102 mmol), epoxide 3 (48.1 mg, 0.154 mmol), Cs₂CO₃ (100 mg, 0.307 mmol) and DMF (3 mL), at 80 °C for 18 h, yielded the title compound (27 mg, 34%) as a colorless glassy substance. LCMS (Method B): R T =1.62 min, m / z = 716,718 [M-Butene + H] + .
[0662] Step 7: 6-chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and 6-chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (1:1): General procedure 7, using (S)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4,4,4-dimethylmorpholin-3-yl)phenyl)-3-((R)-4,4,4-difluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (1:1): (R)-5-(4-(6-chloro-3-((4-hydroxy-1-(((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylic acid tert-butyl ester (1:1) (27 mg, 0.0350 mmol), TFA (1 mL), and DCM (2 mL) were freeze-dried to give the title compound (23 mg, 97%) as a grayish-white solid. T =0.94min, m / z = 672,674 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.05(s,0.5H),8.03(s,0.5H),7.68–7.61(m,2H),7.47–7.27(m,7 H),6.80(s,0.5H),6.80(s,0.5H),4.88(s,1H),4.17–4.05(m,1H),4.03–3.80(m,4H),3.8 0–3.71(m,1H),3.62–3.55(m,1H),3.55–3.44(m,1H),3.28–3.11(m,2H),3.00–2.66(m,5H ),1.63–1.56(m,0.5H),1.46–1.26(m,3H),1.36(s,3H),1.25–1.16(m,0.5H),1.14(s,3H).
[0663] Example 11: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S, 6R)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0664]
[0665] Step 1: (2R,5S)-5-(4-bromophenyl)-2-methylmorpholine: General procedure 8, using 4-bromobenzaldehyde (1.85 g, 10.0 mmol), (R)-2-((tributyltinyl)methoxy)prop-1-amine (prepared from (R)-1-aminoprop-2-ol according to the procedure outlined in Org. Lett. 2014, 16(4), 1236–1239) (3.78 g, 10.0 mmol), Cu(OTf)2 (3.62 g, 10.0 mmol), 2,6-dimethylpyridine (1.07 g, 10.0 mmol), HFIP (40 mL), Molecular sieve (approximately 1 g) and DCM (160 mL) yielded the title compound (1.10 g, 43%). LCMS (Method C): R T =0.81min, m / z = 256,258 [M+H] + .
[0666] Step 2: (2R,5S)-5-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 9, using (2R,5S)-5-(4-bromophenyl)-2-methylmorpholine (1.10 g, 4.30 mmol) and Boc2O (1.12 g, 5.15 mmol) to obtain the title compound (1.4 g, 91%). LCMS (Method C): R T =1.60min,m / z=256,258[M-Boc+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.45 (d, J = 8.4Hz, 2H), 7.24 (d, J = 8.8Hz, 2H), 4.76 (t, J = 5.2Hz, 1H), 4.01 (dd, J = 12.3, 4.6Hz, 1H), 3.98–3.92 (m, 1H), 3.71 (dd, J = 12.3, 5.8Hz, 1H), 3.51 (dd, J = 13.5, 3.8Hz, 1H), 3.36 (dd, J = 13.5, 4.8Hz, 1H), 1.34 (s, 9H), 1.28 (d, J = 6.4Hz, 3H). Chiral purity (Method B): R T =10.61min,>99%ee.
[0667] Step 3: (2R,5S)-2-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using (2R,5S)-5-(4-bromophenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (600 mg, 1.68 mmol), B2Pin2 (642 mg, 2.53 mmol), Pd(dppf)Cl2·CH2Cl2 (143 mg, 0.168 mmol), KOAc (496 mg, 5.05 mmol), and 1,4-dioxane (16.8 mL), stirred at 120 °C (heat) for 1 h to give the title compound (541 mg, 79%) as a colorless glassy substance. LCMS (Method B): R T =1.77min, m / z=348 [M-Butene + H] + . 1 H NMR (500MHz, DMSO-d6) δ7.64(d,J=8.0Hz,2H),7.32(d,J=8.0Hz,2H),4.76(t,J=5.4Hz,1H),3.97-3.88(m,2H),3.66( q,J=6.1Hz,1H),3.46(dd,J=13.6,4.1Hz,1H),3.34(dd,J=13.5,4.5Hz,1H),1.28(s,12H),1.27(s,9H),1.17(s,3H).
[0668] Step 4: (2R,5S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (127 mg, 0.676 mmol), (2R,5S)-2-methyl-5-(4-(4,4,5,5-tetramethyl-1,3,2) tert-butyl dioxoboropentane-2-yl)phenyl)morpholine-4-carboxylate (545 mg, 1.35 mmol), copper(II) acetate (245 mg, 1.35 mmol), 1,10-phenanthroline (243 mg, 1.35 mmol), boric acid (167 mg, 2.70 mmol), and DMF (6.8 mL) were reacted at 50 °C for 4 days to give the title compound (122 mg, 38%) as a colorless, glassy substance. LCMS (Method A): R T =1.69min, m / z = 463,465 [M+H] + .
[0669] Step 5: Tert-butyl (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate: A solution of (2R,5S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate (100 mg, 0.216 mmol) and an aqueous solution of sodium hydroxide (2 M, 1.62 mL, 3.24 mmol) in 1,4-dioxane (2 mL) was heated at 100 °C for 18 h. After cooling to room temperature, water was added and the aqueous phase was extracted with DCM (3 x 15 mL). The combined organic phases were concentrated under reduced pressure to give the title compound (96 mg, quantified) as a white solid. LCMS (Method B): R T =1.24min, m / z = 445, 447 [M+H] + .
[0670] Step 6: (2R,5S)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H- 40 mg (0.0899 mmol) of pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester, epoxide 2 (27.1 mg, 0.108 mmol), Cs2CO3 (64.4 mg, 0.198 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (20 mg, 31%) as a white solid. LCMS (Method B): R T =1.49 min, m / z = 640, 642 [M-Butene + H] + .
[0671] Step 7: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2R,5S)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (20 mg, 0.0287 mmol), TFA (0.35 mL), and DCM (0.7 mL), lyophilized to give the title compound (8.5 mg, 47%) as a white solid. LCMS (Method B): R T =0.97min, m / z = 596,598 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.62–7.58(m,2H),7.52–7.48(m,2H),7.44–7.37(m,4H),6.79 (s,1H),4.95(s,1H),4.22–4.12(m,1H),4.02(s,2H),3.87–3.78(m,2H),3.60–3.50(m,1H),3.42–3 .33(m, 1H), 3.29–3.21(m, 2H), 3.17–3.08(m, 1H), 2.95(dd, J = 11.7, 2.3Hz, 1H), 2.93–2.84(m, 1H), 2.57–2.53(m, 1H), 1.68–1.53(m, 2H), 1.51–1.41(m, 1H), 1.38–1.27(m, 1H), 1.09(d, J = 6.2Hz, 3H). Chiral purity (Method C): R T =3.96min, 100%ee.
[0672] Example 12: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-yl) ((3S,6R)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0673]
[0674] Step 1: (2R,5S)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine: General procedure 8, using 4-bromo-2-methylbenzaldehyde (1.99 g, 10.0 mmol), (R)-2-((tributyltinyl)methoxy)prop-1-amine (prepared from (R)-1-aminoprop-2-ol according to the procedure outlined in Org. Lett. 2014, 16(4), 1236–1239) (3.78 g, 10.0 mmol), Cu(OTf)2 (3.62 g, 10.0 mmol), 2,6-dimethylpyridine (1.07 g, 10.0 mmol), HFIP (40 mL), Molecular sieve (approximately 1 g) and DCM (160 mL) yielded the title compound (1.73 g, 66%). LCMS (Method C): R T =0.88min, m / z = 270, 272 [M+H] + .
[0675] Step 2: (2R,5S)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 9, using (2R,5S)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine (1.73 g, 6.60 mmol) and Boc2O (1.4 g, 7.92 mmol) to obtain the title compound (2.25 g, 92%). LCMS (Method C): R T =1.69min,m / z=270,272[M-Boc+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.36–7.12 (m, 3H), 4.72 (dd, J = 9.1, 4.9Hz, 1H), 3.92 (td, J = 7.2, 6.8, 4.1Hz, 1H), 3.84 (dd, J = 12.3, 4.7Hz, 1H), 3.76 (dd, J = 13.5, 3.8Hz, 1H), 3.45 (dd, J = 12.3, 8.8Hz, 1H), 3.23 (dd, J = 13.5, 6.5Hz, 1H), 2.31 (s, 3H), 1.25 (d, J = 5.9Hz, 3H), 1.19 (s, 9H). Chiral purity (Method D): R T =4.742min,>99%ee.
[0676] Step 3: (2R,5S)-2-methyl-5-(2-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylate tert-butyl ester: General procedure 3 (post-treatment B), using (2R,5S)-5-(4-bromo-2-methylphenyl)-2-methylmorpholine-4-carboxylate tert-butyl ester (1.57 g, 4.24 mmol), B2Pin2 (1.62 g, 6.36 mmol), Pd(dppf)Cl2·CH2Cl2 (359 mg, 0.424 mmol), KOAc (1.25 g, 12.7 mmol), and 1,4-dioxane (42.4 mL), stirred at 100 °C (heat) for 65 min to give the title compound (1.92 g, >100%) as a yellow oil. LCMS (Method A): R T =2.03 min, m / z = 362 [M-Butene + H] + .
[0677] Step 4: (2R,5S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment B), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (620 mg, 3.30 mmol), (2R,5S)-2-methyl-5-(2-methyl-4-(4,4,5,5-tetramethyl-1, tert-butyl 3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylate (1.79 g, 4.29 mmol), copper(II) trifluoroacetate hydrate (1.91 g, 6.60 mmol), 1,10-phenanthroline (1.19 g, 6.60 mmol), boric acid (530 mg, 8.57 mmol), and DMF (33 mL) were reacted at 50 °C for 5 days to give the title compound (970 mg, 61%) as a white foam. LCMS (Method A): R T =1.99min, m / z = 477,479[M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.61(s,1H),7.54(d,J=8.1Hz,1H),7.36–7.28(m,2H),7.08(s,1H),4.81(dd,J=8.9,5.0Hz,1H),4.03–3.97(m,1H),3.95( dd,J=12.1,5.0Hz,1H),3.81(dd,J=13.4,4.0Hz,1H),3.52(dd,J=12.1,9.0Hz,1H),3.23(dd,J=13.5,6.5Hz,1H),2.40(s,3H),1.22–1.16(m,12H).
[0678] Step 5: (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylate tert-butyl ester: General procedure 5, using (2R,5S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylate tert-butyl ester (968 mg, 2.03 mmol), aqueous sodium hydroxide solution (4 M, 5.07 mL, 20.3 mmol), and 1,4-dioxane (10.1 mL), acidified with 2 M hydrochloric acid solution after 47 h at 100 °C to give the title compound (1.07 g, >100%) as a brown foam. LCMS (Method A): R T =1.36min, m / z = 459,461 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ12.16(br.s,1H),7.84(s,1H),7.48(d,J=8.1Hz,1H), 7.25–7.19(m,2H),6.69(s,1H),4.80(dd,J=8.9,5.1Hz,1H),4.04–3.95(m,1H ), 3.93 (dd, J = 12.1, 5.1 Hz, 1H), 3.79 ( dd, J = 13.5, 4.0 Hz, 1H), 3.50 ( dd, J = 12. 1,9.0Hz,1H),3.23(dd,J=13.5,6.3Hz,1H),2.38(s,3H),1.20–1.16(m,12H).
[0679] Step 6: (2R,5S)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrololine-4-carboxylic acid tert-butyl ester): The title compound (119 mg, 52%) was obtained by reacting tert-butyl pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholino-4-carboxylate (150 mg, 0.327 mmol), epoxide 2 (123 mg, 0.490 mmol), Cs2CO3 (213 mg, 0.654 mmol), and DMF (3.3 mL) at 80 °C for 18 h. LCMS (Method B): R T =1.54 min, m / z = 654,656 [M-Butene + H] + .
[0680] Step 7: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2R,5S)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-) Hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (119 mg, 0.168 mmol), TFA (2 mL), and DCM (4 mL) were purified by rapid chromatography and lyophilized to give the title compound (66 mg, 64%) as a white solid. LCMS (Method B): R T =0.85min, m / z = 610,612[M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.73(d,J=7.9Hz,1H),7.56–7.48(m,2H),7.49–7.38 (m,2H),7.23(s,2H),6.78(s,1H),4.96(s,1H),4.17(s,1H),4.00(d,J=21.0Hz,3H),3.80 (dd,J=10.9,3.0Hz,1H),3.46–3.33(m,1H),3.30–3.08(m,3H),3.02–2.92(m,1H),2.83–2 .71(m,1H),2.58(t,J=10.7Hz,1H),2.42(s,3H),1.71–1.26(m,4H),1.10(d,J=6.2Hz,3H).
[0681] Example 13: 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl 3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0682]
[0683] Step 1: (2R,5S)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-) Dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (40 mg, 0.0899 mmol), epoxide 3 (33.8 mg, 0.108 mmol), Cs₂CO₃ (64.4 mg, 0.198 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (18.5 mg, 27%) as a colorless glassy substance. LCMS (Method B): R T =1.57 min, m / z = 702, 704 [M-Butene + H] + .
[0684] Step 2: 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2R,5S)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4) 4,4-Trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (18.5 mg, 0.0244 mmol), TFA (0.35 mL), and DCM (0.7 mL) were freeze-dried to give the title compound (7.4 mg, 43%) as a white solid. LCMS (Method B): R T =0.89min, m / z = 658,660 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.05(s,0.5H),8.03(s,0.5H),7.76–7.13(m,9H), 6.79(s,0.5H),6.79(s,0.5H),4.88(s,1H),4.17–3.69(m,7H),3.60–3.51( m,1H),3.29–3.10(m,3H),3.06–2.72(m,4H),2.57–2.52(m,1H),1.64–1.5 5(m,0.5H),1.49–1.27(m,3H),1.22–1.17(m,0.5H),1.09(d,J=6.2Hz,3H).
[0685] Example 14: 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl )-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine- 4-keto
[0686]
[0687] Step 1: (2R,5S)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: (2R,5S)-5-(4-(6-chloro-4- A solution of tert-butyl oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylate (40 mg, 0.0872 mmol), epoxide 3 (34 mg, 0.109 mmol), and DIPEA (76 μL, 0.436 mmol) in DMF (0.87 mL) was stirred at 100 °C for 20 h. After cooling to room temperature, the reaction mixture was diluted with saturated sodium bicarbonate aqueous solution (15 mL) and used... The resulting suspension was extracted with DCM (3 x 10 mL) using a phase separator. The combined organic phases were concentrated under reduced pressure, and the residue was purified by rapid chromatography to give the title compound (38.6 mg, 57%) as a white solid. LCMS (Method A): R T =1.61 min, m / z = 716,718 [M-Butene + H] + .
[0688] Step 2: 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2R,5S)-5-(4-(6-chloro-3-((4-hydroxy-1-((R)-4, 4,4-Trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-2-methylphenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (38.6 mg, 0.0500 mmol), TFA (0.25 mL), and DCM (0.5 mL) were freeze-dried to give the title compound (31.3 mg, 91%) as a grayish-white solid. LCMS (Method B): R T =0.96min, m / z = 672,674 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.04(s,0.5H),8.02(s,0.5H),7.73(d,J=8.0Hz,1H),7.51–7.28(m,5H),7 .28–7.11(m,2H),6.78(s,1H),4.88(s,1H),4.17–4.04(m,1H),4.05–3.85(m,4H),3.84–3.71(m,2H ),3.58(ddd,J=8.9,6.3,2.3Hz,1H),3.29–3.10(m,3H),3.04–2.67(m,4H),2.58(t,J=10.9Hz,1H) ,2.41(s,3H),1.63–1.56(m,0.5H),1.45–1.27(m,3H),1.23–1.17(m,0.5H),1.10(d,J=6.2Hz,3H).
[0689] Example 15: 6-Chloro-7-(4-(5,5-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclo) (propane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0690]
[0691] Step 1: 5-(4-Bromophenyl)-3,3-Dimethylmorpholine: General Procedure 8, using 4-bromobenzaldehyde (1.85 g, 10.0 mmol), 2-methyl-1-((tributyltinyl)methoxy)prop-2-amine (Helv. Chim. Acta 2020, 103, e2000179) (3.92 g, 10.0 mmol), Cu(OTf)2 (3.62 g, 10.0 mmol), 2,6-dimethylpyridine (1.07 g, 10.0 mmol), HFIP (40 mL). Molecular sieve (approximately 1 g) and DCM (160 mL) yielded the title compound (360 mg, 13%). LCMS (Method C): R T =0.78min, m / z = 270, 272 [M+H] + . 1 H NMR (500MHz, chloroform-d) δ7.44(d,J=8.9Hz,2H),7.28(d,J=8.4Hz,2H),4.19(dd,J=10.5,3.6Hz,1H),3.82(dd,J=10. 9, 3.6Hz, 1H), 3.52 (d, J = 10.8Hz, 1H), 3.28 (d, J = 10.9Hz, 2H), 3.16 (d, J = 10.6Hz, 1H), 1.35 (s, 3H), 1.06 (s, 3H).
[0692] Step 2: tert-butyl 5-(4-bromophenyl)-3,3-dimethylmorpholine-4-carboxylate: General procedure 10, using 5-(4-bromophenyl)-3,3-dimethylmorpholine (360 mg, 1.33 mmol) and Boc2O (580 mg, 2.66 mmol) to give the title compound (310 mg, 63%). LCMS (Method C): R T =1.60min,m / z=270,272[M-Boc+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.44 (d, J = 8.4Hz, 2H), 7.26 (d, J = 7.4Hz, 2H), 4.92 (t, J = 4.7Hz, 1H), 4.12–4.03 (m, 2H), 3.48 (d, J = 11.6Hz, 1H), 3.31 (d, J = 11.7Hz, 1H), 1.47 (s, 3H), 1.37 (d, J = 3.2Hz, 12H).
[0693] Step 3: 3,3-Dimethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylate tert-butyl ester: General procedure 3 (post-treatment B), using 5-(4-bromophenyl)-3,3-dimethylmorpholine-4-carboxylate tert-butyl ester (310 mg, 0.8372 mmol), B2Pin2 (319 mg, 1.26 mmol), Pd(dppf)Cl2·CH2Cl2 (70.9 mg, 0.0837 mmol), KOAc (247 mg, 2.51 mmol), and 1,4-dioxane (8.4 mL), stirred at 100 °C (heat) for 2 h 10 min to obtain the title compound (390 mg, >100%) as a pale yellow oil. LCMS (Method A): R T =2.09min, m / z = 418[M+H] + . 1 H NMR (500MHz, DMSO-d6) δ 7.64 (d, J = 8.1Hz, 2H), 7.35 (d, J = 7.8Hz, 2H), 4.89 (t, J = 4.6Hz, 1H), 4.02 (d, J = 4.6Hz, 2H), 3.36 (d, J = 11.7Hz, 1H), 3.30 (d, J = 11.8Hz, 1H (signal overlaps with HDO)), 1.13-1.49 (m, 27H).
[0694] Step 4: 5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment B), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (130 mg, 0.692 mmol), 3,3-dimethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl- 2-(2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester (346 mg, 0.830 mmol), copper(II) trifluoroacetate hydrate (290 mg, 1.38 mmol), 1,10-phenanthroline (249 mg, 1.38 mmol), boric acid (103 mg, 1.66 mmol), and DMF (7 mL) were reacted at 50 °C for 4 days to yield the title compound (181 mg, 54%) as a grayish-white foam. LCMS (Method B): R T =1.77min, m / z = 477,479 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.62(s,1H),7.58–7.53(m,2H),7.53–7.48(m,2H),7.10(s,1H),4.96(t,J=4.9Hz,1H),4.11(dd,J=11.8, 4.8Hz, 1H), 4.03 (dd, J = 11.7, 5.1Hz, 1H), 3.46 (d, J = 11.7Hz, 1H), 3.40 (d, J = 11.6Hz, 1H), 1.44 (s, 3H), 1.42 (s, 3H), 1.30 (s, 9H).
[0695] Step 5: 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholine-4-carboxylate tert-butyl ester: General procedure 5, using 5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholine-4-carboxylate tert-butyl ester (179 mg, 0.375 mmol), aqueous sodium hydroxide solution (4 M, 937 μL, 3.75 mmol), and 1,4-dioxane (1.9 mL), at 100 °C for 18 h 30 min, followed by acidification with 2 M hydrochloric acid solution to give the title compound (171.3 mg, 99.5%) as a yellow solid. LCMS (Method A): R T =1.43min, m / z = 459,461 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ12.16(br.s,1H),7.84(s,1H),7.52–7.47(m,2H),7.42–7.37(m,2H),6.68(s,1H),4.94(t,J=4.8Hz,1H),4.10(dd ,J=11.7,4.8Hz,1H),4.04(dd,J=11.7,5.0Hz,1H),3.45(d,J=11.7Hz,1H),3.38(d,J=11.6Hz,1H),1.43(s,3H),1.41(s,3H),1.30(s,9H).
[0696] Step 6: 5-(4-(6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholine-4-carboxylic acid tert-butyl ester: [-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholino-4-carboxylic acid tert-butyl ester (10 mg, 0.0218 mmol), epoxide 1 (6.4 mg, 0.0327 mmol), Cs2CO3 (14.2 mg, 0.0436 mmol), and DMF (0.44 mL) were reacted at 80 °C for 19 h to give the title compound (8 mg, 56%) as a yellow glassy substance. LCMS (Method A): R T =1.55min, m / z = 654,656 [M+H] + .
[0697] Step 7: 6-Chloro-7-(4-(5,5-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: A solution of 5-(4-(6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholin-4-carboxylic acid tert-butyl ester (8 mg, 0.0122 mmol) in TFA (0.2 mL) and DCM (0.4 mL) was stirred for 30 min, and then the reaction mixture was concentrated under reduced pressure. The residue was dissolved in 1:1 DCM / triethylamine (1 mL) and analyzed by rapid chromatography (…). The solution was purified by purifying a KP-Amino D 11g filter cartridge in cyclohexane (0-100% DCM), followed by 0-10% MeOH in DCM. The resulting solution was lyophilized to give the title compound (6.6 mg, 94%) as a white solid. LCMS (Method B): R T =0.71min, m / z = 554,556 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.66–7.58(m,2H),7.42–7.34(m,2H),6.80(s,1H),4.91 (s,1H),4.22(dd,J=10.5,3.4Hz,1H),4.00(s,2H),3.95(dt,J=13.2,4.1Hz,2H),3.84(dd,J=1 0.5,3.5Hz,1H),3.46(d,J=10.6Hz,1H),3.22–2.98(m,4H),2.43(s,1H),1.57–1.45(m,2H),1. 43–1.35(m,2H),1.28(s,3H),1.21(s,3H),1.02(s,3H),0.81–0.72(m,2H),0.57–0.45(m,2H).
[0698] Example 16: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(5,5-di) Methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0699]
[0700] Step 1: 5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]) tert-butyl pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholine-4-carboxylate (10 mg, 0.0218 mmol), epoxide 2 (8.2 mg, 0.0327 mmol), Cs₂CO₃ (14.2 mg, 0.0436 mmol), and DMF (0.44 mL) were reacted at 80 °C for 19 h to give the title compound (8.1 mg, 52%) as a yellow glassy substance. LCMS (Method A): R T =1.74min, m / z = 710,712[M+H] + .
[0701] Step 2: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(5,5-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: A solution of 5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-3,3-dimethylmorpholin-4-carboxylic acid tert-butyl ester (8.1 mg, 0.0114 mmol) in TFA (0.2 mL) and DCM (0.4 mL) was stirred for 30 min, and then the reaction mixture was concentrated under reduced pressure. The residue was dissolved in 1:1 DCM / triethylamine (1 mL) and analyzed by rapid chromatography (…). The solution was purified using a KP-Amino D 11g filter cartridge in cyclohexane (0-100% DCM), followed by purification in DCM (0-10% MeOH). The resulting solution was lyophilized to give the title compound (7.1 mg, 94%) as a white solid. LCMS (Method B): R T =0.84min, m / z = 610,612[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.66–7.59(m,2H),7.53–7.47(m,2H),7.44–7.40(m,2 H),7.40–7.35(m,2H),6.79(s,1H),4.95(s,1H),4.25–4.19(m,1H),4.16(br.s,1H),4.02(s ,2H),3.84(dd,J=10.6,3.4Hz,1H),3.46(d,J=10.6Hz,1H),3.41–3.03(m,5H (signal overlaps with HDO)),2.42(br.s,1H),1.60(br.s,2H),1.46(br.s,1H),1.33(br.s,1H),1.27(s,3H),1.02(s,3H).
[0702] Example 17: Racemic-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0703]
[0704] Step 1: Racemic (2R,5S)-5-(4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4-chloro-7H-pyrrolo[2,3-d]pyrimidin (41 mg, 0.267 mmol), racemic (2R,5S)-2-methyl-5-(4-(4,4,5,5-tetramethyl-1,3, 2-Dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester (215 mg, 0.534 mmol), copper(II) acetate (97 mg, 0.534 mmol), 1,10-phenanthroline (96 mg, 0.534 mmol), boric acid (66 mg, 1.07 mmol), and DMF (23 mL) were reacted at 50 °C for 5 days to give the title compound (95 mg, 83%) as a colorless, glassy substance. LCMS (Method B): R T =1.57min, m / z = 429,431 [M+H] + .
[0705] Step 2: Racemic-(2R,5S)-2-methyl-5-(4-(4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: A solution of racemic-(2R,5S)-5-(4-(4-chloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester (95 mg, 0.222 mmol) and an aqueous solution of sodium hydroxide (2 M, 1.66 mL, 3.32 mmol) in 1,4-dioxane (2.5 mL) was heated at 100 °C for 18 h. After cooling to room temperature, water was added and the resulting mixture was extracted with DCM (3 x 15 mL). The combined organic phases were concentrated under reduced pressure to give the title compound (90.3 mg, 99%) as a white solid. LCMS (Method B): R T =1.14min, m / z = 411[M+H] + .
[0706] Step 3: Racemic-(2R,5S)-5-(4-(3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using racemic-(2R,5S)-2-methyl-5-(4-(4-oxo-3,4-dihydro-7H-pyrrololine) tert-butyl ester Tert-butyl pyrimidin-7-yl)phenyl)morpholine-4-carboxylate (90 mg, 0.219 mmol), epoxide 2 (66 mg, 0.263 mmol), Cs2CO3 (157 mg, 0.482 mmol), and DMF (1.5 mL) were purified by preparative HPLC at 80 °C for 18 h to obtain the title compound (73.1 mg, 50%) as a white solid. LCMS (Method B): R T =1.40 min, m / z = 606,608 [M-Butene + H] + .
[0707] Step 4: Racemic-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using racemic-(2R,5S)-5-(4-(3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (73 mg, 0.110 mmol), TFA (0.25 mL) and DCM (0.25 mL), freeze-dried to give the title compound (61 mg, 97%) as a white solid. LCMS (Method B): R T =0.77min, m / z = 562,564 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.13(s,1H),7.80–7.64(m,2H),7.64–7.54(m,2H),7.54–7.45 (m,3H),7.45–7.35(m,2H),6.74–6.65(m,1H),4.96(s,1H),4.17(br.s,1H),4.05(br. s,3H),3.87(br.s,1H),3.69(br.s,1H),3.62–3.20(m,3H (signal overlaps with HDO)),3.13(br.s,3H),2.69(br.s,1H),1.61(br.s,2H),1.48(br.s,1H),1.34(br.s,1H),1.13(br.s,3H).
[0708] Example 18: 7-(4-(7-oxa-4-azaspiro[2.5]oct-5-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzyl) Acyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0709]
[0710] Step 1: 5-(4-bromophenyl)-4-(4-methoxybenzyl)morpholin-3-one: A solution of 5-(4-bromophenyl)morpholin-3-one (3.30 g, 12.9 mmol) in DMF (129 mL) was cooled to 0 °C, and sodium hydride (60% in mineral oil) (670 mg, 27.9 mmol) was added. The reaction mixture was heated to room temperature and stirred for 1 h, and then 1-(chloromethyl)-4-methoxybenzene (2.22 g, 14.2 mmol) was slowly added. After stirring at room temperature for 12 h, the reaction mixture was diluted with EtOAc and then washed with water and brine. The organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography to give the title compound (3.9 g, 80%). LCMS (Method C): R T =1.36, m / z = 376, 378 [M+H] + . 1 H NMR (500MHz, chloroform-d) δ7.52(d,J=8.4Hz,2H),7.10(d,J=8.1Hz,2H),7.06(d, J=8.1Hz,2H),6.84(d,J=8.0Hz,2H),5.48(d,J=14.6Hz,1H),4.41(d,J=16. 4Hz,1H),4.31(dd,J=16.8,1.6Hz,1H),4.28–4.23(m,1H),3.91(ddd,J=12. 0,3.9,1.6Hz,1H),3.80(s,3H),3.78–3.73(m,1H),3.35(d,J=14.3Hz,1H).
[0711] Step 2: 5-(4-bromophenyl)-4-(4-methoxybenzyl)-7-oxa-4-azaspiro[2.5]octane: A solution of ethyl magnesium bromide (3.4 M in THF) (9.15 mL, 31.1 mmol) was added to a solution of isopropyl titanate (IV) (3.24 g, 11.4 mmol) in anhydrous THF (55 mL) at -60 °C. 5-(4-bromophenyl)-4-(4-methoxybenzyl)morpholin-3-one (3.90 g, 10.4 mmol) was added dropwise to a solution of THF (10 mL), and the mixture was stirred at -60 °C for 2 h. The mixture was quenched with a saturated aqueous ammonium chloride solution / water and volatiles were removed under reduced pressure. The residue was diluted with water and washed with EtOAc. The organic layer was dried over sodium sulfate, filtered, and concentrated under reduced pressure to give the title compound (0.9 g, 22%). LCMS (Method C): R T =1.58, m / z = 388, 390 [M+H] + . 1 H NMR (400MHz, chloroform-d) δ7.33(d,J=8.5Hz,2H),7.24(d,J=8.5Hz,2H),7.17(d,J= 8.6Hz,2H),6.81(d,J=8.6Hz,2H),4.04(dd,J=11.9,3.5Hz,1H),3.95(dd,J=1 1.9,5.6Hz,1H),3.81–3.76(m,4H),3.74–3.70(m,1H),3.66(d,J=11.2Hz,1H) ,3.54–3.45(m,2H),0.36–0.28(m,2H),0.68–0.60(m,1H),0.43–0.36(m,1H).
[0712] Step 3: 5-(4-bromophenyl)-7-oxa-4-azaspiro[2.5]octane: A solution of 5-(4-bromophenyl)-4-(4-methoxybenzyl)-7-oxa-4-azaspiro[2.5]octane (0.9 g, 2.32 mmol) in TFA (10 mL) was heated overnight at 70 °C. The reaction mixture was concentrated under reduced pressure and the residue was purified by rapid chromatography to give the title compound (0.3 g, 47%). LCMS (Method C): R T =0.72, m / z = 268,270 [M+H] + . 1¹H NMR (500MHz, chloroform-d) δ 7.44 (d, J = 8.1 Hz, 2H), 7.21 (d, J = 8.4 Hz, 2H), 4.08 (dd, J = 10.3, 3.2 Hz, 1H), 3.97–3.90 (m, 2H), 3.35 (d, J = 11.3 Hz, 1H), 3.16 (d, J = 11.2 Hz, 1H), 0.79–0.69 (m, 1H), 0.67–0.53 (m, 3H).
[0713] Step 4: tert-butyl 5-(4-bromophenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylate: A solution of 5-(4-bromophenyl)-7-oxa-4-azaspiro[2.5]octane (0.3 g, 1.10 mmol) and Boc₂O (0.48 g, 2.2 mmol) in MeCN (2 mL) was stirred overnight at 70 °C. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure, and the residue was purified by rapid chromatography to give the title compound (368 mg, 91%). LCMS (Method C): R T 1.50min,m / z=268,270[M-Boc+H] + . 1 ¹H NMR (500MHz, chloroform-d) δ 7.59–7.35 (m, 4H), 5.29–5.20 (m, 1H), 4.37 (dd, J = 12.3, 2.2Hz, 1H), 4.05 (dd, J = 11.0, 2.2Hz, 1H).
[0714] 3.91(dd,J=12.2,4.2Hz,1H),3.00(d,J=11.0Hz,1H),1.50(s,9H),1.23(dt,J=10.0,7.1Hz,1H),0. 65(dt,J=9.9,6.8Hz,1H), 0.38(ddd,J=10.0,7.2,5.2Hz,1H), -0.03(ddd,J=10.9,7.7,5.4Hz,1H).
[0715] Step 5: 5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using 5-(4-bromophenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylic acid tert-butyl ester (385 mg, 1.05 mmol), B2Pin2 (398 mg, 1.57 mmol), Pd(dppf)Cl2·CH2Cl2 (88.5 mg, 0.105 mmol), KOAc (308 mg, 3.14 mmol) and 1,4-dioxane (11 mL), stirred at 100 °C (microwave) for 1 h to obtain the title compound (374 mg, 85%) as a pale yellow oil. LCMS (Method B): R T =1.74min, m / z = 316[M - Boc + H] + .
[0716] Step 6: 5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2,5]octane-4-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (113 mg, 0.601 mmol), 5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentan-2-yl)phenyl)-7-oxa- 4-Zazaspiro[2.5]octane-4-carboxylic acid tert-butyl ester (374 mg, 0.902 mmol), copper(II) trifluoroacetate hydrate (348 mg, 1.20 mmol), 1,10-phenanthroline (217 mg, 1.20 mmol), boric acid (149 mg, 2.40 mmol), and DMF (11.3 mL) were reacted at 65 °C for 1 day and at 80 °C for 12 h to give the title compound (62 mg, 21%) as a colorless glassy substance. LCMS (Method B): R T =1.74min, m / z = 475, 477 [M+H] + .
[0717] Step 7: 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylic acid tert-butyl ester: General procedure 5, using 5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylic acid tert-butyl ester (62 mg, 0.130 mmol), sodium hydroxide aqueous solution (4 M, 0.98 mL, 3.91 mmol), and 1,4-dioxane (1 mL), acidified with 1 M potassium hydrogen sulfate aqueous solution after 18 h at 100 °C to give the title compound (60 mg, quantitative) as a yellow glassy substance. LCMS (Method B): R T =1.29min, m / z = 457,459[M+H] + .
[0718] Step 8: 5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2,3-d]octane-4-carboxylic acid tert-butyl ester: General procedure 6, using 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo ... tert-butyl pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylate (30 mg, 0.0657 mmol), epoxide 2 (24.8 mg, 0.0985 mmol), Cs2CO3 (64.2 mg, 0.197 mmol), and DMF (1.3 mL) were reacted at 80 °C for 18 h to give the title compound (24 mg, 51%) as a colorless glassy substance. LCMS (Method B): R T =1.54 min, m / z = 652,654 [M-Butene + H] + .
[0719] Step 9: 7-(4-(7-oxa-4-azaspiro[2.5]oct-5-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using 5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylic acid tert-butyl ester (24 mg, 0.0339 mmol), TFA (1 mL), and DCM (2 mL), freeze-dried to give the title compound (20 mg, 97%) as a grayish-white solid. LCMS (Method B): R T =0.83min, m / z = 608,610 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.64–7.56(m,2H),7.54–7.46(m,2H),7.46–7.40(m ,2H),7.40–7.35(m,2H),6.79(s,1H),4.95(s,1H),4.28–4.10(m,1H),4.09–4.03(m,1H) ,4.02(s,2H),3.91(dd,J=10.7,3.2Hz,1H),3.88–3.82(m,1H),3.44–3.33(m,1H),3.30– 3.20(m,2H),3.20–3.03(m,2H),2.83–2.68(m,1H),1.70–1.25(m,4H),0.64–0.45(m,4H).
[0720] Example 19: 7-(4-(7-oxa-4-azaspiro[2.5]oct-5-yl)phenyl)-6-chloro-3-((4-hydroxy-1- (1-Methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0721]
[0722] Step 1: 5-(4-(6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2,3]octane-4-carboxylic acid tert-butyl ester: General procedure 6, using 5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo ... [-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2.5]octane-4-carboxylic acid tert-butyl ester (30 mg, 0.0657 mmol), epoxide 1 (19.23 mg, 0.0985 mmol), Cs2CO3 (64.2 mg, 0.197 mmol) and DMF (1.3 mL) were reacted at 80 °C for 18 h to give the title compound (25 mg, 58%) as a colorless glassy substance. LCMS (Method B): R T =1.39 min, m / z = 596,598 [M-Butene + H] + .
[0723] Step 2: 7-(4-(7-oxa-4-azaspiro[2.5]oct-5-yl)phenyl)-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using 5-(4-(6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-) Carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-7-oxa-4-azaspiro[2,5]octane-4-carboxylic acid tert-butyl ester (25 mg, 0.0383 mmol), TFA (1 mL), and DCM (2 mL) were freeze-dried to give the title compound (21 mg, 99%) as a grayish-white solid. LCMS (Method B): R T =0.70min, m / z = 552,554 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.67–7.54(m,2H),7.45–7.30(m,2H),6.80(s,1H),4.91(s,1H),4.10–4.03(m,1H),4.00(s,2H),3.98–3. 88(m,3H),3.88–3.82(m,1H),3.30–3.02(m,4H),2.76(d,J=6.2Hz,1H) ,1.62–1.32(m,4H),1.21(s,3H),0.81–0.72(m,2H),0.61–0.44(m,6H).
[0724] Example 20: 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methyl) (3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0725]
[0726] Step 1: (2S,5R)-5-(4-(3-(((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrololine) Tert-butyl pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylate (40 mg, 0.0899 mmol), epoxide 4 (29.3 mg, 0.135 mmol), Cs₂CO₃ (88 mg, 0.270 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (40 mg, 67%) as a colorless glassy substance. LCMS (Method A): R T =1.51 min, m / z = 606,608 [M-Butene + H] + .
[0727] Step 2: 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General Procedure 7, using (2S,5R)-5-(4-(3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (40 mg, 0.0604 mmol), TFA (1 mL), and DCM (2 mL), lyophilized to give the title compound (32 mg, 94%) as a grayish-white solid. LCMS (Method B): R T =0.75min, m / z = 562,564 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.65–7.56(m,2H),7.49–7.42(m,3H),7.42– 7.33(m,4H),6.80(s,1H),4.95(s,1H),4.32–4.11(m,1H),4.03(s,2H),3.91–3.75 (m,2H),3.63–3.49(m,1H),3.47–3.34(m,1H),3.30–3.21(m,2H),3.21–3.07(m,1H ),3.04–2.81(m,2H),2.60–2.53(m,1H),1.74–1.22(m,4H),1.10(d,J=6.2Hz,3H).
[0728] Example 21: 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0729]
[0730] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H) -Pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (40 mg, 0.0899 mmol), epoxide 5 (31.7 mg, 0.135 mmol), Cs₂CO₃ (88 mg, 0.270 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (36 mg, 58%) as a colorless glassy substance. LCMS (Method B): R T =1.42 min, m / z = 624,626 [M-Butene + H] + .
[0731] Step 2: 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (36 mg, 0.0529 mmol), TFA (1 mL) and DCM (2 mL), freeze-dried to give the title compound (29 mg, 94%) as a grayish-white solid. LCMS (Method B): R T =0.77min, m / z = 580, 582 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.63–7.58(m,2H),7.51–7.43(m,2H),7.43–7.36(m,2 H),7.32–7.23(m,2H),6.80(s,1H),4.96(s,1H),4.32–4.07(m,1H),4.03(s,2H),3.88–3.78 (m,2H),3.61–3.50(m,1H),3.49–3.35(m,1H),3.30–3.22(m,2H),3.22–3.03(m,1H),2.99–2 .93(m,1H),2.93–2.84(m,1H),2.60–2.53(m,1H),1.76–1.25(m,4H),1.10(d,J=6.2Hz,3H).
[0732] Example 22: 6-Chloro-3-((1-(2,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4- ((3R,6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0733]
[0734] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(2,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (40 mg, 0.0899 mmol), epoxide 6 (34.2 mg, 0.135 mmol), Cs₂CO₃ (88 mg, 0.270 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (38 mg, 60%) as a colorless, glassy substance. LCMS (Method B): R T =1.44 min, m / z = 642,644 [M-Butene + H] + .
[0735] Step 2: 6-Chloro-3-((1-(2,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(2,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (38 mg, 0.0544 mmol), TFA (1 mL) and DCM (2 mL), freeze-dried to give the title compound (31 mg, 95%) as a white solid. LCMS (Method B): R T =0.79min, m / z = 598,600 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.64–7.58(m,2H),7.55–7.44(m,1H),7.43–7.31(m,3 H),7.18(td,J=8.4,2.4Hz,1H),6.80(s,1H),4.99(s,1H),4.28–4.16(m,1H),4.13–3.91(m ,2H),3.91–3.76(m,2H),3.61–3.50(m,1H),3.30–3.20(m,3H),3.19–3.11(m,1H),3.04–2. 81(m,2H),2.59–2.53(m,1H),1.68–1.44(m,3H),1.42–1.28(m,1H),1.10(d,J=6.2Hz,3H).
[0736] Example 23: (S)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6, 6-Dimethylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0737]
[0738] Step 1: (S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylic acid tert-butyl ester and (R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylic acid tert-butyl ester: 5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylic acid tert-butyl ester (776 mg) was resolved into a single stereoisomer by chiral SFC using a Lux A1 (21.2 mm x 250 mm, 5 μm) column and isocratic solvent conditions: 25:75 MeOH:CO2. The first eluted material was arbitrarily designated as (S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester (288 mg, recovery 37%). Chiral purity (Method E): R T = 1.45 min, 100% ee. The first eluted material was arbitrarily designated as (R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester (320.9 mg, recovery 41%), a grayish-white solid. Chiral purity (Method E): R T =2.25min,100%ee.
[0739] Step 2: (S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylate tert-butyl ester: General procedure 5, using (S)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylate tert-butyl ester (288 mg, 0.603 mmol), aqueous sodium hydroxide solution (4 M, 4.52 mL, 18.1 mmol), and 1,4-dioxane (4.5 mL), acidified with 1 M potassium hydrogen sulfate solution after 18 h at 100 °C to give the title compound (286 mg, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.40min, m / z = 459,461 [M+H] + .
[0740] Step 3: (S)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo) [2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester (80 mg, 0.174 mmol), epoxide 2 (65.8 mg, 0.262 mmol), Cs2CO3 (170 mg, 0.523 mmol), and DMF (3 mL) were reacted at 80 °C for 18 h to give the title compound (85 mg, 68%) as a colorless, glassy substance. LCMS (Method B): R T =1.77 min, m / z = 654,656 [M-Butene + H] + .
[0741] Step 4: (S)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (S)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylic acid tert-butyl ester (85 mg, 0.120 mmol), TFA (2 mL), and DCM (4 mL), lyophilized to give the title compound (69 mg, 94%) as a grayish-white solid. LCMS (Method B): RT =0.86min, m / z = 610,612[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.69–7.60(m,2H),7.54–7.47(m,2H),7.47–7.34( m,4H),6.80(s,1H),4.96(s,1H),4.32–4.09(m,1H),4.03(s,2H),3.81(dd,J=10.3,3.5 Hz,1H),3.58(dd,J=11.1,3.6Hz,1H),3.47(t,J=10.7Hz,1H),3.43–3.33(m,1H),3.30– 2.98(m,2H),2.90–2.72(m,2H),2.68(d,J=11.5Hz,1H),1.75–1.23(m,7H),1.14(s,3H).
[0742] Example 24: 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3S,6R)-6-methyl) (3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0743]
[0744] Step 1: (2R,5S)-5-(4-(3-(((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester [-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (70 mg, 0.157 mmol), epoxide 4 (41 mg, 0.189 mmol), Cs₂CO₃ (113 mg, 0.346 mmol), and DMF (1.5 mL) were purified by preparative HPLC at 80 °C for 18 h to obtain the title compound (64 mg, 61%) as a white solid. LCMS (Method B): R T =1.39 min, m / z = 606,608 [M-Butene + H] + .
[0745] Step 2: 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General Procedure 7, using (2R,5S)-5-(4-(3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (64 mg, 0.0967 mmol), TFA (1 mL), and DCM (2 mL), purified by rapid chromatography and lyophilized to give the title compound (29.1 mg, 53%) as a white solid. LCMS (Method B): R T =0.74min, m / z = 562,564 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.62–7.57(m,2H),7.46–7.41(m,3H),7.38(t d,J=7.6,7.0,2.8Hz,4H),6.79(s,1H),4.95(s,1H),4.17(s,1H),4.02(s,2H),3.8 2(ddd,J=19.5,10.3,3.2Hz,2H),3.58–3.51(m,1H),3.39(s,1H),3.29–3.05(m,3H ),2.99–2.82(m,2H),2.57–2.52(m,1H),1.69–1.25(m,4H),1.09(d,J=6.2Hz,3H).
[0746] Example 25: 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S, 6R)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0747]
[0748] Step 1: (2R,5S)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2R,5S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: [d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (70 mg, 0.157 mmol), epoxide 5 (44.4 mg, 0.189 mmol), Cs₂CO₃ (113 mg, 0.346 mmol), and DMF (1.5 mL) were purified by preparative HPLC at 80 °C for 18 h to obtain the title compound (91.4 mg, 85%) as a white solid. LCMS (Method B): R T =1.42 min, m / z = 624,626 [M-Butene + H] + .
[0749] Step 2: 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2R,5S)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxy) Piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (95.4 mg, 0.140 mmol), TFA (1.5 mL), and DCM (3 mL) were purified by rapid chromatography and lyophilized to give the title compound (42.8 mg, 52%) as a white solid. LCMS (Method B): R T =0.73min, m / z = 580, 582 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.62–7.57(m,2H),7.48–7.43(m,2H),7.41–7.36(m ,2H),7.29–7.23(m,2H),6.79(s,1H),4.95(s,1H),4.16(s,1H),4.02(s,2H),3.82(ddd,J =19.6,10.3,3.3Hz,2H),3.55(dqd,J=12.4,6.1,2.1Hz,1H),3.39(s,1H),3.28–3.04(m, 3H), 2.99–2.82 (m, 2H), 2.57–2.52 (m, 1H), 1.53 (d, J = 72.6Hz, 4H), 1.09 (d, J = 6.2Hz, 3H).
[0750] Example 26: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 5S)-5-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0751]
[0752] Step 1: (3R,5S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylic acid tert-butyl ester and (3S,5R)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylic acid tert-butyl ester: racemic-(3R,5S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylic acid tert-butyl ester (664.7 mg) was resolved into a single stereoisomer using a chiral SFC with a Chiralpak IH (20 mm x 250 mm, 5 μm) column and isocratic solvent conditions: 15:85 MeOH:CO2. The first eluted material was arbitrarily designated as (3R,5S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester (309 mg, recovery 46%). Chiral purity (Method F): R T = 1.45 min, 100% ee. The first eluted material was arbitrarily designated as (3S,5R)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester (318.8 mg, recovery 47%). Chiral purity (Method F): R T =1.70min, 99.4%ee.
[0753] Step 2: (3R,5S)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylate tert-butyl ester: General procedure 5, using (3R,5S)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylate tert-butyl ester (309 mg, 0.667 mmol), sodium hydroxide aqueous solution (4 M, 5 mL, 20.0 mmol), and 1,4-dioxane (5 mL), acidified with 1 M potassium hydrogen sulfate aqueous solution after 18 h at 100 °C to give the title compound (337 mg, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.32min, m / z = 445, 447 [M+H] + .
[0754] Step 3: (3R,5S)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (3R,5S)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-yl) H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholino-4-carboxylic acid tert-butyl ester (80 mg, 0.180 mmol), epoxide 2 (68 mg, 0.270 mmol), Cs2CO3 (176 mg, 0.539 mmol), and DMF (3 mL) were reacted at 80 °C for 18 h to give the title compound (69 mg, 55%) as a colorless glassy substance. LCMS (Method B): R T =1.50 min, m / z = 640, 642 [M-Butene + H] + .
[0755] Step 4: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,5S)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (3R,5S)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylic acid tert-butyl ester (69 mg, 0.0990 mmol), TFA (2 mL), and DCM (4 mL), lyophilized to give the title compound (54 mg, 91%) as a grayish-white solid. LCMS (Method A): RT =0.76min, m / z = 596,598 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.64–7.60(m,2H),7.54–7.48(m,2H),7 .46–7.37(m,4H),6.80(s,1H),4.96(s,1H),4.29–4.09(m,1H),4.03(s,2H),4 .00–3.88(m,1H),3.85–3.64(m,2H),3.49–3.34(m,1H),3.31–3.20(m,1H),3. 21–3.07(m,2H),3.08–2.78(m,3H),1.76–1.27(m,4H),0.97(d,J=6.0Hz,3H).
[0756] Example 27: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S, 5R)-5-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0757]
[0758] Step 1: (3S,5R)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylate tert-butyl ester: General procedure 5, using (3S,5R)-3-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylate tert-butyl ester (319 mg, 0.688 mmol), aqueous sodium hydroxide solution (4 M, 5.16 mL, 20.7 mmol), and 1,4-dioxane (5.2 mL), acidified with 1 M potassium hydrogen sulfate solution after 18 h at 100 °C to give the title compound (360 mg, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.32min, m / z = 445, 447 [M+H] + .
[0759] Step 2: (3S,5R)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (3S,5R)-3-(4-(6-chloro-4-oxo-3,4-dihydro-7H-yl) tert-butyl ester H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholino-4-carboxylic acid tert-butyl ester (80 mg, 0.180 mmol), epoxide 2 (68 mg, 0.270 mmol), Cs2CO3 (176 mg, 0.539 mmol), and DMF (3 mL) were reacted at 80 °C for 18 h to give the title compound (78 mg, 62%) as a colorless glassy substance. LCMS (Method A): R T =1.64min, m / z = 696,698 [M+H] + .
[0760] Step 3: 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,5R)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (3S,5R)-3-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-methylmorpholin-4-carboxylic acid tert-butyl ester (69 mg, 0.0990 mmol), TFA (2 mL), and DCM (4 mL), lyophilized to give the title compound (59 mg, 99%) as a white solid. LCMS (Method B): R T =1.08min, m / z = 596,598 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.64–7.60(m,2H),7.53–7.47(m,2H),7.44–7.36(m, 4H),6.79(s,1H),4.95(s,1H),4.25–4.08(m,1H),4.02(s,2H),3.96(dd,J=10.2,3.1Hz,1H ),3.78(dd,J=10.5,3.2Hz,1H),3.71(dd,J=10.3,2.6Hz,1H),3.44–3.32(m,1H),3.30–3. 19(m,1H),3.19–3.06(m,2H),3.05–2.83(m,3H),1.73–1.26(m,4H),0.95(d,J=6.0Hz,3H).
[0761] Example 28: (S)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl) )-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0762]
[0763] Step 1: (S)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[ 2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester (40 mg, 0.0872 mmol), epoxide 5 (30.8 mg, 0.131 mmol), Cs₂CO₃ (85.2 mg, 0.262 mmol), and DMF (3 mL) were reacted at 80 °C for 18 h to give the title compound (45 mg, 74%) as a colorless, glassy substance. LCMS (Method A): R T =1.61 min, m / z = 638,640 [M-Butene + H] + .
[0764] Step 2: (S)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (S)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylic acid tert-butyl ester (45 mg, 0.0648 mmol), TFA (1 mL), and DCM (2 mL), lyophilized to give the title compound (38 mg, 98%) as a white solid. LCMS (Method A): R T =0.74min, m / z = 594,596 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.67–7.59(m,2H),7.49–7.43(m,2H),7.43–7.37(m,2H ),7.30–7.23(m,2H),6.79(s,1H),4.95(s,1H),4.33–4.07(m,1H),4.02(s,2H),3.80(dd,J= 10.3,3.6Hz,1H),3.57(dd,J=11.1,3.6Hz,1H),3.46(t,J=10.7Hz,1H),3.43–3.33(m,1H),3 .30–2.97(m,2H),2.93–2.72(m,2H),2.68(d,J=11.6Hz,1H),1.74–1.25(m,7H),1.13(s,3H).
[0765] Example 29: (R)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl) )-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0766]
[0767] Step 1: (R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylate tert-butyl ester: General procedure 5, using (R)-5-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylate tert-butyl ester (321 mg, 0.672 mmol), aqueous sodium hydroxide solution (4 M, 5.04 mL, 20.2 mmol), and 1,4-dioxane (5.1 mL), acidified with 1 M potassium hydrogen sulfate solution after 18 h at 100 °C to give the title compound (321 mg, >100%) as a yellow glassy substance. LCMS (Method B): R T =1.40min, m / z = 459,461 [M+H] + .
[0768] Step 2: (R)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[ 2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester (40 mg, 0.0872 mmol), epoxide 5 (30.8 mg, 0.131 mmol), Cs₂CO₃ (85.2 mg, 0.262 mmol), and DMF (3 mL) were reacted at 80 °C for 18 h to give the title compound (29 mg, 47%) as a colorless glassy substance. LCMS (Method B): R T =1.64 min, m / z = 638,640 [M-Butene + H] + .
[0769] Step 3: (R)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (R)-5-(4-(6-chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylic acid tert-butyl ester (29 mg, 0.0418 mmol), TFA (1 mL), and DCM (2 mL), lyophilized to give the title compound (24 mg, 96%) as a white solid. LCMS (Method A): RT =0.75min, m / z = 594,596 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.67–7.59(m,2H),7.51–7.42(m,2H),7.42–7.37(m,2 H),7.31–7.21(m,2H),6.79(s,1H),4.95(s,1H),4.30–4.08(m,1H),4.02(s,2H),3.80(dd, J=10.3,3.6Hz,1H),3.57(dd,J=11.1,3.6Hz,1H),3.51–3.43(m,1H),3.43–3.33(m,1H),3. 29–3.01(m,2H),2.96–2.72(m,2H),2.68(d,J=11.6Hz,1H),1.72–1.26(m,7H),1.13(s,3H).
[0770] Example 30: 6-Chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4- ((3R,6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0771]
[0772] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (40 mg, 0.0899 mmol), epoxide 7 (36.4 mg, 0.135 mmol), Cs₂CO₃ (88 mg, 0.270 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (32 mg, 49%) as a colorless glassy substance. LCMS (Method A): R T =1.69 min, m / z = 658,660 [M-Butene + H] + .
[0773] Step 2: 6-Chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (32 mg, 0.0448 mmol), TFA (1 mL) and DCM (2 mL), lyophilized to give the title compound (23 mg, 83%) as a white solid. LCMS (Method A): R T =0.79min, m / z = 614,616 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.63–7.58(m,2H),7.57–7.53(m,1H),7.50–7.42(m ,1H),7.41–7.34(m,3H),6.79(s,1H),4.98(s,1H),4.26–4.15(m,1H),4.11–3.95(m,2H) ,3.89–3.75(m,2H),3.61–3.49(m,1H),3.30–3.19(m,4H),3.19–3.10(m,1H),3.00–2.91 (m,1H),2.58–2.52(m,1H),1.69–1.42(m,3H),1.37–1.29(m,1H),1.09(d,J=6.2Hz,3H).
[0774] Example 31: 6-Chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0775]
[0776] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-yl) H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (40 mg, 0.0899 mmol), epoxide 8 (34 mg, 0.135 mmol), Cs₂CO₃ (88 mg, 0.270 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (45 mg, 71%) as a colorless glassy substance. LCMS (Method A): R T =1.62 min, m / z = 640, 642 [M-Butene + H] + .
[0777] Step 2: 6-Chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (45 mg, 0.0646 mmol), TFA (1 mL) and DCM (2 mL), freeze-dried to give the title compound (33 mg, 85%) as a white solid. LCMS (Method A): R T =0.71min, m / z = 596,598 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.06(d,J=1.8Hz,1H),7.63–7.56(m,2H),7.56–7.48(m,1H),7 .47–7.27(m,5H),6.78(d,J=2.2Hz,1H),4.97(d,J=2.3Hz,1H),4.28–4.17(m,1H),4.1 0–3.92(m,2H),3.87–3.75(m,2H),3.60–3.48(m,1H),3.29–3.03(m,4H),3.01–2.81(m ,2H),2.59–2.52(m,1H),1.72–1.43(m,3H),1.37–1.27(m,1H),1.09(d,J=6.2Hz,3H).
[0778] Example 32: 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl) Piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d] Pyrimidin-4-one or 6-chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidine- 4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine- 4-keto
[0779]
[0780] Step 1: (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester or (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester tert-butyl pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate (100 mg, 0.225 mmol), epoxide 9 (71 mg, 0.270 mmol), Cs₂CO₃ (161 mg, 0.495 mmol), and DMF (2 mL), after incubation at 80 °C for 18 h, followed by preparative HPLC purification to obtain the title compound (72.9 mg, 45%) as a white solid. LCMS (Method B): R T =1.48 min, m / z = 652,654 [M-Butene + H] + .
[0781] Step 2: 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one or 6-chloro-3-((4-hydroxy-1-((1R,2R)) -1-Methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl) -2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester or (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl) Piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (72.9 mg, 0.103 mmol), TFA (1 mL), and DCM (2 mL) were purified by rapid chromatography and lyophilized to give the title compound (45.6 mg, 72%) as a white solid. LCMS (Method A): R T =0.69min, m / z = 608, 610 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.63–7.56(m,2H),7.42–7.36(m,2H),6. 81(s,1H),4.93(s,1H),4.08–3.77(m,6H),3.60–3.50(m,1H),3.48–3.33(m,1H ),3.25(t,J=10.3Hz,1H),3.12–2.76(m,3H),2.57–2.52(m,1H),2.19–2.03(m, 1H), 1.74–1.35 (m, 5H), 1.34 (s, 3H), 1.15–1.11 (m, 1H), 1.09 (d, J = 6.3Hz, 3H).
[0782] Example 33: 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl) Piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d] Pyrimidin-4-one or 6-chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidine- 4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidine- 4-keto
[0783]
[0784] Step 1: (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester or (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester tert-butyl pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylate (100 mg, 0.225 mmol), epoxide 10 (71 mg, 0.270 mmol), Cs₂CO₃ (161 mg, 0.495 mmol), and DMF (2 mL), after incubation at 80 °C for 18 h, followed by preparative HPLC purification to obtain the title compound (111 mg, 69%) as a white solid. LCMS (Method B): R T =1.48 min, m / z = 652,654 [M-Butene + H] + .
[0785] Step 2: 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one or 6-chloro-3-((4-hydroxy-1-((1S,2S)) -1-Methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl- 2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester or (2S,5R)-5-(4-(6-chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin (111 mg, 0.157 mmol) tert-butyl pyrimidin-7-yl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid ester (TFA) and (3 mL) were purified by rapid chromatography and lyophilized to give the title compound (73 mg, 75%) as a very pale yellow solid. LCMS (Method A): R T =0.71min, m / z = 608,610 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.63–7.58(m,2H),7.41–7.36(m,2H),6. 81(s,1H),4.93(s,1H),4.06–3.78(m,6H),3.59–3.51(m,1H),3.47–3.33(m,1H ),3.25(t,J=10.3Hz,1H),3.08–2.79(m,3H),2.57–2.52(m,1H),2.18–2.05(m, 1H), 1.73–1.36 (m, 5H), 1.34 (s, 3H), 1.14–1.10 (m, 1H), 1.09 (d, J = 6.3Hz, 3H).
[0786] Example 34: (R)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6, 6-Dimethylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0787]
[0788] Step 1: (R)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]) The title compound (87 mg, 70%) was purified by preparative HPLC after incubation at 80 °C for 18 h with pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylate (80 mg, 0.174 mmol), epoxide 2 (52.7 mg, 0.209 mmol), Cs₂CO₃ (125 mg, 0.384 mmol), and DMF (1.5 mL) as a white solid (1.5 mL). LCMS (Method B): R T =1.55 min, m / z = 654,656 [M-Butene + H] + .
[0789] Step 2: (R)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (R)-5-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholin-4-carboxylic acid tert-butyl ester (87 mg, 0.122 mmol), TFA (1.5 mL), and DCM (3 mL), purified by rapid chromatography and lyophilized to give the title compound (45.8 mg, 61%) as a grayish-white solid. LCMS (Method B): R T =0.78min, m / z = 610,612[M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.66–7.61(m,2H),7.53–7.47(m,2H),7.45–7.37(m,4H),6.79(s,1H),4 .95(s,1H),4.25–4.09(m,1H),4.02(s,2H),3.80(dd,J=10.3,3.6Hz,1H),3.57(dd,J=11.1,3.6Hz,1H),3.46( t,J=10.7Hz,1H),3.40–3.33(m,1H),3.30–3.20(m,1H),3.19–3.07(m,1H),2.80(s,1H),2.77(d,J=11.6Hz,1H ), 2.68(d,J=11.6Hz,1H),1.68–1.55(m,2H),1.52–1.41(m,1H),1.40–1.27(m,1H),1.35(s,3H),1.13(s,3H).
[0790] Example 35: 6-Chloro-3-((1-(3-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0791]
[0792] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(3-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-yl) H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (50 mg, 0.112 mmol), epoxide 11 (34 mg, 0.135 mmol), Cs2CO3 (80.6 mg, 0.247 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (55 mg, 70%) as a colorless gel. LCMS (Method A): R T =1.61 min, m / z = 640, 642 [M-Butene + H] + .
[0793] Step 2: 6-Chloro-3-((1-(3-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(3-chlorobenzoyl)-4-hydroxy) Piperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (55 mg, 0.0790 mmol), TFA (0.74 mL), and DCM (1.5 mL) were purified by rapid chromatography and lyophilized to give the title compound (35 mg, 73%) as a white solid. LCMS (Method B): R T =0.73min, m / z = 596,598 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.63–7.57(m,2H),7.53–7.44(m,3H),7.41–7.37(m,2H),7.37–7.32(m,1H),6.79(s ,1H),4.95(s,1H),4.23–4.12(m,1H),4.07–3.96(m,2H),3.87–3.77(m,2H),3.60–3.51(m,1H),3.39–3.20(m,3H(signals overlap with HDO)),3.17–3.07(m,1H),3.00–2.92(m,1H),2.89(s,1H),2.58–2.53(m,1H),1 .69–1.56(m,2H),1.51–1.41(m,1H),1.37–1.29(m,1H),1.09(d,J=6.2Hz,3H).
[0794] Example 36: 6-Chloro-3-((1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0795]
[0796] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H) -Pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (50 mg, 0.112 mmol), epoxide 12 (31.7 mg, 0.135 mmol), Cs2CO3 (80.6 mg, 0.247 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (42 mg, 54%) as a colorless gel. LCMS (Method A): R T =1.52 min, m / z = 624,626 [M-Butene + H] + .
[0797] Step 2: 6-Chloro-3-((1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(2-fluorobenzoyl)-4-hydroxypiperidin) (42 mg, 0.0617 mmol) tert-butyl pyrimidin-7-yl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid ester (TFA) (0.75 mL) and DCM (1.5 mL) were purified by rapid chromatography and lyophilized to give the title compound (30.1 mg, 83%) as a white solid. LCMS (Method A): R T =0.66min, m / z = 580, 582 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.63–7.57(m,2H),7.52–7.46(m,1H),7.44–7.35(m,3H),7.3 2–7.25(m,2H),6.79(s,1H),4.98(s,1H),4.22(dt,J=12.6,4.0Hz,1H),4.10–3.94(m,2H),3.87–3. 77(m,2H),3.55(dqd,J=12.5,6.1,2.2Hz,1H),3.29–3.19(m,3H),3.19–3.11(m,1H),2.99–2.92(m ,1H),2.89(s,1H),2.57–2.52(m,1H),1.67–1.45(m,3H),1.38–1.29(m,1H),1.09(d,J=6.2Hz,3H).
[0798] Example 37: 6-Chloro-3-((1-(3,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4- ((3R,6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0799]
[0800] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(3,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro- 7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (50 mg, 0.112 mmol), epoxide 13 (34 mg, 0.135 mmol), Cs₂CO₃ (80.6 mg, 0.247 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (50 mg, 63%) as a colorless gel. LCMS (Method A): R T =1.57 min, m / z = 642,644 [M-Butene + H] + .
[0801] Step 2: 6-Chloro-3-((1-(3,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(3,4-difluorobenzoyl)-4-yl)-4-yl)-7-(4-(3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 50 mg (0.0716 mmol), TFA (0.75 mL), and DCM (1.5 mL) were purified by rapid chromatography and lyophilized to give the title compound (35 mg, 80%) as a white solid. LCMS (Method B): R T =0.72min, m / z = 598,600 [M+H] + . 1 HNMR(500MHz,DMSO-d6)δ8.06(s,1H),7.63–7.57(m,2H),7.57–7.46(m,2H),7.42–7.35(m,2H),7.30 –7.23(m,1H),6.79(s,1H),4.95(s,1H),4.15(br.s,1H),4.09–3.90(m,2H),3.89–3.77(m,2H),3.55( dqd,J=12.5,6.1,2.2Hz,1H),3.36(br.s,1H),3.25(t,J=10.3Hz,2H),3.12(br.s,1H),3.00–2.92(m, 1H), 2.89 (br.s, 1H), 2.58–2.52 (m, 1H), 1.70–1.56 (m, 2H), 1.51–1.27 (m, 2H), 1.09 (d, J = 6.2Hz, 3H).
[0802] Example 38: 6-chloro-3-((1-(3-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R, 6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0803]
[0804] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(3-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrololine) Tert-butyl pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylate (40 mg, 0.0899 mmol), epoxide 14 (25.4 mg, 0.108 mmol), Cs₂CO₃ (64.4 mg, 0.198 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (29.5 mg, 48%) as a colorless gel. LCMS (Method A): R T =1.53 min, m / z = 624,626 [M-Butene + H] + .
[0805] Step 2: 6-Chloro-3-((1-(3-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(3-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholin-4-carboxylic acid tert-butyl ester (29 mg, 0.0426 mmol), TFA (0.75 mL), and DCM (1.5 mL), lyophilized to give the title compound (18 mg, 72%) as a white solid. LCMS (Method A): R T =0.69min, m / z = 580, 582 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.64–7.56(m,2H),7.49(td,J=7.9,5.8Hz,1H),7.42–7.35(m,2H), 7.31–7.19(m,3H),6.79(s,1H),4.95(s,1H),4.17(s,1H),4.10–3.95(m,2H),3.82(ddd,J=19.6,10.3,3. 2Hz, 2H), 3.55(dqd, J = 12.4, 6.1, 2.2Hz, 1H), 3.25(t, J = 10.3Hz, 3H (signal overlaps with HDO)), 3.12(t, J = 14.9Hz, 1H), 2.99–2.79(m, 2H), 2.54(d, J = 11.1Hz, 1H), 1.61(s, 2H), 1.47(s, 1H), 1.33(s, 1H), 1.09(d, J = 6.2Hz, 3H).
[0806] Example 39: 6-Chloro-3-((1-(2,3-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4- ((3R,6S)-6-methylmorpholino-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0807]
[0808] Step 1: (2S,5R)-5-(4-(6-chloro-3-((1-(2,3-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H-yl)phenyl) H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (50 mg, 0.112 mmol), epoxide 15 (34.2 mg, 0.135 mmol), Cs₂CO₃ (80.6 mg, 0.247 mmol), and DMF (1 mL) were reacted at 80 °C for 18 h to give the title compound (30 mg, 38%) as a white solid. LCMS (Method B): R T =1.56 min, m / z = 642,644 [M-Butene + H] + .
[0809] Step 2: 6-Chloro-3-((1-(2,3-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(6-chloro-3-((1-(2,3-difluorobenzoyl)-4-yl) Hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (30 mg, 0.0430 mmol), TFA (0.75 mL), and DCM (1.5 mL) were purified by rapid chromatography and lyophilized to give the title compound (22.3 mg, 86%) as a white solid. LCMS (Method B): R T =0.79min, m / z = 598,600 [M+H] + . 1 HNMR(500MHz,DMSO-d6)δ8.06(s,1H),7.60(d,J=8.5Hz,2H),7.56–7.46(m,1H),7.39(d,J=8.5Hz,2H),7. 34–7.26(m,1H),7.26–7.15(m,1H),6.79(s,1H),4.99(s,1H),4.22(dt,J=13.3,4.2Hz,1H),4.10–3.94(m ,2H),3.89–3.75(m,2H),3.55(dqd,J=12.5,6.1,2.2Hz,1H),3.28–3.21(m,3H),3.21–3.12(m,1H),2.98– 2.92(m,1H),2.89(s,1H),2.58–2.53(m,1H),1.67–1.45(m,3H),1.40–1.30(m,1H),1.09(d,J=6.2Hz,3H).
[0810] Example 40: (S)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)- 6-Chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0811]
[0812] Step 1: (S)-5-(4-(3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (S)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H) -Pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylic acid tert-butyl ester (45 mg, 0.0981 mmol), epoxide 16 (32.6 mg, 0.147 mmol), Cs₂CO₃ (95.8 mg, 0.294 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (55 mg, 82%) as a colorless glassy substance. LCMS (Method B): R T =1.47 min, m / z = 624,626 [M-Butene + H] + .
[0813] Step 2: (S)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (S)-5-(4-(3-((1-([1,1'-bi(cyclopropane)]- 1-Carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester (55 mg, 0.0809 mmol), TFA (1 mL), and DCM (2 mL) were freeze-dried to give the title compound (40 mg, 85%) as a white solid. LCMS (Method B): R T =0.78min, m / z = 580, 582 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.67–7.60(m,2H),7.44–7.35(m,2H),6.81(s,1H),4.9 2(s,1H),4.19–3.89(m,4H),3.81(dd,J=10.4,3.5Hz,1H),3.57(dd,J=11.1,3.6Hz,1H),3.46 (t,J=10.7Hz,1H),3.38–2.89(m,2H),2.88–2.65(m,3H),1.69–1.38(m,4H),1.36(s,3H),1. 17–1.09(m,4H),0.73–0.64(m,2H),0.52–0.42(m,2H),0.42–0.33(m,2H),0.14–0.05(m,2H).
[0814] Example 41: (R)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)- 6-Chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0815]
[0816] Step 1: (R)-5-(4-(3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (R)-5-(4-(6-chloro-4-oxo-3,4-dihydro-7H) -Pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholino-4-carboxylic acid tert-butyl ester (45 mg, 0.0981 mmol), epoxide 16 (32.6 mg, 0.147 mmol), Cs₂CO₃ (95.8 mg, 0.294 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (46 mg, 69%) as a colorless solid. LCMS (Method B): R T =1.47 min, m / z = 624,626 [M-Butene + H] + .
[0817] Step 2: (R)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (R)-5-(4-(3-((1-([1,1'-bi(cyclopropane)]- 1-Carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2,2-dimethylmorpholine-4-carboxylic acid tert-butyl ester (46 mg, 0.0676 mmol), TFA (1 mL), and DCM (2 mL) were freeze-dried to give the title compound (37 mg, 94%) as a white solid. LCMS (Method B): R T =0.77min, m / z = 580, 582 [M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.68–7.60(m,2H),7.44–7.37(m,2H),6.81(s,1H),4.9 2(s,1H),4.08–3.93(m,4H),3.81(dd,J=10.3,3.5Hz,1H),3.57(dd,J=11.1,3.6Hz,1H),3.46 (t,J=10.7Hz,1H),3.37–2.91(m,2H),2.89–2.65(m,3H),1.66–1.38(m,4H),1.36(s,3H),1. 20–1.03(m,4H),0.72–0.62(m,2H),0.50–0.43(m,2H),0.42–0.32(m,2H),0.15–0.04(m,2H).
[0818] Example 42: 3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro- 7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0819]
[0820] Step 1: (2S,5R)-5-(4-(3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 6, using (2S,5R)-5-(4-(6-chloro-4-oxo-3,4) Dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid tert-butyl ester (45 mg, 0.101 mmol), epoxide 16 (34 mg, 0.152 mmol), Cs2CO3 (98.9 mg, 0.303 mmol), and DMF (2 mL) were reacted at 80 °C for 18 h to give the title compound (47 mg, 69%) as a colorless glassy substance. LCMS (Method B): R T =1.41 min, m / z = 610, 612 [M-Butene + H] + .
[0821] Step 2: 3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using (2S,5R)-5-(4-(3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one The title compound (36 mg, 90%) was obtained by freeze-drying tert-butyl ester of 2-methylmorpholino-4-carboxylic acid (47 mg, 0.0705 mmol), TFA (1 mL), and DCM (2 mL) after 1 mL of lyso[2,3-d]pyrimidin-7-yl)phenyl)-2-methylmorpholino-4-carboxylic acid. LCMS (Method B): R T =0.76min, m / z = 566,568 [M+H] + . 1¹H NMR (500MHz, DMSO-d6) δ 8.07 (s, 1H), 7.64–7.57 (m, 2H), 7.43–7.36 (m, 2H), 6.80 (s, 1H), 4.91 (s, 1H), 4.12–3.91 (m, 4H), 3.90–3.77 (m, 2H), 3.61–3.51 (m, 1H), 3.46–2.75 (m, 5H) (signal and HD) O overlap), 2.59–2.53(m,1H), 1.62–1.46(m,2H), 1.46–1.35(m,2H), 1.17–1.11(m,1H), 1.09(d,J=6.2Hz,3H), 0.71–0.62(m,2H), 0.50–0.41(m,2H), 0.41–0.34(m,2H), 0.13–0.04(m,2H).
[0822] Example 43: 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-3-((1-([1,1'-bi(cyclopropane) [alkyl)-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0823]
[0824] Step 1: 8-(tert-butyl)-7-(4,5,6,7-tetrachloro-1,3-dioxoisoindoline-2-yl)5-oxa-8-azaspiro[3.5]nonane-7,8-dicarboxylate: General procedure 11, using 8-(tert-butyloxycarbonyl)-5-oxa-8-azaspiro[3.5]nonane-7-carboxylic acid (2.60 g, 9.59 mmol), 4,5,6,7-tetrachloro-2-hydroxyisoindoline-1,3-dione (2.89 g, 9.59 mmol), EDC (2.21 g, 11.5 mmol) and DMAP (117 mg, 0.959 mmol) to obtain the title compound (2.34 g, 46%). 1 ¹H NMR (500MHz, chloroform-d) δ 5.11–4.62 (m, 1H), 4.34–4.18 (m, 1H), 4.05–3.81 (m, 2H), 3.24–3.02 (m, 1H), 2.23–2.05 (m, 2H), 2.04–1.90 (m, 2H), 1.89–1.79 (m, 1H), 1.70–1.61 (m, 1H), 1.58–1.40 (m, 9H).
[0825] Step 2: tert-butyl 7-(4-bromophenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylate: 1,4-dioxane (48.5 mL) was added to 100 mL of RBF containing 8-(tert-butyl)-7-(4,5,6,7-tetrachloro-1,3-dioxoisoindoline-2-yl)-5-oxa-8-azaspiro[3.5]nonane-7,8-dicarboxylate (710 mg, 1.28 mmol) and (4-bromophenyl)boronic acid (772 mg, 3.84 mmol). The reaction mixture was heated to 75–80 °C (internal temperature), and then triethylamine (1.79 mL, 12.8 mmol) and NiCl₂⁶H₂O: phenanthroline complex in DMF (0.05 M, 4.85 mL, 0.243 mmol, (Angew. Chem. Int. Ed. 2016, 55, 9676–9679)) were added sequentially. The resulting mixture was stirred overnight at 75 °C. After cooling to room temperature, the reaction mixture was diluted with EtOAc (250 mL) and washed with brine. The organic layer was dried over MgSO₄, filtered, and concentrated under reduced pressure. The residue was purified by rapid chromatography to give the title compound (366 mg, 74%) as a colorless, glassy substance. LCMS (Method B): R T =1.75min,m / z=282,284[M-Boc+H] + This material can be used without further purification.
[0826] Step 3: 7-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment A), using 7-(4-bromophenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester (415 mg, 1.09 mmol), B2Pin2 (414 mg, 1.63 mmol), Pd(dppf)Cl2·CH2Cl2 (91.9 mg, 0.109 mmol), KOAc (320 mg, 3.26 mmol) and 1,4-dioxane (11 mL), stirred at 100 °C (heat) for 4 h to obtain the title compound (460 mg, 98%) as a yellow solid. LCMS (Method B): R T =1.84min, m / z = 330[M - Boc + H] + This material can be used without further purification.
[0827] Step 4: 7-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3,5]nonane-8-carboxylic acid tert-butyl ester: General procedure 4 (post-treatment A), using 4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin (200 mg, 1.06 mmol), 7-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboropentan-2-yl)phenyl)- 5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester (457 mg, 1.06 mmol), copper(II) trifluoroacetate hydrate (616 mg, 2.13 mmol), 1,10-phenanthroline (383 mg, 2.13 mmol), boric acid (263 mg, 4.26 mmol), and DMF (20 mL) were reacted at 50 °C for 3 days to give the title compound (127 mg, 24%) as a colorless glassy substance. LCMS (Method B): R T =1.80min, m / z = 489,491 [M+H] + .
[0828] Step 5: 7-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester: General procedure 5, using 7-(4-(4,6-dichloro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester (20 mg, 0.0409 mmol), sodium hydroxide aqueous solution (4 M, 0.31 mL, 1.23 mmol), and 1,4-dioxane (0.3 mL), acidified with 1 M potassium hydrogen sulfate aqueous solution after 18 h at 100 °C to give the title compound (19 mg, quantitative) as a yellow glassy substance. LCMS (Method B): R T =1.38min, m / z = 471,473 [M+H] + .
[0829] Step 6: 7-(4-(3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3,5]nonane-8-carboxylic acid tert-butyl ester: General procedure 6, using 7-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2 [3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester (10 mg, 0.0212 mmol), epoxide 16 (7.1 mg, 0.0319 mmol), Cs2CO3 (20.8 mg, 0.0637 mmol) and DMF (0.5 mL) were reacted at 80 °C for 18 h to give the title compound (7.5 mg, 51%) as a colorless glassy substance. LCMS (Method B): R T =1.54 min, m / z = 636,638 [M-Butene + H] + .
[0830] Step 7: 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using 7-(4-(3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl) 4-Hydroxypiperidin-4-yl)methyl)-6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3,5]nonane-8-carboxylic acid tert-butyl ester (7.5 mg, 0.0108 mmol), TFA (1 mL), and DCM (2 mL) were freeze-dried to give the title compound (6 mg, 93%) as a white solid. LCMS (Method B): R T =0.81min, m / z = 592,594 [M+H] + . 1H NMR(500MHz,DMSO-d6)δ8.07(s,1H),7.67–7.56(m,2H),7.45–7.33(m,2H),6.80(s,1H),4.91 (s,1H),4.12–3.93(m,4H),3.84(dd,J=10.1,3.2Hz,1H),3.60(dd,J=10.9,3.3Hz,1H),3.47–2 .75(m,5H),2.70(dd,J=11.7,1.9Hz,1H),2.35–2.27(m,1H),2.08–1.69(m,4H),1.70–1.32(m, 5H),1.18–1.08(m,1H),0.67(s,2H),0.52–0.41(m,2H),0.41–0.32(m,2H),0.12–0.07(m,1H).
[0831] Example 44: 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzyl) Acyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0832]
[0833] Step 1: 7-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3,5]nonane-8-carboxylic acid tert-butyl ester: General procedure 6, using 7-(4-(6-chloro-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d] [Pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester (10 mg, 0.0212 mmol), epoxide 2 (8.02 mg, 0.0319 mmol), Cs2CO3 (20.8 mg, 0.0637 mmol) and DMF (0.5 mL) were reacted at 80 °C for 18 h to give the title compound (6 mg, 39%) as a colorless glassy substance. LCMS (Method B): R T =1.61 min, m / z = 666,668 [M-Butene + H] + .
[0834] Step 2: 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one: General procedure 7, using 7-(4-(6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-4-oxo-3,4-dihydro-7H-pyrrolo[2,3-d]pyrimidin-7-yl)phenyl)-5-oxa-8-azaspiro[3.5]nonane-8-carboxylic acid tert-butyl ester (6 mg, 0.0083 mmol), TFA (1 mL) and DCM (2 mL), freeze-dried to give the title compound (5 mg, 96%) as a white solid. LCMS (Method B): R T =0.88min, m / z = 622,624[M+H] + . 1 H NMR(500MHz,DMSO-d6)δ8.06(s,1H),7.63–7.57(m,2H),7.53–7.47(m,2H),7.46–7.36(m ,4H),6.79(s,1H),4.95(s,1H),4.27–4.07(m,1H),4.02(s,2H),3.84(dd,J=10.2,3.2Hz, 1H),3.59(dd,J=10.9,3.3Hz,1H),3.42–3.33(m,1H),3.29–2.96(m,4H),2.96–2.76(m,1H ), 2.70(dd,J=11.7,1.9Hz,1H),2.35–2.22(m,1H),2.01–1.70(m,4H),1.69–1.27(m,5H).
[0835] Example 45: 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl) )-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one
[0836]
[0837] Step 1: (2S,5R)-5-(4-bromophenyl)-2-ethylmorpholine: General procedure 8, using 4-bromobenzaldehyde (2.36 g, 12.8 mmol), (S)-2-((tributyltinyl)methoxy)but-1-amine (prepared from (S)-1-aminobutane-2-ol according to the procedure outlined in Org. Lett. 2014, 16(4), 1236–1239) (5.00 g, 12.8 mmol), Cu(OTf)2 (4.63 g, 12.8 mmol), 2,6-dimethylpyridine (1.37 g, 12.8 mmol), HFIP (51 mL), Molecular sieve (approximately 1.28 g) and DCM (205 mL) yielded the title compound (1.93 g, 56%). LCMS (Method C): R T =0.93min, m / z = 270, 272 [M+H] + . 1 ¹H NMR (400MHz, chloroform-d) δ 0.97 (t, J = 7.5 Hz, 3H), 1.40–1.66 (m, 2H), 2.72 (dd, J = 11.5, 10.2 Hz, 1H), 3.08 (dd, J = 11.5, 2.3 Hz, 1H), 3.33–3.50 (m, 2H), 3.76–3.93 (m, 2H), 6.96 (d, J = 7.7 Hz, 2H), 7.46 (d, J = 7.7 Hz, 2H).
[0838] Step 2: (2S,5R)-5-(4-bromophenyl)-2-ethylmorpholine-4-carboxylic acid tert-butyl ester: General procedure 9, using (2S,5R)-5-(4-bromophenyl)-2-ethylmorpholine (1.93 g, 7.15 mmol) and Boc2O (1.87 g, 8.58 mmol) to give the title compound (1.77 g, 67%). LCMS (Method C): R T =1.40min,m / z=270,272[M-Boc+H] + . 1 ¹H NMR (400MHz, chloroform-d) δ 0.95 (t, J = 7.4 Hz, 3H), 1.35 (s, 9H), 1.48–1.61 (m, 1H), 1.65–1.79 (m, 1H), 3.38–3.52 (m, 2H), 3.58–3.67 (m, 1H), 3.73 (dd, J = 12.3, 5.4 Hz, 1H), 3.96 (dd, J = 12.2, 4.5 Hz, 1H), 4.79 (t, J = 5.1 Hz, 1H), 7.24 (d, J = 8.1 Hz, 2H), 7.43 (d, J = 8.1 Hz, 2H).
[0839] Step 3: (2S,5R)-2-ethyl-5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxoboronyl-2-yl)phenyl)morpholine-4-carboxylic acid tert-butyl ester: General procedure 3 (post-treatment B), using (2S,5R)-5-(4-bromophenyl)-2-ethylmorpholine-4-carboxylic acid tert-butyl ester (741 mg, 2.00 mmol), B2Pin2 (762 mg, 3.00 mmol), Pd(dppf)Cl2·CH2Cl2 (169 mg, 0.200 mmol), KOAc (589 mg, 6.00 mmol) and 1,4-dioxane (20 mL), stirred at 100 °C (heat) for 70 min to obtain the title compound (914 mg, >100%) as a yellow oil. LCMS (Method A): R T =2.07 min, m / z = 362 [M-Butene + H] + . 1 H NMR (500MHz, DMSO-d6) δ7.65(d,J=8.1Hz,2H),7.32(d,J=7.8Hz,2H),4.80(t,J=5. 4Hz,1H),3.91(dd,J=12.2,4.9Hz,1H),3.69(dd,J=12.2,6.0Hz,1...
Claims
1. A compound according to formula (I), including its stereoisomers: in: "m" is 0, 1, or 2, and each R 1 Independently selected from: halo; C1-C6 alkyl optionally substituted by halo; and C3-C6 cycloalkyl; "n" is 0, 1, or 2, and each R 2 is independently selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, wherein each of the one or more optional substituents is independently selected from C1-C6 alkyl, and halo, or where "n" is 2 and each R 2 Together with the one or more carbon ring atoms to which they are attached, they form a C3-C6 fused cycloalkyl ring, a C3-C6 spirocycloalkyl ring, or a C3-C4 bridge; R 3 is selected from optionally substituted C1-C6 alkyl, optionally substituted C3-C6 cycloalkyl, optionally substituted phenyl, optionally substituted C7-C 10 Arylalkyl, optionally substituted C8-C 10 Arylalkenyl and optionally substituted C3-C6 heteroaryl; wherein each of the one or more optional substituents is independently selected from: halo; C1-C6 alkyl optionally substituted by halo; and C3-C6 cycloalkyl optionally substituted by methyl or CF3; R 4 is H, Cl, C1-C6 alkyl; wherein one of X and Z is O and one of X and Z is NR', such that the ring comprising X and Z is a morpholine ring, wherein R' is H or C1-C6 alkyl, optionally H; or a pharmaceutically acceptable salt or solvate thereof.
2. A compound according to claim 1 and according to formula (Ia), including its stereoisomers: in: "m", "n", R 1 -R 4 and R' as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof.
3. A compound according to claim 1 or claim 2, which is a compound according to formula (Ic), including its stereoisomers: in: "m", "n", R 1 -R 4 and R' as defined in claim 1, or a pharmaceutically acceptable salt or solvate thereof.
4. The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, wherein X is NR' and Z is O.
5. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein "m" is 0 or 1.
6. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein "m" is 0.
7. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein "n" is 1 or 2.
8. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 1 Independently selected from Cl; F; methyl optionally substituted by F, optionally CF3; ethyl optionally substituted by F, propyl and cyclopropyl.
9. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 1 Independently is methyl optionally substituted with F.
10. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 2 Independently selected from: methyl optionally substituted with F; ethyl; and cyclopropyl.
11. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 2 Independently selected from: methyl; ethyl; and cyclopropyl.
12. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein each R 2 Independently selected from methyl or ethyl.
13. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein "n" is 1 and R 2 It's methyl.
14. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt or solvate thereof, wherein "n" is 2 and each R 2 It's methyl.
15. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt or solvate thereof, wherein "n" is 2 and each R 2 Together with the carbon ring atoms to which they are attached, they form a C3 or C4 spirocyclic cycloalkyl ring.
16. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt or solvate thereof, wherein "n" is 2 and each R 2 Together with the carbon ring atoms to which they are attached, they form a C3-C6 fused cycloalkyl ring, optionally a C3, C5 or C6 fused cycloalkyl ring.
17. A compound according to any one of claims 1 to 13, or a pharmaceutically acceptable salt or solvate thereof, wherein "n" is 2 and each R 2 Together with the carbon ring atoms to which they are attached, they form a C4 bridge.
18. The compound according to any one of claims 1-12, or a pharmaceutically acceptable salt or solvate thereof, wherein "n" is 1.
19. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one R 2 The group is located at the 6-position of the morpholinyl ring, and optionally each R 2 The substituent is located at the 6-position of the morpholinyl ring.
20. A compound according to any one of claims 1 to 19, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one R 2 The group is located at the 2-position of the morpholinyl ring, and optionally each R 2 The substituent is located at the 2-position of the morpholinyl ring.
21. A compound according to any one of claims 1 to 20, or a pharmaceutically acceptable salt or solvate thereof, wherein at least one R 2 The group is located at the 5-position of the morpholinyl ring, and optionally each R 2 The substituent is located at the 5-position of the morpholine ring.
22. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 It's chlorine.
23. A compound according to any one of claims 1 to 21, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 Is H or C 1- C6 alkyl.
24. The compound according to claim 23, or a pharmaceutically acceptable salt or solvate thereof, wherein R 4 It is H or methyl.
25. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is optionally substituted C3-C6 cycloalkyl, wherein each of the one or more optional substituents is independently selected from halo; C1-C2 alkyl optionally substituted with F; and C3-C6 cycloalkyl.
26. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is optionally substituted cyclopropyl, wherein each of the one or more optional substituents is independently selected from methyl, CHF2, CF3 and cyclopropyl.
27. A compound according to any one of claims 1 to 25, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is an optionally substituted cyclopropyl group having the general formula: Where R 5 and R 6 Each is independently selected from hydrogen, halo; C1-C2 alkyl optionally substituted by F; and C3-C6 cycloalkyl.
28. The compound according to claim 27, wherein R 5 and R 6 Each independently selected from hydrogen, methyl, CHF2, CF3 and cyclopropyl, preferably wherein R 5 are independently selected from hydrogen and CF3 and R 6 Independently selected from methyl and cyclopropyl.
29. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is optionally substituted phenyl, wherein each of the one or more optional substituents is independently selected from halo, C1-C2 alkyl optionally substituted with F, and C3-C6 cycloalkyl optionally substituted with methyl or CF3.
30. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is optionally substituted phenyl, wherein each of the one or more optional substituents is independently selected from Cl, F, methyl, CF3, CHF2, and cyclopropyl optionally substituted with methyl or CF3.
31. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is optionally substituted C7-C 10 Arylalkyl, wherein each of the one or more optional substituents is independently selected from halo; C1-C6 alkyl optionally substituted with halo; and C3-C6 cycloalkyl optionally substituted with methyl or CF3.
32. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein R 3 is optionally substituted (CH2)2-phenyl, wherein each of the one or more optional substituents is independently selected from: halo; C1-C6 alkyl optionally substituted by halo; and C3-C6 cycloalkyl optionally substituted by methyl or CF3.
33. A compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof, wherein when R 3 When arylalkyl, each of the one or more optional substituents of the arylalkyl is independently selected from halo, methyl, ethyl, CHF2 and CF3.
34. The compound according to claim 1, or a pharmaceutically acceptable salt or solvate thereof, selected from: rac-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one rac-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,5S)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(3-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2S,3S)-2-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((2R,3R)-2-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one rac-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6R)-6-(trifluoromethyl)morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-(5,5-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(5,5-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one rac-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-(7-oxa-4-azaspiro[2.5]oct-5-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-(7-oxa-4-azaspiro[2.5]oct-5-yl)phenyl)-6-chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 3-((1-benzoyl-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,5S)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,5R)-5-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-6-Chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-6-Chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(3-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(3,4-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(3-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2,3-difluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-(5-oxa-8-azaspiro[3.5]non-7-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-((1R,2S,5S)-8-oxa-3-azabicyclo[3.2.1]oct-2-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-((1R,2S,5S)-8-oxa-3-azabicyclo[3.2.1]oct-2-yl)phenyl)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chloro-2-fluorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(3-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(octahydro-2H-benzo[b][1,4]oxazin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(octahydrocyclopenta[b][1,4]oxazin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(4-methylbenzoyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(4-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2-chloro-4-methylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2,4-dimethylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2,4-dimethylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-(2-oxa-5-azabicyclo[4.1.0]hept-4-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6R)-6-cyclopropylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-cinnamoyl-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-cyclopropylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(4-(trifluoromethyl)benzoyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((R)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((S)-6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3S,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(3-fluoro-4-(morpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(3-methyl-4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(4-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-6-Chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-3-((1-([1,1'-bi(cyclopropane)]-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-6-chloro-7-(4-(morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-((R)-4,4-difluoro-3-phenylbutyryl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-((R)-4,4-difluoro-3-phenylbutyryl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(3-chloro-4-((S)-morpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(3-chloro-4-((R)-morpholin-3-yl)phenyl)-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)-3-(trifluoromethyl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((R)-4,4,4-trifluoro-3-phenylbutyryl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)-3-(trifluoromethyl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-(morpholin-2-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chloro-2-methylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-chloro-2-methylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-(difluoromethyl)benzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-(difluoromethyl)benzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(4-cyclopropylbenzoyl)-4-hydroxypiperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(4-(1-methylcyclopropyl)benzoyl)piperidin-4-yl)methyl)-7-(3-methyl-4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-((1S,2S)-1,2-dimethylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-((1R,2R)-1,2-dimethylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 7-(4-((1S,2R,5R)-8-oxa-3-azabicyclo[3.2.1]oct-2-yl)phenyl)-6-chloro-3-((1-(4-chlorobenzoyl)-4-hydroxypiperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (R)-6-Chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one (S)-6-Chloro-7-(4-(6,6-dimethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(2,2-dicyclopropylacetyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((3R,6S)-6-cyclopropylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methylcyclobutane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((1-(3-cyclopropylpropionyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((3S,6R)-6-cyclopropylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((3S,6R)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-7-(4-((3R,6S)-6-ethylmorpholin-3-yl)phenyl)-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-(1-methylcyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1S,2S)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((3S,6R)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((S)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-Chloro-3-((4-hydroxy-1-((1R,2R)-1-methyl-2-(trifluoromethyl)cyclopropane-1-carbonyl)piperidin-4-yl)methyl)-7-(4-((R)-morpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one 6-chloro-3-((1-((1S,2S)-2-(difluoromethyl)-1-methylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, and 6-Chloro-3-((1-((1R,2R)-2-(difluoromethyl)-1-methylcyclopropane-1-carbonyl)-4-hydroxypiperidin-4-yl)methyl)-7-(4-((3R,6S)-6-methylmorpholin-3-yl)phenyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one.
35. A pharmaceutical composition comprising a compound according to any preceding claim, or a pharmaceutically acceptable salt or solvate thereof.
36. A compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 35, for use in a method of treatment.
37. A compound according to any one of claims 1 to 34, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 35, for use in a method of treating cancer.
38. Use of a compound according to any one of claims 1 to 34 or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 35, in the manufacture of a medicament for use in a method for treating cancer.
39. A method of treating cancer in a subject, comprising administering to the subject an effective amount of a compound according to any one of claims 1-34, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutical composition according to claim 35.
40. The use according to claim 38 or the method according to claim 39, or the compound for use or the pharmaceutical composition according to claim 36 or claim 37, wherein the method comprises administering a further therapeutic agent.
41. The use according to claim 38 or the method according to claim 39, or the compound for use or the pharmaceutical composition according to claim 36 or claim 37, wherein the method comprises administering an immune checkpoint inhibitor.
